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Abstract 
The consortium of microorganisms inhabiting the human gastrointestinal tract, our gut 
microbiota, has an extensive set of metabolic capabilities that directly influence human health. Over the 
past decade, DNA sequencing has significantly improved our knowledge of this microbial community’s 
composition. However, the molecular details of how gut bacterial metabolism impacts human health and 
disease are largely unknown. We propose that by combining chemical knowledge with bioinformatics, we 
can uncover microbial metabolic pathways that contribute to human disease. By developing small 
molecule inhibitors specifically targeting these pathways, we can further elucidate the roles of bacterial 
metabolism in disease and create a new paradigm for therapeutics.  
To illustrate this strategy’s potential, we are investigating the catabolism of the essential nutrient 
choline by anaerobic gut microbes. Within the human gastrointestinal tract, bacteria can process choline 
in an entirely different manner than human cells, cleaving its C–N bond to produce trimethylamine 
(TMA), which is subsequently oxidized to trimethylamine N-oxide by hepatic enzymes. This microbial-
human co-metabolic pathway has been linked to several diseases, including non-alcoholic fatty liver 
disease and atherosclerosis. Even though anaerobic microbial choline conversion into TMA has been 
known for over a century, its genetic and biochemical bases had not been identified prior to our work. 
This thesis presents the discovery and validation of a gene cluster responsible for anaerobic choline 
utilization (cut gene cluster), as well as the characterization and inhibition of the key TMA-forming 
enzyme, choline TMA-lyase (CutC).  
Chapter 2 details the bioinformatic approach used to discover the cut gene cluster, and the 
genetic, spectroscopic and cultivation-based strategies to connect these genes to anaerobic choline 
metabolism.  We also reveal the involvement of a C–N bond cleaving glycyl radical enzyme (CutC) in 
! iv 
TMA production, an unprecedented reactivity for this enzyme family. Overall, our experimental and 
computational findings suggest that the cut pathway may be a major mechanism for the direct conversion 
of choline to TMA by gut bacteria. 
Chapter 3 describes the in vitro reconstitution and study of choline-TMA lyase CutC and its 
activating protein, the radical S-adenosylmethionine dependent enzyme CutD. We demonstrate that CutC 
can be activated to the glycyl radical form by CutD under anaerobic conditions, and can process choline 
to TMA and acetaldehyde with high specificity. Homology modeling and mutagenesis experiments 
further allow us to conclude that CutC is a glycyl radical enzyme of unique function and a molecular 
marker for anaerobic choline metabolism. 
Chapter 4 presents the results of a close collaboration with the Drennan group at Massachusetts 
Institute of Technology. They elucidated four high-resolution X-ray structures of wild-type CutC and 
mechanistically informative mutants in the presence of choline, while I characterized the impact of 
mutations on choline binding and catalysis. Our data uncover unexpected interactions between the 
trimethylammonium group of choline and polar amino acids side chains and provide new insight into the 
mechanism of C–N cleavage by CutC. This work broadens our understanding of radical-based enzyme 
catalysis and will aid in the rational design of inhibitors of bacterial trimethylamine production. 
Chapter 5 depicts initial efforts towards discovering small molecule inhibitors of CutC-mediated 
choline cleavage. A first round of structure-guided rational design revealed betaine aldehyde as a 
promising lead. This molecule inhibited choline conversion to TMA by a panel of cut gene cluster-
containing bacteria and by a human fecal sample. I also describe our high throughput screening approach 
to identify new inhibitors of choline metabolism by gut microbes, as an orthogonal strategy to rational 
design. Towards this end, we optimized a media formulation containing choline as sole carbon source, 
such that survival of gut bacteria grown in this media would be dependent on the cut pathway. Overall, 
our preliminary results show that small molecules can interfere with choline metabolism by anaerobic gut 
microbes and set the stage for more extensive efforts to discover potent inhibitors of this pathway.  
!
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Chapter 1: Introduction to the host-gut microbiota metabolic dialogue and  
glycyl radical enzymes 
 
 
1.1: General introduction to the human gut microbiota  
Humans exist in symbiosis with a large number of commensal microorganisms (primarily 
members of the Bacterial kingdom, as well as some Archaea, Eukarya, and their viruses), collectively 
known as the human microbiota. Of the many communities that comprise our microbiota, the one residing 
in our gastrointestinal tract has been the subject of numerous studies due to its profound impact on our 
physiology and health (1). The beneficial functions of our gut microbes include essential vitamin and 
nutrient synthesis, immune-cell development and homeostasis, digestion of inaccessible food 
components, fat metabolism support, epithelial homeostasis, enteric nerve regulation, and angiogenesis 
promotion (2). Disruption of the gut microbiota (dysbiosis) stemming from either environmental factors 
(e.g, antibiotic use, diet, stres, and injury) or mammalian metabolism (e.g, immune signaling, hormone 
synthesis), has been associated with a number of diseases, such as allergy, inflammatory bowel disease 
(IBD), obesity, nonalcoholic fatty liver disease (NAFLD), colon cancer, and diabetes (3). In addition, the 
gut microbiota can metabolize therapeutic drugs, altering their safety and efficacy (4), and plays a crucial 
role in protecting against the establishment of pathogenic microbes (5). 
It is currently estimated that the number of bacteria in our bodies is on the same order as the 
number of human cells, but with 1011 bacterial cells/mL, our colon represents an anaerobic bioreactor that 
is considered the most densely populated microbial habitat on Earth (6). A metagenomic sequencing 
study of the gut microbiota found that the total number of genes possessed by this community outnumbers 
human genes ~150 fold (7). This implies that our gut microbes have metabolic and biosynthetic 
capabilities that greatly surpass those of human cells. Despite numerous reports linking changes in the 
composition of this microbial community to various health and disease states (8), our current knowledge 
of specific gut bacterial enzymes, metabolites and pathways remains limited, thus providing exciting 
opportunities for discovery.      
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Analyses of the identities of our gut microbes have revealed that this complex community 
consists of more than 500 species belonging to eight bacterial divisions, with Firmicutes and 
Bacteroidetes as the dominant phyla (90 % of the distal gut microbiota) (8, 9). The diversity within this 
community is considered the result of coevolution with the host and a strong selection for specific 
bacteria whose collective metabolic capacity is beneficial to the host (10). The gut microbiota of an infant 
is seeded at birth, and it is influenced by a series of factors, including method of delivery, breast feeding 
and weaning (11). During the early years, the microbiota changes and develops rapidly, reaching a steady 
state in adulthood. A final set of changes occurs during old age, when the immune system starts to decline 
(3). Thus, throughout our lives, the function and composition of our gut microbiota are continually 
influenced not just by external environmental factors, but also by our own genome and metabolism.    
Through a substantial high throughput sequencing effort, the Human Microbiome Project (HMP) 
has provided a comprehensive picture of the human microbiota from multiple body sites, including the 
gut. Interestingly, researchers from the HMP were unable to identify a set of common gut microbial 
species shared among all individuals, comparable to our shared genome. Instead, they uncovered that the 
diversity and abundance of gut microbes highly vary among individuals (12). Nonetheless, metagenomic 
sequencing performed by the HMP and its European equivalent, the Metagenomics of the Human 
Intestinal Tract (MetaHIT) Consortium (7), revealed a functional core shared by each individual in the 
cohort and encoded across many microbial species. This finding implies that the metabolic pathways 
necessary for human-associated microbial life are conserved, despite the variability in bacterial taxonomic 
composition. One of the most striking results of these metagenomic studies is the abundance of unknown 
biochemical functions encoded by the human gut microbiota. Of the assembled HMP stool metagenomes, 
~70% of the genes could not be assigned a GO (Gene Ontology) or EC (Enzyme Commission) annotation 
(13). Thus, a timely characterization of novel biochemical functions from our microbiota is necessary in 
order to establish causality relationships between microbial metabolites, genes, metabolic pathways and 
human health. 
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1.2: Tools to study the gut microbiota 
One of the most common techniques used to investigate human-associated microbial 
communities is the study of cultured isolates. When used in conjunction with whole genome sequencing, 
this approach enables researchers to link phenotypes to specific microbial genes (4). However, given that 
a large proportion of gut bacteria remain unculturable, this strategy cannot be applied universally. In order 
to simulate some of the complexity of the gut environment in vitro, a number of models were developed, 
ranging from simple single vessel batch cultures to complex multistage pH-regulated continuous cultures 
(e.g, SHIME or TIM-1) (14). These in vitro systems provide a facile and cost-effective means of studying 
the gut microbiome in one or more gut compartments, but they still lack an epithelial mucosa, as well as 
immunological and neuroendocrine interactions with a host (14). Recent advances in microfluidics have 
allowed the development of a human gut-on-a-chip microdevice that was used to coculture multiple 
commensal microbes in contact with living human intestinal epithelial cells and analyze the effect of 
peristalsis-associated mechanical deformations on inflammatory bowel disease (15). Despite representing 
a proof-of-principle device, the human gut-on-a-chip appears as a robust platform for the modeling of 
human intestinal disease in a modular manner.  
 
Figure 1.1: Approaches for studying the human gut microbiota. (A) Taxonomic profiling provides 
information about the identities and abundances of different organisms in communities. (B) Functional 
profiling can be performed by determining the total gene content of microbial communities, as well as the 
abundance of gene transcripts, proteins, and metabolites. (C) Gnotobiotic (germ-free) animal models 
represent a method to connect specific organisms and functions to host phenotypes. 
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First employed in environmental microbiology, taxonomic profiling (or 16S rRNA sequencing) 
represents the most widely used method for characterizing the identities and abundances of different 
bacterial taxa from the gut microbiota, because it uses the variable region of the bacterial 16S rRNA gene 
as a phylogenetic marker (16) (Figure 1.1.A). Optimized for high throughput sequencing by the HMP and 
MetaHIT, this approach has provided an unprecedented insight into the bacterial diversity of healthy 
individuals (7, 12), as well as correlations between gut community composition and various health and 
disease states (2). A substantial limitation of taxonomic profiling is that closely related bacteria often 
possess different metabolic pathways due to mechanisms such as gene loss and horizontal gene transfer 
(17), thus limiting our ability to correlate community composition to biochemical function. In addition, 
taxonomic profiling cannot distinguish between active and inactive, or resident and transient members of 
the gut microbial community.  
In recent years, research concerning host-gut microbiota interactions has focused on the 
functional profiling of this microbial community through approaches such as metagenomics, 
metatranscriptomics, metaproteomics, and metabolomics (Figure 1.1.B). These methods provide 
information regarding the total microbial gene abundance, which genes are expressed and active at the 
moment of sampling, and which metabolites are enriched or depleted in different tissues and bodily fluids 
(18). Correlating this information with different host and disease states has revealed unexpected potential 
contributions of the gut microbiota to various host processes (e.g., inflammation, DNA damage, energy 
homeostasis) (3). However, it is still difficult to determine specific molecular mechanisms though which 
gut microbes elicit an effect on host health. This obstacle ultimately limits our ability to harness beneficial 
activities of our gut bacteria or intervene therapeutically in associated diseases. 
Another strategy to investigate the impact of gut microbial metabolism on the mammalian host is 
the development of animal models (mice, zebrafish, etc.) with non-existent or simplified microbiotas, e.g., 
germ-free (gnotobiotic) mice, antibiotic-treated rodents with a temporary knockout of select bacterial 
groups, and animals with transplanted microbiota from human patients (Figure 1.1.C). By allowing 
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disruptions of the gut microbiota to be studied within a controlled experimental setting, animal models 
represent the best method to assess causality and establish mechanistic hypotheses regarding the 
connection between gut bacterial function and disease (19). Mouse models have proved particularly 
effective because gnotobiotic mice can support the growth of the majority of human-associated bacterial 
genera, and one can leverage the comprehensive knowledge of mouse genetics and availability of 
genetically modified mouse strains (19). However, translating the results of mouse model studies to 
humans is complicated by intrinsic differences in intestinal anatomy and function, as well as by specific 
chemical-mediated crosstalk between the host and gut microbes (19). 
The large fraction of uncharacterized genes in the gut microbiome drastically hampers our ability 
to understand and prevent detrimental metabolic functions of this microbial community. Joice et al. (13) 
proposed to combine the techniques presented above in a pipeline for the identification and validation of 
unknown biochemical functions of our gut microbiota. Starting with microbial genomic, metagenomic or 
transcriptomic data, standard sequence analysis methods (homology-based assignment or domain 
profiling) can be used to assign a putative activity to a gene of unknown function. Additional 
bioinformatic approaches can further help to refine this prediction. Useful tools include: comparative 
metagenomics (association of uncharacterized microbial products with characterized genes across 
samples through the use of data integration), supervised curation (manual establishment of a consensus 
among multiple complementary automated annotations), phylogenetic profiling (analysis of co-
occurrence of genes across isolates), and network context (analysis of isolate co-expression, interaction or 
functional linkage). Following putative classification of the unknown gene, bioactivity must be validated 
and characterized by experimental methods, such as microbial culture, heterologous expression of genes, 
and direct isolation of products. Functional assays (e.g. enzymatic assays, microbial co-culture to 
determine microbial inhibitory effects, host cell profiling, or assessments of in vivo host phenotype) can 
then be performed in order to investigate the gene’s putative activity. Even though this pipeline is taking 
advantage of stat-of-the-art approaches for functional assignment and validation, the chemical diversity 
associated with the gut microbiota is still poorly understood. More than 50% of the genes identified in the 
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assembled HMP stool metagenomes lack homology to characterized proteins (13), and novel functions 
are continuously uncovered even for enzymes that can be annotated (20, 21). As a result, there is an 
urgent need for biochemical studies that characterize novel enzymology of gut bacteria.  
1.3: Host-gut microbiota metabolic interactions 
The metabolic communication between the host and its gut microbiota is established via several 
ways: gut microbes biosynthesize unique molecules, process dietary components and pharmaceuticals in a 
different manner than the host, and engage in co-metabolic pathways (Figure 1.2). Possessing expanded 
chemical capabilities that have evolved to benefit the host, gut bacteria produce valuable nutrients such as 
vitamins B12, K, biotin, folate, thiamine, riboflavin, and pyridoxine (22). Symbiosis is also facilitated by 
microbial cellular components such as zwitterionic bacterial capsular polysaccharides (ZPS), which can 
modulate the host immune system (23). Through their unique metabolism of dietary components, gut 
bacteria provide the host with the ability to harvest energy from indigestible foods, such as soluble dietary 
fibers (fructans, pectin, inulin and xylans) and resistant starch. This metabolism leads to the production of 
short chain fatty acids (SCFAs) such as butyrate, propionate and acetate whose total concentrations in the 
lumen can reach 80–130 mM under physiological conditions (24). SCFAs serve as a major energy source 
(~70% of energy intake) for intestinal epithelial cells, and are implicated in various processes beneficial 
to the host, such as maintaining epithelial barrier function, regulating inflammation through G-coupled 
protein receptors, diminishing oxidative DNA damage and regulating epithelial cell proliferation (25). 
Recognition of this impact of gut microbial metabolism on the immune system opened up an entirely new 
approach to the understanding and treatment of human inflammatory disease. Ongoing research in this 
area currently focuses on isolation of other immunomodulatory molecules produced by gut microbes, and 
assessment of the beneficial effects of different probiotics and prebiotics on immune homeostasis (25). 
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Figure 1.2: Host-gut microbiota metabolic interactions. 
Gut bacteria also affect our capacity to metabolize therapeutic drugs. Since the human gut lumen 
is an anaerobic environment (8), the bacteria that inhabit it are capable of reactions opposite in nature to 
those performed by human cells (oxidative and conjugative). As a result, gut microbes were found to 
transform clinical drugs by reduction of double bonds, hydrolysis, dehydroxylation, deacetylation, and 
deconjugation of glucuronides and sulfates (26). These transformations can have a variety of 
consequences: drug activation (e.g., sulfasalazine, used for IBD treatment), inactivation (e.g., digoxin, a 
cardiac glycoside), or severe drug toxicity (e.g., the anticancer drug CPT-11) (26). The detrimental effects 
of gut microbial drug metabolism on health provided the impetus for the first selective inhibition of a 
class of nonessential protein targets from gut bacteria, the !-glucuronidases (27). These enzymes remove 
the glucuronide group from the active form of CPT-11, releasing the DNA-intercalating drug into the gut 
lumen, which results in severe diarrhea (27). Reducing the gastrointestinal damage caused by in situ gut 
bacterial reactivation of therapeutic metabolites was also successful in a study in which a microbial !-
glucuronidase inhibitor was co-administered with nonsteroidal anti-inflammatory drugs (28). Given the 
profound impact of gut bacterial metabolism on human health, a molecular understanding of host-gut 
microbe interactions holds the promise of revealing new therapeutic targets among bacterial proteins. Gut 
microbial degradation of choline represents an auspicious opportunity due to its association with disease.  
1.4: Metabolism of choline by mammalian cells 
Choline is an essential nutrient for humans, participating in important processes that extend from 
fetal development into adulthood and old age (Figure 1.2). The most concentrated sources of dietary 
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choline include liver, eggs, and wheat germ. In foods, choline is found in free or esterified forms, such as 
phosphocholine, glycerophosphocholine, phosphatidylcholine (PC), and sphingomyelin (29). PC is the 
major dietary source of choline via its hydrolysis by phospholipase enzymes (type A, C or D) (30), and 
direct ingestion of PC was shown to increase the level of choline and its metabolites in mice and in 
humans (31, 32). In the liver, the major fates of PC are secretion into bile and formation of lipoproteins 
that circulate in the plasma. Approximately 95% of biliary PC is reabsorbed by the intestine, thus 
exposing the gut microbiota to concentrations of up to 10-20 g of PC/day (33). Besides diet, up to ~15% 
of choline in the human bloodstream can also be acquired via de novo biosynthesis through the 
methylation of phosphatidylethanolamine to PC (34) (Figure 1.3). However, de novo synthesis of choline 
alone is insufficient to meet optimal intake requirements, which have been set by the Institute of Medicine 
at 425 mg/day for women and 550 mg/day for men (29). Once ingested, dietary choline is absorbed by the 
small intestine, where low affinity choline transporters mediate its uptake (35, 36). Recent studies indicate 
that choline is recycled in the liver and redistributed from kidney, lung, and intestine to the liver and brain 
when choline supply is low (29).  
 
Figure 1.3: Metabolic pathways involving choline. CTP, cytidine 5'-triphosphate; CDP, cytidine 5'-
diphosphate; PE, phosphatidylethanolamine; PC, phosphatidylcholine. Enzyme names are indicated by 
numbers: 1, choline acetyltransferase; 2, choline oxidase; 3, betaine aldehyde dehydrogenase; 4, choline 
kinase; 5, CTP:phosphocholine cytidylyltransferase; 6, CDP-choline:1,2-diacylglycerol choline phospho-
transferase; 7, phosphatidylethanolamine N-methyltransferase; 8, phospholipases (type A, C or D). 
 
The primary role of choline is in maintaining cell membrane function by its conversion via the 
Kennedy pathway in all nucleated cells to PC, the predominant phospholipid (>50%) in most mammalian 
membranes (29) (Figure 1.3). Choline can easily cross the blood-brain barrier and is converted in the 
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brain to the neurotransmitter acetylcholine, which is involved in sleep, learning, memory and muscle 
control (37). Choline is also a major dietary source of methyl groups, as it is irreversibly oxidized in the 
mitochondria of liver and kidney cells to glycine betaine, which participates in the biosynthesis of 
methionine and S-adenosyl methionine (SAM). Because of its wide-ranging role in human metabolism, 
choline is implicated in a number of diseases including non-alcoholic fatty liver disease, defects in fetal 
brain development, and cardiovascular disease (via lipoprotein secretion) (29). 
1.5: Bacterial metabolism of choline  
Due to its abundance in eukaryotic cells, choline is present in many different habitats. 
Consequently, choline can be metabolized aerobically by a diverse array of environmental bacteria 
(coryneform bacteria, Cyanobacteria) and opportunistic pathogens (Proteobacteria including 
Pseudomonas aeruginosa) (38, 39). While phosphatidylcholine is ubiquitous in eukaryotic membranes, it 
is estimated that only 15% of bacteria (primarily Actinomycetales, !- and "-Proteobacteria) can 
biosynthesize PC (40). The relative amount of PC detected in different bacterial species can vary widely, 
ranging from a few percent of the total membrane lipid (0-4% in Pseudomonas aeruginosa) to up to 73% 
in Acetobacter aceti (41). Choline is thus catabolized by bacteria under aerobic conditions for the main 
purpose of generating glycine betaine (GB), a molecule that can enhance bacterial survival in high-
salinity environments due to its osmoprotectant properties (42). In the case of pathogens such as 
Pseudomonas aeruginosa, aerobic choline utilization as a carbon and nitrogen source directly regulates 
virulence factor production. Both glycine betaine and its downstream metabolite, dimethylglycine, induce 
the transcription of hemolytic phospholipase C (plcH), which was found to be important for virulence in 
several animal models of infection (43, 44).  
The most complex bacterial uptake system for choline characterized to date is present in P. 
aeruginosa and involves four transporters that differ in their contributions to growth and osmoprotection 
in various salt concentrations. CbcXVW and BetT1 contribute most under hypo- and iso-osmolar 
conditions, whereas BetT2 and BetT3 appear to be the primary transporters under hyperosmolar 
conditions (45). The metabolic intermediates of aerobic choline catabolism are conserved among the 
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different bacterial species, and their biosynthesis requires O2 to proceed. Interestingly, members of at 
least two different enzyme families can carry out each chemical conversion (Figure 1.4.A). The oxidation 
of choline to form GB can be catalyzed either by monomeric choline oxidases (flavin-dependent) or by 
the concerted action of an oxidase and an aldehyde dehydrogenase (pyrroloquinoline quinone-dependent) 
through the intermediacy of betaine aldehyde (46). The demethylation of GB to dimethylglycine can 
proceed through a zinc-dependent betaine-homocysteine methyltransferase (in Cyanobacteria) or a 
Rieske-type dioxygenase (in Proteobacteria) (47). Further demethylation to sarcosine and glycine is 
catalyzed by flavin-dependent oxidases that exist either as single-subunit (Arthrobacter, Bacillus), or 
multi-subunit (Pseudomonads) enzymes (48, 49). Due to the contribution of choline catabolism to 
bacterial pathogenesis in organisms such P. aeruginosa, current efforts are aimed at developing small 
molecule inhibitors that would be useful tools for studying this pathway in clinical and environmental 
isolates and potential new therapeutics (50).  
 
Figure 1.4: Choline catabolic pathways in (A) aerobic and (B) anaerobic bacteria. 
Under strictly anaerobic conditions, certain environmental (51, 52), human-associated (53), and 
vertebrate-associated (54) bacteria process choline in a different manner, by converting it to 
trimethylamine (TMA) and acetaldehyde. This metabolic pathway was first reported in 1910 (55), and 
subsequently found to exist in both facultative and obligate anaerobes, such as Desulfovibrio 
desulfuricans, Aerobacter aerogenes, Shigella alkalescens, Proteus mirabilis, and Streptococcus sanguis 
(56-59). By generating acetaldehyde, anaerobic choline catabolism allows bacteria to utilize choline as a 
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carbon source (56), while TMA can be used as a substrate for methanogenesis by Archaea within both the 
gastrointestinal tract of ruminants (51) and marine sediments (52). In the human body, most of the TMA 
produced in the gut is transported via the portal circulation to the liver, where flavin-dependent 
monooxygenase enzymes (FMOs) (particularly FMO3), which oxidize it to the water-soluble metabolite 
trimethylamine N-oxide (TMAO) (Figure 1.5). Upon entering circulation, TMAO is predominantly 
excreted by the kidneys into urine (60). Although TMA has been considered a normal constituent of 
human urine since the beginning of the past century, the microbial origin of the metabolite was not 
conclusively established until 1992 (54).  
 
Figure 1.5: Choline metabolism to TMAO within the human body. 
 The pathway for anaerobic bacterial choline metabolism was first studied by Hayward and 
Stadtman in 1959 (56). Using mud from North Carolina, they isolated a species of Vibrio (later 
reclassified as Desulfovibrio desulfuricans) that was able to ferment choline anaerobically and produce 
TMA. Their subsequent reports revealed that the first step in choline catabolism is a C–N bond cleavage 
reaction, and that the resulting co-product acetaldehyde is converted into ethanol and acetate for 
utilization as a carbon source (61). Using bacterial lysates able to convert choline into TMA (from 
Desulfovibrio, Clostridia, Proteus and Streptococcus), several studies (56-59) attempted to identify the 
enzymes responsible for C–N cleavage via protein purification, but were unsuccessful. However, these 
efforts reached some common conclusions. For instance, conversion of choline to TMA was found to 
require both particulate and soluble protein fractions, potassium ions and a bound divalent cation, such as 
Fe2+. This activity was improved by conducting enzymatic assays under a nitrogen atmosphere and by the 
addition of sulfhydryl-reducing agents, but was lost upon all attempts at protein purification. In addition, 
the reaction was consistently found to be independent of the presence of vitamin B12. This result was quite 
unexpected because ethanolamine ammonia-lyase, a microbial enzyme that catalyzes a chemically similar 
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reaction to choline cleavage (ethanolamine conversion into ammonia and acetaldehyde), was found to 
utilize vitamin B12 as cofactor (62). Thus, the genetic and biochemical basis of anaerobic choline 
metabolism remained a mystery prior to our work.  
1.6: Health consequences of gut microbial metabolism of choline  
Multiple human diseases are associated with gut microbial TMA production. Studies in humans 
revealed that the most significant dietary precursors of this microbial metabolite are choline, L-carnitine 
(primarily from red meat), and TMAO (primarily from fish) (31, 63, 64). The metabolic disorder 
trimethylaminuria is caused by functional defects in FMO3, the liver enzyme responsible for the 
detoxification and elimination of TMA through oxidation to the odorless TMAO (60). This genetic 
condition is inherited in an autosomal recessive manner as a consequence of mutations in the FMO3 gene 
(65). While the accumulation of TMA is not known to have a deleterious effect on physical health, it 
often causes social and psychological debilitation due to TMA’s distinctive odor of decaying fish being 
present in urine, sweat or breath, saliva, and other bodily fluids (66). Since many people suffering from 
trimethylaminuria remain undiagnosed for long periods of time, the incidence of this disorder is not 
precisely known. However, genetic studies have estimated the incidence of heterozygous carriers to range 
from 0.5% to 11% depending on the ethnicity examined, with overrepresentation among females of 
African descent (67, 68). Approaches for managing TMA accumulation include restricting the intake of 
choline-containing foods and marine fish, ingesting activated charcoal that can absorb TMA, intermittent 
use of antibiotics to reduce gut bacterial load, and personal hygienic measures (e.g, low pH soaps, lotions) 
(67). However, these treatment options are not universally efficacious for trimethylaminuria.  
Low-choline diets are associated with health problems in humans and in mouse models, including 
NAFLD, neural tube defects, hepatic cancer, and an increased risk of breast cancer (29). Since NAFLD 
affects ~ 30% of the US population and the mechanisms underlying this condition are incompletely 
understood (69), several studies in mice and humans have investigated the contribution of gut microbial 
metabolism to choline deficiency as it relates to this disorder (70, 71). Using 1H NMR spectroscopy-based 
plasma and urine metabolomics in a mouse model susceptible to fatty liver disease and insulin resistance, 
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Dumas et al. described a gut microbiota-mediated mechanism underlying the development of fatty liver. 
Feeding a high-fat diet to mice that are genetically predisposed to NAFLD resulted in low plasma 
phosphatidylcholine concentrations, mimicking choline deficiency (70). The authors concluded that host 
genetics could lead to a gut microbiota abundant in choline-utilizing bacteria that ultimately reduce 
choline bioavailability. More recently, Le Roy et al. demonstrated that NAFLD is transmissible to germ-
free mice via microbiota transplant (72). In a different report, Spencer et al. present the results of a 2-
month inpatient study of 15 female subjects who were placed on well-controlled diets in which choline 
levels were manipulated. Taxonomic profiling was used to characterize gut microbiota composition in 
stool samples (71). Even though each individual’s gut microbial community remained distinct over the 
course of the study, restricted availability of dietary choline was correlated with increased levels of 
Gammaproteobacteria and Erysipelotrichi, as well as increases in the amount of liver fat (71). By 
identifying bacterial biomarkers of fatty liver disease resulting from choline deficiency, this study further 
contributed to the accumulating evidence that gastrointestinal microbes have a role in metabolic disorders.  
 An additional, unexpected connection between TMA and human health is the recent association 
of high levels of TMAO in plasma and urine with susceptibility to both chronic kidney disease and 
cardiovascular disease (31, 73). In a study of over 500 patients with chronic kidney disease and 3,000 
controls, TMAO levels were found to predict future mortality risk after adjustment for traditional risk 
factors (73). In addition, dietary choline (1% wt/wt of chow) and TMAO (0.12% wt/wt of chow) exposure 
appeared to contribute to renal injury and dysfunction in conventionally housed mice (with intact gut 
microbiota) (73). These results point towards a direct involvement of TMAO in kidney disease 
development and progression, but the molecular details of this involvement of are still unknown.  
The correlation between TMAO levels in plasma and urine and risk for cardiovascular disease 
was discovered in an untargeted metabolomics study of almost 2,000 American subjects undergoing 
elective cardiac evaluation, and it was further supported by a study of over 4,000 subjects undergoing 
elective coronary angiography (31, 74). TMAO levels were found to predict the risk of major adverse 
cardiovascular events independently of traditional cardiovascular risk factors, renal function, and 
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medication use (74). Hazen and co-workers conducted several studies in which deuterated PC (believed to 
be the main source of choline in our diet (32)) and L-carnitine were fed to both mice and humans, and the 
gut microbiota was suppressed through the use of antibiotics. Their results confirmed that gut microbes 
play an obligatory role in generating TMAO from these trimethylammonium-containing nutrients, and 
revealed that TMAO can directly contribute to aortic plaque formation in mice (31, 63, 74). However, 
these conclusions remain controversial, as recent studies of over 10,000 Japanese men and women (75), 
and over 300 Austrian patients (76) failed to observe correlations between either choline intake or TMAO 
levels and cardiovascular disease mortality risk. It is likely that complex interactions between diet, host 
genetics and gut microbes have lead to these discrepancies. Consequently, it is of great importance to 
determine the molecular mechanisms by which TMAO influences all these host processes.  
Known to function as osmolyte in marine fish and as small molecule chaperone for protein 
folding, TMAO was believed until recently to be devoid of biological activity in humans (77, 78). No 
molecular targets are known for TMAO within the human body and the conclusions drawn from recent 
experiments with mice disagree regarding the involvement of this small molecule in atherosclerotic 
plaque development (31, 79). Plaque lesions are typically initiated by foam cell formation, which is 
characterized by the engorgement of arterial macrophages by oxidized low-density lipoprotein (LDL) 
cholesterol (80). One study that supplemented the diet of female apolipoprotein E–null (ApoE-/-) 
(atherosclerosis prone) mice with a single high dose of TMAO (0.12% wt/wt of chow) observed enhanced 
macrophage foam cell formation in both the artery wall and the peritoneal cavity in 3 out of 11 mice (31). 
While investigating the reasons behind this effect, researchers observed that protein surface levels of 
previously implicated scavenger receptors (CD36 and SR-A1) were augmented on macrophages involved 
in cholesterol accumulation and foam cell formation (31). TMAO also elicited significant reductions in 
reverse cholesterol transport and altered the bile acid pool size and composition in this mouse model (63). 
A follow-up study in mice and human cell lines (primary aortic endothelial cells and vascular smooth 
muscle cells) showed that TMAO can promote recruitment of activated leukocytes to endothelial cells and 
induce inflammation by activating the mitogen-activated protein kinase (MAPK) and nuclear factor kB 
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(NF-kB) signaling cascade (81). Recent findings also from Hazen and co-workers have further 
strengthened the connection between TMAO and cardiovascular disease by determining that TMAO has a 
direct contribution to thrombosis by enhancing platelet aggregation in mice fed TMAO- or choline-
supplemented diets (82). In addition, treating washed platelets isolated from mice with TMAO was found 
to alter inositol-1,4,5-triphosophate (IP3) signaling, and result in Ca2+ release from intracellular stores, 
thus increasing platelet responsiveness (82). Despite this novel insight into the connection between 
TMAO and cardiovascular disease, the molecular targets or receptors for TMAO still remain unknown. 
A different study with apolipoprotein E–null male mice transfected with human cholesteryl ester 
transfer protein (hCETP) determined that TMAO and L-carnitine are likely to provide a protective effect 
on atherosclerosis development, and do not impact plasma lipid and lipoprotein levels (79). This mouse 
strain could be a better model for atherosclerosis because CETP is a key enzyme in reverse cholesterol 
transport, transferring cholesterol ester from high-density lipoprotein (HDL) to LDL cholesterol (83). The 
use of male mice also avoided the variability and high expression levels of FMO isoforms reported in 
female mice. Additionally, this study examined the dose-dependent effect of TMAO on mouse 
macrophages, and found that TMAO does not contribute to foam cell formation, even at concentrations 
10-fold higher than the reported human plasma maximum concentration (79). The differences in diet of 
this mouse model (atherogenic, with L-carnitine amounts in the range seen in dietary supplements) 
compared to the diet of mice used by Hazen and co-workers (normal chow supplemented with 5-fold 
higher levels of L-carnitine) (63) might account for the discrepancy in their results. Nonetheless, follow-
up studies are needed to verify the accuracy of the claims made by either group of researchers.     
A recent investigation of TMAO-promoted atherosclerosis in multiple strains of inbred mice 
revealed that the levels of this metabolite explain 11% of the variation in the disease, and that FMO3 
expression is induced by dietary bile acids via a mechanism involving the farnesoid X receptor (FXR), a 
bile acid-activated nuclear receptor (84). A mechanistic link between FMO3, cholesterol, and bile acid 
metabolism recently emerged during a transcriptional profiling study in mouse models of altered 
cholesterol transport.  Knockdown of FMO3 was found to reorganize whole-body cholesterol balance and 
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exacerbate downstream inflammatory responses in the liver (85).  Another study of FMO3 knockdown in 
insulin-resistant mice concluded that FMO3 is required for the expression of a central node for metabolic 
control, transcription factor FoxO1, and that it is increased in obese/insulin-resistant humans, thus 
confirming the central role of this enzyme in metabolic dysfunction (86). Despite the controversy 
regarding the direct effect of TMAO on aortic plaque development, these studies have opened the 
possibility that FMO3 could have regulatory functions distinct from its enzymatic activity. It also seems 
likely that TMAO levels might influence FMO3 regulation, which highlights the importance of studying 
TMAO formation within the human body.   
1.7: Glycyl radical enzymes play key roles in anaerobic microbial metabolism  
 
The glycyl radical enzyme (GRE) family has emerged as an important class of catalysts for 
anaerobic microorganisms from the environment as well as from the human body. These biocatalysts 
perform chemically difficult reactions through the utilization of a glycine-centered radical generated by a 
separate activating enzyme (AE or activase), a [4Fe-4S] cluster containing member of the radical S-
adenosylmethionine (SAM or AdoMet) protein family (87). GREs play central roles in anoxic microbial 
metabolic pathways, such as nucleotide reduction (class III ribonucleotide reductase (RNR)), carbon-
source utilization (pyruvate formate-lyase (PFL), benzylsuccinate synthase (BSS), glycerol dehydratase 
(GDH)) or biosynthesis of bacteriostatic compounds (4-hydroxyphenylacetate decarboxylase (HPD)) 
(Figure 1.6). The impact of GRE-catalyzed reactions on human health has only recently begun to be 
appreciated. Several metagenomic studies have found GREs to be among the most abundant protein 
families in the human gut microbiota and strongly overrepresented in this environment relative to other 
microbial habitats (88, 89). These observations are also supported by proteomic data revealing GREs to 
be highly abundant in proteomes from human intestinal samples (90).  
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Figure 1.6: Functionally characterized GRE classes. Pi, phosphate; A, adenine; U, uracil; G, guanine, C, 
cytosine.  
 
As of 2016, six classes of GREs have been functionally verified and biochemically characterized 
(Figure 1.6): 
Pyruvate formate-lyase (PFL, EC 2.3.1.54) was the first enzyme found to contain a glycyl 
radical via electron paramagnetic resonance spectroscopy (EPR) (91, 92) by the Knappe group at 
Heidelberg University. PFL is one of the key enzymes in prokaryotic glycolysis. It catalyzes the 
homolytic C–C bond cleavage of pyruvate to produce formate and acetyl-CoA, two central metabolites 
that can be used in biosynthesis or to generate ATP, the energy currency of the cell (93). One of the most 
studied members of the GRE superfamily, PFL from E. coli was the first GRE found to be overexpressed 
and post-translationally modified by the activating enzyme (PFL-AE) only under anaerobic conditions 
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(94). Although the E. coli genome encodes another !-ketoacid formate lyase that can catalyze the same 
reaction (TdcE), knockout of the PFL gene resulted in severe anaerobic growth impairment (95). In line 
with these results, the PFL-catalyzed pyruvate cleavage by the non-recombinant enzyme is very efficient, 
with kcat values of 1100 s-1 for the forward reaction, and 260 s-1 for the reverse reaction, with the 
equilibrium favoring the forward step (Keq ~ 750) (96).  
Class III or anaerobic ribonucleotide reductase (class III RNR, EC 1.17.4.2) catalyzes the 
anaerobic reduction of ribonucleotide triphosphates (NTPs) to 2’-deoxynucleotides (dNTPs), the building 
blocks of DNA, with the oxidation of either formate (97) or an active site thiol pair (98). Ribonucleotide 
reduction is the only known pathway for de novo synthesis of deoxyribonucleotides and it is required in 
all living organisms. This reaction is accomplished by three different classes of ribonucleotide reductases 
hypothesized to have evolved from the same common ancestor and diversified depending on the presence 
of oxygen in the surrounding environment (99). Even though they rely on different cofactors, all RNRs 
generate an active site thiyl radical that initiates the reduction chemistry. The class I RNRs use cofactors 
resulting from the reaction of reduced metals (Fe, Mn, and Fe/Mn) with O2 and are present only in aerobic 
organisms, whereas the class II RNRs use adenosylcobalamin in an O2-independent reaction and are 
present in both aerobes and anaerobes (100). The class III RNRs are distributed throughout facultative 
and obligate anaerobic bacteria and are also found in some archaea, primarily strictly anaerobic 
methanogens (98). The activity of an O2-sensitive RNR was first detected in extracts of the strictly 
anaerobic methanogenic archaeon, Methanobacterium marburgensis (101) and later found in E. coli 
(102). Similarities between PFL and class III RNR were noted soon after these discoveries, and 
investigations of the mechanism of glycyl radical generation and activity proceeded in parallel for these 
two classes of GREs (102). The most well characterized class III RNRs to date are from Escherichia coli, 
Lactococcus lactis, Thermotoga maritima, and T4 bacteriophage.  
X-succinate synthases (XSSs) are a class of GREs responsible for functionalizing a variety of 
hydrocarbons (toluene, 2-methylnaphthalene, cresols, n-alkanes) via addition of a terminal or subterminal 
aliphatic C–H bond across the double bond of fumarate, initiating the decontamination of hydrocarbon-
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polluted environments (103). The resulting succinate derivatives further undergo thioesterification, 
carbon-skeleton rearrangement (or ring cleavage), decarboxylation and beta-oxidation, resulting in the 
production of either acetate or propionate, depending on whether the produced fatty acids are even or odd 
numbered (104). The most well studied member of this class is benzylsuccinate synthase (BSS, EC 
4.1.99.11) from Thauera aromatica, which catalyzes the addition of toluene to fumarate, generating 
benzylsuccinate (105, 106). BSS is one of a few GREs composed of multiple subunits, as it was isolated 
as a stable (!"#)2 heterohexamer. Biochemical and structural studied revealed that the !-subunit contains 
the glycyl radical and is responsible for the catalytic activity, and binding of toluene and fumarate, 
whereas the accessory subunits " and # display folds related to high potential iron–sulfur proteins, and 
appear to play redox and structural roles (105). BSS# binds distally to the active site and buries a 
hydrophobic region of BSS!, while BSS" is proposed to modulate the conformational dynamics required 
for activity by binding to a hydrophilic surface of BSS! proximal to the active site (105). Despite the 
successful purification and crystallization of the BSS complex, BSS-AE has resisted purification attempts 
and the activity has not yet been reconstituted and studied in vitro. XSS activity has been observed in a 
variety of anaerobic phototrophic bacteria, as well as in metal-ion-reducing Geobacter metalireducens 
and in syntrophic communities of methanogenic archaea and sulfate-reducing bacteria (107-109), thus 
underscoring the importance of these metabolic pathways for bacterial survival in hydrocarbon-rich 
environments. 
4-Hydroxyphenylacetate decarboxylase (HPD, EC 4.1.1.83) is primarily present in commensal 
and pathogenic Clostridia and catalyzes the last step in the biosynthesis of the bacteriostatic metabolite p-
cresol (4-methylphenol), decarboxylation of 4-hydroxyphenylacetate, which is derived from tyrosine 
(110-112). P-cresol production by Clostridium difficile might contribute to virulence, since these bacteria 
can withstand 35-fold greater concentrations of p-cresol than other strains (113). Structural studies of 
HPD revealed that, similarly to BSS, HPD is composed of a main catalytic subunit (!) harboring the 
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glycyl radical, and a small subunit (!) that binds two [4Fe-4S] clusters and is believed to be involved in 
regulating the oligomeric state and activity of the heterooctameric complex ("!)4.  
 Glycerol dehydratase (GDH, EC 4.2.1.30) catalyzes the first step in glycerol utilization as a 
carbon source by Clostridium butyricum, dehydrating glycerol to 3-hydroxypropionaldehyde, which can 
be further reduced by aldehyde dehydrogenases from the organism to the valuable polyester precursor 
1,3-propanediol (114, 115). Recent structural and biochemical efforts have primarily focused on 
characterizing GDH from Clostridium butyricum (115, 116), but other diol dehydrating GREs have been 
uncovered. A transcriptional profiling study found that a GRE homologous to GDH mediates the 
dehydration of propanediol during growth of human-associated gut bacteria such as Roseburia 
inulinivorans on host-derived fucose (117). This metabolic pathway eventually leads to the production of 
propionate, a short chain fatty acid that is beneficial for the host (1). A second GRE-containing gene 
cluster also upregulated in the presence of L-fucose was found in the environmental organism Clostridium 
phytofermentans (118), but the distribution of GREs from this class has not been yet investigated.  
Choline TMA-lyase (CutC, EC 4.3.99.4) catalyzes choline cleavage to trimethylamine and 
acetaldehyde in bacteria from the human gut and the environment. Its discovery, characterization, 
distribution, and inhibition will be described in this thesis.   
1.8: Common structural characteristics of glycyl radical enzymes  
 
It is believed that the selection of a simple glycine residue as a radical storage element represents 
an ancient strategy in the evolution of life (99, 119). The conversion of RNA- to DNA-based life was 
likely performed by a common ancestor of the three classes of ribonucleotide reductase, most closely 
related to class III RNR (120). Bioinformatic analyses suggest that this class is the most primitive RNR, 
while the other types of RNRs arose by duplication followed by divergence, as they adapted to increasing 
levels of oxygen in the Earth’s atmosphere. (120). Since PFL is a key enzyme in anaerobic metabolism of 
glucose, it likely appeared early in the evolution of life, perhaps even predating RNR (119). Interestingly, 
formate, the product of the PFL reaction, is the reductant used by many members of the class III RNR. 
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The similarities in chemistry and structural features between these two enzymes despite lower sequence 
homology (99) thus suggest that PFL and class III RNRs are evolutionarily related, but have undergone 
divergent evolution.  
Crystallographic and biochemical studies of GREs such as PFL, BSS, HPD, and class III RNR 
have revealed that GREs conserved structural features that facilitate catalysis (87). Their common barrel 
architecture has been named the “GRE fold”: a ten-stranded !/" barrel with two loops containing catalytic 
residues inserted into the center of the barrel (Figure 1.7.A).  It is hypothesized that this structural motif 
shields radicals generated in the active site from solvent, similar to the case of adenosylcobalamin 
(AdoCbl) enzymes or radical SAM enzymes (121, 122). The glycine residue that is converted into the 
glycyl radical is close to the C-terminus (the glycyl radical domain) and is part of a loop (Gly loop) 
comprised of a highly conserved stretch of amino acids (RVXG). A second loop (Cys loop) containing a 
conserved Cys residue is located opposite to the Gly loop and is deeply buried in the barrel such that the 
two residues can contact each other and participate in a radical relay (Figure 1.7.B). The active site of 
each GRE is typically located on or in the vicinity of the Cys loop, such that a direct interaction could be 
established between the Cys residue and the substrate (87).  
 
Figure 1.7: (A) General ten-stranded !/" barrel architecture of glycyl radical enzymes (the structure 
shown here is that of E. coli PFL, PDB ID: 2PFL). (B) The Gly and Cys loops contain the Gly residue 
used for radical storage and the Cys residue used for initiating catalysis. Shown is a superimposition of 
the structures for E. coli PFL (PDB ID: 2PFL) and C. butyricum glycerol dehydratase (PDB ID: 1R9D).     
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1.9: Mechanistic features of glycyl radical enzymes 
The initial activation step of all GREs involves the installation of the glycyl radical by the 
activating enzyme (AE) (123). This activation process is thought to be specific for each functional class 
of GREs, since GREs and AEs are typically encoded adjacently in microbial genomes. To the best of our 
knowledge, an AE from one class can only activate GREs possessing the same activity as its native 
partner. All AEs are members of the radical SAM enzyme superfamily, and they utilize a reduced [4Fe-
4S]+ cluster to convert SAM into the 5’-deoxyadenosyl radical (5’-dA•) (Figure 1.8). Due to the extreme 
oxygen sensitivity of the [4Fe-4S] cluster and the instability of many AEs that have incomplete clusters, it 
is very challenging to express these enzymes in heterologous hosts and to reconstitute their clusters. The 
only AE crystal structure available is that of PFL-AE, which is also the most extensively characterized 
AE (124). Similar to other radical SAM enzymes, the active site of PFL-AE contains three Cys residues 
in a conserved CX3CX2C motif that coordinate a [4Fe-4S] cluster. The Fe atom of the cluster that does not 
interact directly with the protein is instead coordinated by the amino nitrogen and carboxyl oxygen of 
SAM in a square-pyramidal geometry that allows the bottom of the pyramid to be occupied by the 
sulfonium group of SAM. This arrangement allows inner sphere electron transfer between the reduced 
[4Fe-4S] cluster in the +1 oxidation state to the C–S antibonding !" orbital of SAM (125). The electron 
transfer lowers the bond dissociation energy (BDE) of the Cadenosine–S in SAM (~60 kcal/mol prior to 
electron transfer) such that homolytic bond cleavage can occur to form 5’-dA• and methionine (126). The 
radical 5’-dA• is extremely reactive (C–H BDE ~99 kcal/mol), and thus capable of abstracting the C–H 
bond of the GRE active site glycine (C–H BDE ~79.3 kcal/mol) (Figure 1.8) (127).  
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Figure 1.8: General scheme for activation of a glycyl radical enzyme by a GRE activating enzyme. SAM: 
S-adenosyl methionine, 5’-dA: 5’-deoxyadenosine. 
 
The glycyl radical is stabilized via the captodative effect stemming from its adjacency to the 
electron donating amide nitrogen and electron withdrawing carbonyl, and is believed to be the “storage 
form” of the radical (110). Early EPR studies of PFL performed by the Knappe group determined that the 
radical in activated PFL is present on an sp2-hybridized !-carbon atom of a specific glycine residue (91, 
92). When handled under anaerobic conditions, all GREs display a similar EPR signal, a doublet with 
hyperfine coupling of 1.4–1.5 mT (due to the interaction of the glycyl radical with the nucleus of the !-
hydrogen), centered at g = 2.003–2.004 (92, 111, 128-130). This specific EPR signal allows the 
quantification of the extent of activation in vitro (thus enabling kinetic measurements), as well as the 
detection of GRE activity in whole cells overexpressing the enzyme during growth on a specific substrate, 
as in the case of methylpentylsuccinate synthase (131). Under aerobic conditions, the glycyl radical of 
PFL was found to react with oxygen to form !-hydroxyglycine, which leads to the irreversible cleavage 
of the polypeptide backbone (132). This susceptibility of the glycyl radical to irreversible damage by 
oxygen implies that activated GREs need to be handled under strictly anaerobic conditions, and explains 
why GREs are not present in obligate aerobic organisms. Interestingly, facultative anaerobic bacteria such 
as E. coli contain a small protein similar in sequence to the glycyl radical domain of PFL (YfiD), which 
was found to bind oxygen damaged PFL and rescue its activity upon activation by PFL-AE (133). It is 
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currently not known whether other glycyl radical enzymes also utilize this “spare part” strategy. However, 
as more classes of GREs are functionally characterized, other strategies of preventing or mitigating 
oxidative damage are likely to be uncovered.     
Even though a crystal structure of a GRE-AE complex has not been yet elucidated, Vey and 
coworkers were able to crystallize PFL-AE bound to a small peptide containing the Gly loop sequence 
conserved in all GREs (124). Interestingly, the peptide is bound such that the Gly residue was adjacent 
(4.1 Å) to SAM (Figure 1.9). In this conformation, the 5’-dA• resulting from SAM cleavage would be 
perfectly poised to abstract the pro-S hydrogen of the Gly residue in accordance with previous 
experiments (134). In all crystal structures of GREs determined to date, this Gly residue is deeply buried 
8-20 Å from the surface of the protein (87). This paradox has led to a model of activation for PFL in 
which the Gly loop undergoes a conformational change such that it can contact the AE. The model was 
proposed in a study characterizing mixtures of PFL and PFL-AE using circular dichroism (CD) 
spectroscopy and EPR, which concluded that the presence of the AE induces an “open” conformation of 
PFL that makes the glycyl radical more susceptible to quenching by external reductants (dithiothreitol) 
(135). For all the GREs characterized thus far, the maximum extent of activation obtained in vitro is 0.5 
moles of glycyl radical/mol of polypeptide (129, 136). Since most GREs exist as dimeric proteins (87), it 
is hypothesized that activation of one monomer precludes the activation of the other through a 
conformational change, despite the ~70 Å distance between the two glycyl radical domains. Many 
questions thus remain concerning GRE activation, particularly regarding the enzyme’s strategy for 
stabilizing the glycyl radical, the stoichiometry of the process, and its regulation.  
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Figure 1.9: Crystal structure of pyruvate formate-lyase (PDB ID: 3CB8) activating enzyme in complex 
with SAM (green) and a Gly loop peptide (pink and blue) that mimics the glycyl radical domain of PFL. 
 
 In all GREs, the glycyl radical is believed to function as a site of radical storage. Structural and 
mechanistic studies of GREs led to the hypothesis that upon substrate binding, the glycyl radical 
generates a thiyl radical on the cysteine residue of the Cys loop (87). Even though this thiyl radical has 
not yet been directly observed by spectroscopic methods, it is believed to be readily accessible, since the 
S–H BDE was calculated at ~81.7 kcal/mol (137). In addition, the protein might modulate the reactivity 
of the glycyl radical via conformational control to ensure that thiyl radical formation is not rate-
determining (137). The conservation of these catalytic Gly and Cys residues in all known GREs and their 
close proximity in all elucidated GRE structures support a general mechanism for GRE catalysis: 
substrate binding to the activated GRE could induce the generation of the thiyl radical, which would 
initiate the radical reaction and would be regenerated upon product formation (Figure 1.10).  
 
26 
 
Figure 1.10: Shared mechanistic hypothesis for GRE function.  
 
 Mechanistic and spectroscopic studies of GRE-catalyzed reactions have proven very challenging 
to perform, since these reactions are extremely oxygen sensitive and tend to proceed very quickly. As a 
result, researchers have proposed mechanisms for the function of each class of GREs based on the crystal 
structures of unactivated GREs and subsequent computational studies (Figure 1.11-1.15). In the case of 
PFL (Figure 1.11), two Cys residues are present in the active site and were found to participate in the 
reaction (138). Upon conversion of Cys419 (from E. coli PFL) into a thiyl radical by hydrogen atom 
abstraction by the glycyl radical on Gly734, the adjacent Cys residue, Cys418, would be converted into a 
thiyl radical. This radical species could interact with pyruvate to form a tetrahedral intermediate that 
would yield a formyl radical and acylated Cys418 upon collapsing. The formyl radical could regenerate 
the thiyl radical at Cys419, which would convert CoA into a thiyl radical. This species could interact with 
the acylated Cys418 to form a thiyl radical at this residue and acetyl-CoA. For class III RNR, 
ribonucleotide reduction would be initiated by formation of a 3’-nucleotide radical by the active site thiyl 
radical (98) (Figure 1.12). Loss of water to form a 3’-ketyl radical could be facilitated by formate (139), 
and reduction of this species to the 3’-keto-deoxy-nucleotide was found to be accompanied by the 
formation of a thiosulfuranyl radical between the bottom face cysteine thiyl radical and a methionine 
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residue (140). The thiosulfuranyl radical is proposed to convert formate into a radical species that could 
participate in the reduction of the 3’-keto-deoxy-nucleotide via proton-coupled electron transfer using an 
unknown source of protons (98). Based on the crystal structure of BSS in complex with its substrates, it is 
believed that the reaction catalyzed by this enzyme would be initiated by H-atom abstraction from toluene 
to generate a benzyl radical (106) (Figure 1.13). This resulting species could then react with fumarate to 
form a benzylsuccinyl radical intermediate, which would regenerate the thiyl radical to produce (R)-
benzylsuccinate. A computational study of the HPD mechanism proposed that the reaction would be 
initiated through radical transfer between the catalytic cysteine and the substrate carboxylic group and a 
proton transfer from the hydroxyl group of the substrate to a glutamate residue (141) (Figure 1.14). 
Decarboxylation could then be coupled with proton transfer from a glutamate residue to the phenolic 
hydroxyl group to afford a p-hydroxybenzyl radical, which would regenerate the thiyl radical. In the case 
of GDH, a computational study proposed that glycerol dehydration could occur directly from a substrate-
based radical with the assistance of a general base (Glu) and a general acid (His) present in the active site 
(Figure 1.15). The resulting product radical would then abstract a hydrogen atom from the active site Cys 
to reform the thiyl radical. It is thus apparent that for each class of GREs, active site residues are perfectly 
poised to control the chemistry of each radical reaction.  
 
Figure 1.11: Proposed mechanism for the radical reaction of PFL. Amino acids are numbered 
corresponding to PFL from E. coli.  
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Figure 1.12: Proposed mechanism for the radical reaction of class III RNR. R = di- or triphosphate, N = 
nucleobase. 
 
 
Figure 1.13: Proposed mechanism for the radical reaction of BSS.  
 
 
Figure 1.14: Proposed mechanism for the radical reaction of HPD. Amino acids are numbered 
corresponding to HPD from Clostridium scatologenes.  
 
 
Figure 1.15: Proposed mechanism for the radical reaction of GDH.  
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Bioinformatic analyses of GREs in sequenced genomes of both obligate and facultative anaerobic 
bacteria performed by Lehtiö and Goldman (20) and by Balskus group members (manuscript in 
preparation) have revealed many GREs of unknown function, thus highlighting the functional diversity of 
this enzyme superfamily. Given the prevalence of GREs in the human gut (88) and their susceptibility to 
misannotation due to their high amino acid sequence similarity (with the exception of class III RNR) (20), 
there is a great need to understand the molecular basis for the activities of these enzymes. This knowledge 
will enable predictions of the types of metabolism performed by uncharacterized GREs, helping to 
prioritize them for future study. The identification of specific conserved residues involved in substrate 
binding and catalysis will also facilitate future bioinformatic analyses aimed at characterizing the 
distribution of specific GREs in microbial genomes and metagenomes. 
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Chapter 2: Discovery and validation of an anaerobic microbial choline utilization gene clustera 
 
 
2.1: Introduction 
 
As described in Chapter 1, choline and trimethylamine (TMA) are important nitrogen-containing 
metabolites that perform fundamental roles in biological pathways throughout nature. Choline is an 
essential nutrient for higher organisms, including humans, contributing to cell membrane function, methyl 
transfer events, and neurotransmission (1). The volatile odorant TMA is used as a carbon source by 
bacteria, is a precursor to the marine osmolyte trimethylamine N-oxide (TMAO), and is converted to the 
powerful greenhouse gas methane by methanogenic archaea (2-4). The sole biochemical reaction directly 
connecting these two small molecules is the metabolism of choline to TMA by anaerobic microorganisms 
(Figure 2.1). As detailed in Chapter 1, this chemical transformation plays a significant role in many 
biological systems and has a profound effect on human health.  
 
Figure 2.1: Generation of trimethylamine (TMA) from choline by anaerobic microbes and its subsequent 
processing. 
 
 Despite long-standing interest in this microbial metabolic pathway and its broad relevance to 
humans, nothing was known about its underlying genetics or biochemical mechanism prior to our work, 
as the enzymes responsible for anaerobic choline utilization had not been identified. This chapter 
describes our discovery of a gene cluster involved in anaerobic choline cleavage (cut, choline utilization 
cluster), and the identification of the enzymes responsible for TMA formation. Through multiple 
approaches, we demonstrate that the pathway encoded by the cut genes is present and functional in a !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
a  This chapter is an unofficial adaptation of the following articles: Craciun S, Balskus EP (2012) 
Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme. Proc Natl Acad Sci 
USA 109(52):21307–21312, and Martínez-del Campo A, Bodea S, Hamer HA, Marks JA, Haiser HJ, 
Turnbaugh PJ, Balskus EP (2015) Characterization and detection of a widely distributed gene cluster that 
predicts anaerobic choline utilization by human gut bacteria. MBio 6(2):e00042-15.  !
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diverse range of human gut bacteria. We anticipate that our discovery and analyses of the cut gene cluster 
will aid efforts to further understand the role of choline metabolism in the human gut microbiota and its 
link to disease. 
2.2: Results and discussion 
2.2.1: Discovery of a choline utilization gene cluster in Desulfovibrio desulfuricans  
Our strategy to discover a choline utilization gene cluster relied upon the existence of a 
sequenced bacterial species previously found to convert choline into TMA and acetaldehyde under 
anaerobic conditions (5), and the fact that bacteria often tend to co-localize genes encoding proteins 
involved in a particular metabolic pathway into gene clusters. Our search for candidate genes involved in 
microbial choline degradation was also guided by the hypothesis that some of the enzymatic 
transformations in this pathway resemble those used in catabolism of the structurally related metabolite 
ethanolamine (Figure 2.2). Bacteria from the human gut and other environments utilize ethanolamine as a 
carbon and nitrogen source by cleaving its C–N bond to afford acetaldehyde and ammonia. The proteins 
required for ethanolamine utilization are encoded by the eut gene cluster, which has been studied 
extensively in the past 50 years in pathogenic strains of Salmonella enterica and Escherichia coli (6). A 
study of a mouse model of intestinal infection showed that ethanolamine could provide a significant 
growth advantage to Salmonella enterica in the lumen of the inflamed intestine, when its utilization as a 
carbon source is coupled with the use of host-derived tetrathionate as a terminal electron acceptor (7). 
Biochemical studies have determined that the C–N bond cleavage of ethanolamine is performed by 
ethanolamine ammonia-lyase (EutBC), a vitamin B12-dependent enzyme that generates ammonia and 
acetaldehyde (8). The acetaldehyde produced in this initial step is further processed by the alcohol 
dehydrogenase EutG and the aldehyde oxidoreductase EutE to give ethanol and acetyl coenzyme A 
(acetyl-CoA) (6). In addition to genes that encode for catabolic enzymes, eut clusters also typically 
contain genes encoding bacterial microcompartment proteins, which are known to assemble and form 
icosahedral organelle-like structures that encapsulate the entire metabolic pathway (9). It was proposed 
that the eut microcompartment might function to facilitate the sequestration of the volatile acetaldehyde 
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intermediate in a manner analogous to concentration of carbon dioxide by the carboxysome, or to protect 
the cell from the potential toxicity of acetaldehyde (10). 
 
 
Figure 2.2: Anaerobic microbial degradation of ethanolamine. (A) Potential parallel logic between 
anaerobic choline utilization and bacterial ethanolamine utilization pathways. (B) Model for ethanolamine 
catabolism within a protein microcompartment. Microcompartment structural proteins: EutK, EutL, 
EutM, EutN and EutS; ethanolamine ammonia lyase: EutBC; alcohol dehydrogenase: EutG; acetaldehyde 
dehydrogenase, EutE; phosphotransacetylase: EutD. 
 
Recognizing that acetaldehyde is formed in the initial step of both ethanolamine and choline 
degradation pathways (8), we hypothesized that its conversion to downstream products might be similar. 
We used position-specific iterative-basic local alignment search tool (PSI-BLAST) to search for genes 
encoding homologs of EutG, EutE, and microcompartment protein EutM from Salmonella enterica in the 
genome of Desulfovibrio desulfuricans American Type Culture Collection (ATCC) 27774. This sulfate-
reducing bacterium had been previously reported to metabolize choline to TMA (5), a finding that we 
independently reconfirmed by growing the bacteria in media containing (trimethyl-d9)-choline (d9-
choline) (Figure 2.3). Our search revealed homologs of all three eut genes clustered within a 16.6-kb 
genomic region that displays similar organization to the eut cluster (Figure 2.4, Table 2.1). We named 
this portion of the D. desulfuricans genome the choline utilization (cut) gene cluster. Remarkably, 
homologs of eutB and eutC, which encode ethanolamine ammonia-lyase, were absent from both this 19-
gene cluster and the rest of the D. desulfuricans genome. Instead, the cut cluster contained a distinct set of 
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genes predicted to encode a glycyl radical enzyme CutC (Ddes_1357) and a glycyl radical activating 
protein CutD (Ddes_1358). 
 
Figure 2.3: Choline utilization by Desulfovibrio desulfuricans ATCC 27774 proceeds via formation of 
trimethylamine (TMA). (A) Growth of D. desulfuricans ATCC 27774 using various carbon sources. The 
data shown are the average OD600 values of two cultures. Error bars represent standard deviation (SD). 
(B) LC-MS quantification of d9-TMA production during D. desulfuricans ATCC 27774 growth on d9-
choline. Choline-sulfate and choline fermentation media contained 60 mM d9-choline chloride. Bar 
graphs represent the mean ± standard error of mean (SEM) of four replicates. *P < 0.002; **P < 10–4. 
 
 
 
Figure 2.4: Putative choline utilization (cut) gene cluster and proposed biochemical pathway for 
microbial choline metabolism. 
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Table 2.1: Annotation of choline utilization (cut) gene cluster in D. desulfuricans ATCC 27774. 
 
 
Bioinformatic analyses provided strong support for annotation of CutC as a member of the glycyl 
radical enzyme family. As described in Chapter 1, glycyl radical enzymes (GREs) are widespread in 
anaerobic microbes and use highly reactive protein-based radical intermediates to promote a diverse set of 
chemical transformations, including C–C bond formation (benzylsuccinate synthase), C–C bond cleavage 
(pyruvate formate-lyase, 4-hydroxyphenylacetate decarboxylase), and dehydration (glycerol dehydratase) 
(Figure 2.5.A). However, genome sequencing and bioinformatics have revealed numerous 
uncharacterized GREs within microbial genomes, suggesting that the functional diversity of these 
enzymes is underappreciated (11). We hypothesized that CutC might catalyze the initial TMA-forming 
step in choline metabolism, although C–N bond cleavage by glycyl radical enzymes has not previously 
been reported. Maximum likelihood phylogenetic analysis (12) of CutC, its close homologs, and 
biochemically characterized glycyl radical enzymes revealed that these sequences cluster according to 
function and that CutC and its homologs form a separate clade (Figure 2.5.B). Both alignment of the 
CutC amino acid sequence with those of functionally characterized glycyl radical enzymes (Figure 2.6.A) 
and construction of a homology model using Modeller (Figure 2.6.B) revealed conservation of key active 
site glycine and cysteine residues involved in radical catalysis (13). Multiple sequence alignments of the 
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predicted choline TMA-lyase homologs from the new GRE clade showed conservation of predicted active 
site residues, supporting the hypothesis of shared function (Figure 2.6.C). Taken together, these findings 
strongly suggested that CutC possesses a biochemical function distinct from known glycyl radical 
enzymes, that of a choline TMA-lyase.  
 
Figure 2.5: Bioinformatics identify choline trimethylamine-lyase CutC as a distinct type of glycyl radical 
enzyme. (A) Biochemical transformations catalyzed by glycyl radical enzymes. (B) Maximum likelihood 
phylogenetic tree showing the relationship between the amino acid sequences of choline TMA-lyases and 
other biochemically characterized members of the glycyl radical enzyme family. Bootstrap confidence 
values >50 are indicated on the nodes. 
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Figure 2.6: Bioinformatic analyses of choline TMA-lyase CutC. (A) Multiple sequence alignment of 
putative choline TMA-lyases from Desulfovibrio species with characterized glycyl radical enzymes 
reveals conservation of catalytic active site residues (shown with asterisks). E. coli pyruvate formate-
lyase numbering is shown. GenBank accession numbers identify amino acid sequences used. (B) Overlay 
of the active site residues of B12-independent glycerol dehydratase from Clostridium butyricum (crystal 
structure, orange) and choline TMA-lyase CutC (Ddes_1357) from D. desulfuricans (homology model, 
green). Asterisks indicate conserved putative active site residues of D. desulfuricans. (C) Multiple 
sequence alignment of putative choline TMA-lyases from different bacterial genera shows conservation 
of active site residues. Asterisks indicate conserved active site residues identified from the homology 
model shown in (B). D. desulfuricans ATCC 27774 CutC (Ddes_1357) numbering is shown. 
 
2.2.2: Disruption of choline TMA-lyase CutC in Desulfovibrio alaskensis G20 impairs growth on 
choline and abolishes production of TMA 
 
We devised two complementary approaches to evaluate whether the cut gene cluster was 
involved in choline utilization: genetic knockout in a choline-degrading organism and heterologous 
expression of the putative choline TMA-lyase CutC and its activating protein CutD in a non choline-using 
host. Among sequenced bacteria containing homologs of the putative choline degradation gene cluster 
was Desulfovibrio alaskensis G20, a sulfate-reducing bacterium capable of anaerobic choline utilization 
(14). A G20 mutant strain [C10(pB6)] with a disruption in the gene encoding predicted choline TMA-
lyase CutC (Dde_3282) had been generated previously using transposon mutagenesis, but a mutant 
phenotype had not been clearly identified (15). We obtained both wild-type D. alaskensis G20 and strain 
C10(pB6) from the Krumholz group at University of Oklahoma and evaluated their ability to grow using 
lactate and choline as carbon sources (Figure 2.7.A). Consistent with earlier studies (15), we observed no 
! 49 
difference in growth between wild type and C10(pB6) using media containing lactate. In contrast, the two 
strains exhibited a marked discrepancy in their ability to grow on choline. Whereas the wild-type strain 
could both ferment choline and use it for growth with sulfate as a terminal electron acceptor, strain 
C10(pB6) was unable to grow in either choline-containing media. These results clearly connect CutC to 
anaerobic choline metabolism. 
 
Figure 2.7: The cut gene cluster is responsible for choline metabolism and TMA production. (A) Growth 
of D. alaskensis G20 wild type (WT) and C10(pB6) strains at 37 °C on lactate sulfate (black), choline 
sulfate (red), and choline fermentation (blue) media. The data shown are the average OD600 values of four 
cultures. Error bars represent standard error of the mean (SEM). (B) LC-MS quantification of d9-TMA 
produced by D. alaskensis G20 WT and C10(pB6) during incubations in d9-choline sulfate and d9-choline 
fermentation media containing d9-choline chloride (60 mM). Bar graphs represent the mean ± SEM of 
four cultures. *P < 0.02; **P < 10–5; ***P < 10–6. 
 
We performed further experiments to validate the involvement of the cut gene cluster in TMA 
production. To verify that choline utilization in D. alaskensis proceeds via formation of TMA, we used 
liquid chromatography-mass spectrometry (LC-MS) to measure the d9-TMA present after inoculation and 
incubation of wild-type and C10(pB6) strains in media containing d9-choline. Use of isotopically labeled 
substrate ensured quantification of only TMA derived directly from choline. Growth of the wild-type 
organism was accompanied by the formation of d9-TMA, whereas levels for the C10(pB6) mutant did not 
exceed that of an uninoculated media control (Figure 2.7.B). Detection of TMA during growth on choline 
and the lack of TMA production from the mutant confirmed that the identified gene cluster encodes a 
pathway that processes choline via C–N bond cleavage. 
2.2.3: Heterologous expression of choline TMA-lyase in Escherichia coli 
 In parallel with these analyses we evaluated the in vivo activity of the putative TMA-forming 
enzymes CutC and CutD using a heterologous expression strategy. A 3.4-kb fragment of the D. alaskensis 
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G20 gene cluster encoding both choline TMA-lyase CutC (Dde_3282) and its activating protein CutD 
(Dde_3281) was cloned into a pET29b(+) vector and transformed into Escherichia coli BL21(D3). Using 
LC-MS, we measured formation of d9-TMA from d9-choline in vivo by strains harboring either the 
choline-degrading enzymes or an empty expression vector. Only E. coli coexpressing CutC and CutD 
produced d9-TMA at levels above an uninoculated media control (Figure 2.8), verifying that these 
enzymes are responsible for the initial C–N bond cleavage in anaerobic choline degradation. Expression 
of either enzyme on its own completely abolished TMA production, which is consistent with their 
annotations as a glycyl radical enzyme and activating protein; generation of the key active site glycyl 
radical involved in catalysis by glycyl radical enzymes requires the action of a separate radical S-
adenosylmethionine (SAM) enzyme (Figure 2.5.A) (16). Site-directed mutagenesis experiments with 
CutC provided further support for a radical-based mechanism of C–N cleavage, as mutation of either 
Gly821 or Cys489 to Ala prevented TMA formation. These universally conserved active site residues are 
the locations of the two protein-based radicals involved in catalysis and are essential for glycyl radical 
enzyme function (13). 
 
Figure 2.8: CutC and CutD are responsible for choline cleavage. LC-MS quantification of d9-TMA 
produced by E. coli BL21(DE3) during incubations in Luria–Bertani (LB) medium containing d9-choline 
chloride (100 µM). Bar graphs represent the mean ± SEM of four cultures. **P < 10–5. 
 
2.2.4: Growth of Desulfovibrio desulfuricans on choline involves a glycyl radical enzyme 
We obtained additional evidence connecting a glycyl radical enzyme to choline metabolism using 
electron paramagnetic resonance (EPR) spectroscopy. We prepared cell suspensions of D. desulfuricans 
ATCC 27774 grown on either choline or pyruvate fermentation media and recorded their EPR spectra 
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(Figure 2.9). The characteristic signal of a glycine-centered radical was observed only for cells grown on 
choline. The g value (2.003) and strong hyperfine coupling to a single proton (1.3 mT) indicate the 
presence of an organic radical located at the !-carbon of an amino acid and are consistent with previously 
reported EPR spectra of cells expressing glycyl radical enzymes (17, 18). The weaker nonhyperfine 
isotropic signal observed for cells from pyruvate cultures likely originates from flavoproteins, which are 
produced by a related Desulfovibrio strain during growth on pyruvate (19). Overall, these EPR 
experiments link choline utilization to a glycine-centered radical and indicate that choline TMA-lyase 
CutC is a member of the glycyl radical enzyme family. 
 
Figure 2.9: Growth of D. desulfuricans on choline involves a glycyl radical. EPR spectra of D. 
desulfuricans ATCC 27774 cell suspensions grown on choline (red) and pyruvate (black) fermentation 
media. (A) Experimental spectrum of cells grown on choline. (B) Simulation assuming an isotropic signal 
with g = 2.003, line width (W) = 1.14 mT, and isotropic hyperfine interaction with one proton (A) = 1.3 
mT. (C) Experimental spectrum of cells grown on pyruvate. (D) Simulation assuming an isotropic signal 
with g = 2.004 and line width (W) = 1.94 mT. 
 
2.2.5: Bioinformatic analysis of the distribution of the cut gene cluster in sequenced bacterial 
genomes 
 
Our discovery of a choline utilization gene cluster has implications beyond elucidating the 
biochemical basis for TMA formation; it also greatly enhances our understanding of the phylogenetic and 
environmental distribution of this metabolic activity by ascribing function to previously uncharacterized 
or misannotated gene sequences. Together with a postdoctoral fellow in the Balskus group, Dr. Ana 
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Martínez-del Campo, I performed searches for CutC homologs in November 2014 against the 
nonredundant protein database in the National Center for Biotechnology Information (NCBI) and against 
all genomes in the IMG database. The results revealed cut gene clusters in a total of 459 bacterial 
genomes (88% to 61% amino acid identity) distributed across four bacterial phyla (Proteobacteria, 
Firmicutes, Actinobacteria, and Fusobacteria). The majority of the hits were found in Proteobacteria 
(Gammaproteobacteria and Deltaproteobacteria) and Firmicutes (Clostridia and Bacilli), with less than 
3% from Actinobacteria (Coriobacteridae) and Fusobacteria (Fusobacteriia). CutC was conspicuously 
absent from Bacteroidetes, a major phylum of the gut microbiota (20). All CutC-containing organisms 
were facultative or obligate anaerobes, which is consistent with the oxygen sensitivity of GREs (13). 
CutC-encoding strains originated from a range of microbial habitats, including the human body (50% of 
hits), with many of the human isolates obtained from the gut (35%). This finding strengthened earlier 
hypotheses that anaerobic choline degradation is a major source of TMA formation within this 
environment (21) and provided initial insights regarding which symbiotic microbes may harbor this 
metabolic activity. We also identified cutC in three genomes assembled from human gut metagenomic 
DNA (Clostridium hathewayi CAG:224 [PRJNA221953], Collinsella sp. CAG:289 [PRJNA222147], and 
Klebsiella variicola CAG:634 [PRJNA221971]). CutC was also observed in gut isolates from other 
animals, including insects, fish, and mammals. Other strains harboring a copy of cutC were isolated from 
different parts of the human body (urogenital tract, oral cavity, and airways), as well as from the 
environment. The environmental microbes were largely found in marine sediments, habitats that are rich 
in TMA-based methanogenesis, confirming that choline metabolism contributes to TMA production in 
these ecosystems. Overall, we observed a discontinuous distribution of the cut gene cluster across most 
microbial species (Figure 2.10). For example, only 4% (98) of the 2,719 Escherichia coli genomes and 
15% (16) of the 101 Streptococcus suis genomes encode a CutC homolog. Desulfosporosinus (6/6 
genomes) and Proteus (17/17 genomes) are the only two bacterial genera that universally harbor the cut 
cluster. Other species that frequently harbor cutC include Clostridium botulinum (41/62 genomes; 66%) 
and Pectobacterium (18/29 genomes; 62%). These results suggest that anaerobic choline utilization is a 
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widely distributed pathway that may be important for survival in many microbial habitats. In addition to 
providing insights from genomes of cultured microbes, the ability to identify the choline utilization 
pathway in sequencing data will also permit characterization of its role in natural microbial communities 
through use of culture-independent methods such as metagenomics and metatranscriptomics (22). 
 
Figure 2.10: The cut gene cluster is widely but unevenly distributed in sequenced human gut bacteria. 
The pie charts depict the proportions of bacterial genomes that contain the cut gene cluster (green) in 
selected bacterial genera that possess this pathway and have been isolated from the human gut. 
 
We examined the genomic context of the cutC homologs and found that the additional elements 
of the D. desulfuricans cut gene cluster are largely conserved in other bacteria. The majority of the cutC 
sequences (~95%) clustered with homologs of 10 or more D. desulfuricans cut genes. A subset of these 
cut clusters (~10%) lacked genes encoding the acetaldehyde oxidoreductase, alcohol dehydrogenase, 
and/or microcompartment structural proteins, but in all cases homologs of the missing enzymes were 
identified elsewhere in the genome. CutC and cutD homologs failed to cluster with any other cut genes in 
only 3 of the 459 genomes, and only one strain possessed cutC but lacked cutD (Olsenella sp. oral taxon 
809 F0356). We classified cut clusters into two groups (type I and type II), based on their gene content 
(Figure 2.11.A). Type I clusters, found in Firmicutes, Actinobacteria, and Deltaproteobacteria, contained 
~20 genes, including homologs of BMC-encoding genes (cutAEGKLNQR), cutB, cutC, cutD, cutF, 
cutHIJ, cutO, cutS, and in some cases cutP. Although gene content was consistent for these clusters, gene 
order and transcriptional orientation varied. In contrast to the type I clusters, type II cut clusters, found 
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exclusively in facultative anaerobes from Gammaproteobacteria, typically contained only 10 genes, 
including the central enzymes involved in choline fermentation (cutC, cutD, cutF, cutO, and cutH) and 
four BMC structural proteins. The CutC homologs from these clusters possess an additional N-terminal 
domain and are longer by ~300 amino acids than homologs from type I clusters. There is a possibility that 
the differences in the arrangement and distribution of cut clusters and CutC sequences have arisen in 
response to various exposures of choline-metabolizing organisms to molecular oxygen. Further 
experiments will need to be carried out to verify this hypothesis.  
 
Figure 2.11: (A) Representative type I and type II cut gene cluster arrangements. (B) Maximum- 
likelihood phylogenetic trees showing the relationship between 16S rRNA genes (left) and the 
relationship between CutC amino acid sequences (right). Bootstrap confidence values of >50 are 
indicated by circles on the nodes. The CutC tree also contains the amino acid sequence of the glycyl 
radical enzyme glycerol dehydratase as an outgroup. Sequences from experimentally characterized 
choline-metabolizing strains are indicated with a red asterisk. 
 
With the exception of the extra N-terminal domain found in CutC homologs from type II clusters, 
we found that the amino acid sequence of this key TMA-generating enzyme is highly conserved across 
organisms possessing the cut cluster (88% to 61% amino acid identity). To deduce the phylogenetic 
relationship between choline TMA-lyases from different organisms, Dr. Martínez-del Campo, constructed 
a maximum-likelihood phylogenetic tree of CutC amino acid sequences and compared it to the phylogeny 
of the 16S rRNA gene (Figure 2.11.B). She observed two distinct clades of CutC sequences, one 
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consisting of sequences from Actinobacteria, Deltaproteobacteria, and Firmicutes (clade 1) and the other 
containing sequences from Gammaproteobacteria and Peptococcaceae (clade 2). Notably, this 
arrangement is incongruent with the 16S rRNA-based phylogeny, suggesting that cutC has been acquired 
through horizontal gene transfer. This hypothesis is also supported by the presence of putative mobile 
genetic elements in the vicinity of 35% of the cut clusters, including the uropathogenic E. coli strain 536, 
whose cluster is located within a known pathogenicity island (PAII) (23). We propose that acquisition of 
cut genes might occur in habitats in which choline is an abundant growth substrate, as it would confer a 
competitive advantage in such environments. Recent work has suggested that horizontal gene transfer 
occurs more frequently in the human gut than in other habitats, potentially due to the high population 
densities and increased metabolic activity in this setting (24). While exchange of antibiotic resistance 
genes among gut microbes has received particular attention (25), there is growing evidence for transfer of 
genes encoding metabolic pathways (26, 27). The cut gene cluster therefore represents an additional 
example of a bacterial metabolic function that may have been exchanged in the gut environment. 
2.2.6: The cut gene cluster is a genetic marker for anaerobic choline metabolism 
 
To confirm that the cut gene cluster is a functional marker for anaerobic choline metabolism, Dr. 
Martínez-del Campo and I tested whether its presence in a genome was predictive of an organism’s ability 
to convert choline to TMA under anaerobic conditions. We obtained nine sequenced strains containing 
type I cut clusers (Clostridium citroniae WAL-17108, Streptococcus dysgalactiae subsp. equisimilis 
ATCC 12394, Olsenella sp. oral taxon 809 F0356, Olsenella uli DSM 7084) and type II cut clusters 
(Escherichia coli MS 69-1, Klebsiella sp. MS 92-3, Proteus mirabilis ATCC 29906, P. mirabilis HI4320, 
and P. mirabilis BB2000). These organisms represented each of the phyla identified in our bioinformatics 
search and, with the exception of S. dysgalactiae, were all human isolates. Each strain was grown 
anaerobically in rich medium supplemented with 1 mM d9-choline to approximate choline availability in 
the human gut (28). All organisms generated d9-TMA except for one of the Olsenella strains (Figure 
2.12). This strain, Olsenella sp. oral taxon 809 F0356, was missing the GRE activase cutD, whereas the 
other Olsenella strain, Olsenella uli DSM 7084, contained both cutC and cutD. The failure of the strain 
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harboring an incomplete cut cluster to metabolize choline provided further evidence that activated CutC is 
required for this activity. Interestingly, all of the strains metabolized choline in rich media containing 
alternate carbon and energy sources. This observation suggests that choline is a preferred substrate or that 
this pathway contributes to cellular processes distinct from growth. Deciphering the specific advantages 
associated with this mode of metabolism will require further experiments, but we hypothesize that 
preferential use of choline is indicative of resource partitioning, providing bacteria harboring this cluster 
with a unique metabolic niche and allowing them to avoid competition for more energy-rich growth 
substrates available in the gut environment (29). 
 
Figure 2.12: The cutC functional gene is diagnostic of anaerobic choline utilization. LC-MS 
quantification of d9-TMA produced by selected cutC-containing bacterial species grown in rich medium 
supplemented with d9-choline (1 mM); Olsenella sp. oral taxon 809 F0356 has cutC but is missing the 
gene encoding activase cutD. Each bar represents the mean ± standard deviation (SD) of d9-TMA from 
three cultures. 
 
2.2.7: Development and validation of a PCR method for detection of choline TMA-lyase  
 
Understanding the role of anaerobic choline metabolism in the human gut and its connection to 
disease requires a means of identifying and quantifying this activity in individual gut communities. The 
discovery that bacterial phylogeny is not a good marker for choline utilization led us to explore methods 
for direct detection of the functional gene cutC. We began these efforts by developing a PCR method that 
could selectively amplify cutC in the presence of additional genes encoding functionally diverse GREs 
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possessing similar sequences (13). Our primer design took advantage of our understanding of the 
relationship between CutC’s amino acid sequence and catalytic activity derived from the homology model 
from Figure 2.6. By aligning 85 sequences, we identified conserved stretches of amino acids not found in 
other GREs and designed over 20 potential pairs of degenerate PCR primers targeting these regions. We 
screened each of these candidate primer pairs for their ability to amplify cutC from genomic DNA 
isolated from a subset of sequenced strains with cut gene clusters. One of these primer pairs displayed 
particularly robust amplification across a range of strains and was chosen for further optimization. These 
primers, which target regions of the cutC gene that encode conserved active site residues (Phe395, 
Cys489, and Glu491 from D. alaskensis G20 CutC), amplify a 314-bp portion of the gene that is readily 
distinguished from the corresponding regions of genes encoding unrelated GREs. 
We validated the utility of this degenerate PCR approach by successfully amplifying cutC from 
the genomic DNA of 11 strains containing cut clusters. A product of the expected size was observed in all 
of the PCRs, with amplification efficiency varying moderately among the different isolates (Figure 
2.13.A). Dr. Martínez-del Campo confirmed the identity of each PCR product through cloning and 
sequencing; in all cases, cutC was the only sequence obtained. No amplification was observed with DNA 
from a strain lacking a cut cluster but possessing other GREs (Roseburia inulinovorans A2-194). Because 
these PCR primers selectively amplified cutC from phylogenetically diverse isolates, they should be 
useful for surveying strains from different taxonomic groups. Finally, Dr. Martínez-del Campo performed 
serial dilutions to establish that our primers can detect as little as ~10 pg of cutC-containing genomic 
DNA template, even in the presence of an excess of genomic DNA from an organism lacking this gene. 
 
 
 
! 58 
 
Figure 2.13: The functional gene cutC can be detected using degenerate PCR. (A) Agarose gel 
electrophoresis results for degenerate PCRs using cutC-specific degenerate primers and genomic DNA 
from representative cutC-containing, choline-utilizing strains and two sequenced organisms that lack 
cutC. (B) Recovery of cutC sequences from a mixed DNA sample by applying degenerate primers. The 
sample contained equal amounts of DNA from four different cut-cluster containing isolates.  
 
We also utilized the degenerate primers to amplify cutC sequences directly from human gut 
metagenomic DNA. Dr. Martínez-del Campo first assessed whether biases in amplification efficiency 
might impact recovery of cutC sequences from a mixed DNA template by applying the primers to a mock 
community containing equal amounts of template DNA from four different isolates possessing the cut 
cluster, including a strain that had displayed lower levels of amplification in our original survey (S. 
dysgalactiae). Successful amplification of cutC sequences from 4 ng of community template DNA was 
followed by construction and sequencing of a 57-member clone library. All of the sequences present in 
the original sample were recovered, although in different proportions (Figure 2.13.B). This promising 
result prompted us to perform a proof-of-concept degenerate PCR with metagenomic DNA isolated from 
a human fecal sample that possessed the ability to convert choline to TMA ex vivo (Figure 2.14.A). We 
observed a band of the appropriate size in the PCR product from this complex sample and constructed a 
clone library of the amplified products. Sequencing of 66 clones revealed 33 unique cutC nucleotide 
sequences encoding 23 distinct amino acid sequences with high identity to CutC proteins from seven 
sequenced bacteria spanning three different genera (Figure 2.15.B). This experiment provided a first 
glimpse into the diversity of cutC sequences present in an individual human gut microbial community, 
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revealing that multiple types of bacteria have the capacity to perform anaerobic choline metabolism in 
this environment. We note that while the translated cutC sequences obtained in this experiment matched 
CutC protein sequences from sequenced bacteria, many of these sequences did not show significant 
similarity to known cutC nucleotide sequences, suggesting we have accessed sequences from organisms 
that are not yet represented in genome sequence databases.  
 
Figure 2.14: (A) LC-MS quantification of d9-TMA produced ex vivo by a human fecal sample upon 
anaerobic incubation in BHI medium supplemented with (trimethyl-d9)-choline (1 mM) for 18 h at 37°C. 
Bar graphs represent the means ± SD of three independent incubations. (B) Abundances of translated 
cutC sequences in the 66-member clone library constructed from degenerate PCR with human gut 
metagenomic DNA and the percent identity to CutC proteins from sequenced isolates. 
 
Studies of particular metabolic pathways in microbial habitats are greatly facilitated by the use of 
molecular approaches that target functional genes, particularly when the activities of interest have a broad 
phylogenetic distribution. Previous efforts to characterize gut microbial metabolism using function-
oriented strategies had largely focused on pathways and activities that are well understood in comparison 
to anaerobic choline metabolism, including bile acid metabolism, short-chain fatty acid synthesis, and 
glucuronidase activity (30-32). These studies have provided important insights into the distribution and 
abundance of these core functions in gut microbial communities, including information about how 
activities and pathways vary between individuals and how functional gene abundance changes with diet. 
Our work illustrates the benefits of applying such approaches, which are greatly enabled by the wealth of 
available bacterial genome sequences, to study newly characterized functions.  
 2.2.8: Isolation and characterization of new choline-utilizing human gut isolates 
 
An important unanswered question regarding the pathway encoded by the cut gene cluster is the 
extent to which it represents a predominant route for choline utilization and TMA generation in the 
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human gut. We explored this problem by screening new choline-metabolizing isolates from this 
environment for the presence of the cutC functional gene. We obtained isolates from two human fecal 
samples via enrichment culturing on six different media formulations that contained choline as a single 
carbon source (Figure 2.15.A). We thus aimed to isolate only bacteria that could utilize choline for 
growth and minimize the possibility of other media components being used as carbon sources. We 
included either ammonium, Casitone, or Trypticase peptone as the nitrogen source, and also varied the 
electron acceptors present (nitrate, tetrathionate, fumarate, or none). Organisms were chosen for further 
characterization based on their ability to convert d9-choline to d9-TMA in either brain heart infusion 
(BHI) or enrichment medium (Figure 2.15.B, C). Using this approach, we accessed a total of nine distinct 
choline-utilizing strains from four genera (Clostridium, Klebsiella, Escherichia, and Enterococcus) as 
determined by 16S rRNA gene sequencing. We obtained cutC sequences from each of the isolates by 
using degenerate PCR (Figure 2.15.D), and analyzed the phylogeny of each translated cutC sequence 
(Figure 2.15.E). This experiment revealed that our new choline-utilizing strains universally possess the 
cutC gene. To our knowledge, our approach represents the first targeted isolation of choline-utilizing 
bacteria from the human gut. Importantly, we were able to correlate anaerobic choline metabolism in each 
isolate with the presence of the cutC gene. These results further establish the validity of the cutC gene as a 
molecular marker for anaerobic choline metabolism and demonstrate the utility of directly detecting this 
biochemical function. Most significantly, the observation that these gut isolates universally possess cutC 
confirms that choline-utilizing organisms are present in human gut microbial communities, and suggests 
that the pathway encoded by the cut cluster could be the dominant mechanism for choline degradation and 
TMA production within this environment. 
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Figure 2.15: Choline-utilizing isolates from the human gut universally possess cutC. (A) General strategy 
for enrichment culturing. (B) LC-MS quantification of d9-TMA produced by human gut isolates grown 
anaerobically in BHI medium supplemented with d9-choline (1 mM) for 20 h at 37°C. Bar graphs 
represent the means ± standard deviations (SD) of three independent cultures. (C) LC-MS quantification 
of d9-TMA produced by isolate Pep7 grown anaerobically in enrichment medium supplemented with d9-
choline (1 mM) for 20 h at 37°C. Bar graphs represent the means ± SD of three independent cultures. (D) 
Agarose gel electrophoresis results for PCRs with cutC-specific degenerate primers and genomic DNA 
isolated from choline-utilizing human isolates. (E) Phylogenetic analysis of the cutC sequences from the 
choline-utilizing strains accessed through enrichment culturing.  
 
 2.2.9: Conclusions 
 
The search for genes involved in bacterial choline utilization has led to the discovery of an 
additional member of the glycyl radical enzyme family, choline TMA-lyase. At the outset of our studies, 
it was not obvious what type of enzyme would be involved in producing TMA from choline. From the 
standpoint of biochemical logic, the initial C–N bond cleavage event in choline utilization is most similar 
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to catabolic pathways involving vitamin B12-dependent radical rearrangements (ethanolamine and 
propanediol utilization) (33). However, no gene cluster encoding a vitamin B12-dependent enzyme has 
been linked to choline degradation and no enzyme from this family has ever been shown to catalyze this 
transformation. A critical distinction between choline and metabolites processed by B12-dependent 
pathways, such as ethanolamine, is the presence of a trimethylammonium substituent. Choline lacks N–H 
bonds and therefore cannot make all of the hydrogen bonding contacts within an enzyme-active site that 
are considered important for catalysis of B12-dependent eliminations (8, 33). Although this crucial 
structural difference called into question whether analogies in pathway logic between choline and 
ethanolamine utilization would extend to the C–N bond cleaving event, it was evident that powerful 
enzymatic chemistry would be needed to perform this transformation. The annotation of CutC as a glycyl 
radical enzyme provided a potential solution to supplying the requisite catalytic activity for C–N bond 
scission. 
Large-scale microbial genome sequencing has afforded an unprecedented opportunity to uncover 
the genetic basis for important activities associated with complex microbial communities. Our discovery 
of the genes involved in anaerobic choline utilization illustrates the power of combining biochemical 
knowledge with bioinformatics to correlate sequence data with function. These findings immediately 
increased our understanding of this metabolic pathway’s distribution in biology and expanded the scope 
of known radical-mediated enzymatic chemistry. Ultimately, our work will enable a better understanding 
of anaerobic choline metabolism, both in the environment, where it impacts the global carbon cycle and 
greenhouse gas production, and within the human body, where it contributes to disease-associated 
interspecies metabolism. 
Our preliminary experimental and bioinformatic findings suggest that the pathway encoded by the 
cut gene cluster may be a major mechanism for the direct conversion of choline to TMA in gut bacteria. 
However, many central questions remain regarding the factors influencing TMA production by the human 
gut microbiota and TMAO levels in humans. Choline may be utilized via alternate pathways that do not 
yield TMA, such as oxidation to betaine (34) and demethylation to produce dimethylaminoethanol (35). 
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The factors that influence levels of choline and other potential TMA precursors in the gut, including diet, 
availability of other bacterial metabolic activities such as lipid metabolism, and other environmental 
factors, are not well established. For example, TMA and TMAO levels may also be influenced by the 
presence of TMA-utilizing archaea (36). We expect that the ability to directly detect choline TMA-lyase 
in gut microbial communities, along with other “omics”-based approaches, will prove broadly useful in 
future efforts to correlate this metabolic pathway with metabolite levels, to identify alternate routes for 
choline utilization, and to understand the connection between this bacterial activity and human disease. 
More generally, our findings illuminate the importance of employing methods that directly detect the 
microbial functional genes responsible for activities of interest. We anticipate that implementation of 
similar function-oriented approaches will help reveal gut microbial processes that are the bases for disease 
and can potentially guide therapeutic development. 
2.3: Materials and methods  
2.3.1: Materials and general methods 
All chemicals were purchased from Sigma-Aldrich, except for d9-trimethylamine (TMA) 
hydrochloride (CDN Isotopes), and (trimethyl-d9)-choline chloride (Cambridge Isotope Laboratories). 
Methanol, acetonitrile and water used for liquid chromatography-mass spectrometry (LC-MS) were B&J 
Brand high-purity solvents (Honeywell Burdick & Jackson). Oligonucleotide primers were synthesized 
by Integrated DNA Technologies (Coralville, IA). Recombinant plasmid DNA was purified with a 
QIAGEN Plasmid Mini Kit (Qiagen, Valencia, CA). Purification of PCR reactions and gel extraction of 
DNA fragments for restriction endonuclease clean-up were performed using an Illustra GFX PCR DNA 
and Gel Band Purification Kit (GE Healthcare) or a QIAquick Gel Extraction Kit (Qiagen). DNA 
sequencing was performed by Beckman Coulter Genomics (Danvers, MA) or by GENEWIZ (Boston, 
MA). SDS/PAGE gels were purchased from Bio-Rad. Optical densities of Desulfovibrio desulfuricans, 
Desulfovibrio alaskensis, and Escherichia coli cultures were determined with a GENESYS 20 
spectrophotometer (Thermo Scientific) or with a DU 730 Life Sciences UV/Vis spectrophotometer 
(Beckman Coulter, Brea, CA) by measuring absorbance at 600 nm. 
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LC-MS/MS analysis was performed in the Small Molecule Mass Spectrometry Facility at 
Harvard University on an Agilent 6460 Triple Quadrupole Mass Spectrometer with Agilent 1290 uHPLC 
(Agilent Technologies, Wilmington, DE) (for derivatized d9-TMA detection) or in our research labs in the 
Department of Chemistry and Chemical Biology, Harvard University, on an Agilent 6410 Triple 
Quadrupole LC/MS instrument (Agilent Technologies, Wilmington, DE) (for derivatized and 
underivatized TMA and d9-TMA). Samples and blanks were introduced via an electrospray ionization 
(ESI) source. The mass spectrometers were operated in multiple reaction monitoring (MRM) mode. The 
capillary voltage was set to 4.0 kV and the fragmentor voltage to 110 V (underivatized and derivatized 
TMA and d9-TMA). The drying gas temperature was maintained at 350 °C (Agilent 6460) or 200 °C 
(Agilent 6410) with a flow rate of 12 L/min (Agilent 6460) or 10 L/min (Agilent 6460) and a nebulizer 
pressure of 25 psi (derivatized TMA and d9-TMA) or 45 psi (underivatized d9-TMA). The precursor-
product ion pairs used in MRM mode were: m/z 69.1!m/z 51 (underivatized d9-TMA), m/z 155.1! m/z 
66.2 (derivatized d9-TMA), m/z 146.1! m/z 58.1 (derivatized TMA). The collision energies for the 
precursor-product ion pairs were 21 V (underivatized d9-TMA) and 43 V (derivatized TMA and d9-
TMA). MS1 resolution was set to wide, MS2 resolution was set to unit, the time filter width used was 
0.07 min, and the "EMV (Electron Multiplier Voltage) was 400 V. Data analysis was performed with 
Mass Hunter Workstation Data Acquisition software (Agilent Technologies). The LC analysis for 
derivatized TMA and d9-TMA was performed in positive ion mode, using a Bio-Bond (Dikma 
Technologies) C4 column (5 µm, 4.6 mm # 50 mm), preceded by a C4 guard column (3.5 µm, 2.0 mm # 
20 mm). The mobile phase consisted of a 50/50 water/methanol mixture, supplemented with 5 mM 
ammonium formate and 0.1% formic acid as solvent modifiers. The flow rate was maintained at 0.3 
mL/min for each run. Run time per sample was 6 min, and the first 1.8 min of flow through was diverted 
to waste. The injection volume was 3 µL. Blanks consisting of 50/50/0.025 (vol/vol/vol) 
acetonitrile/water/ formic acid were run in between each sample. For underivatized d9-TMA, the LC 
analysis was performed in positive mode, using a Kinetex (Phenomenex) HILIC column (2.6 µm, 30 mm 
# 2.1 mm, 100 Å), preceded by a C4 precolumn (3.5 µm, 2.0 mm # 20 mm). The LC conditions were: 
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80% B for 1.6 min, a gradient decreasing to 40% B over 2.4 min, 40% B for 2 min, a gradient increasing 
to 80% B over 2 min, and 80% B for 3 min (solvent A = 5 mM ammonium formate in water with 0.1% 
formic acid, solvent B = 100% acetonitrile). The flow rate was maintained at 0.3 mL/min for each run. 
Run time per sample was 9 min, and the first 1.4 min of flow through was sent to waste. The injection 
volume was 3 µL for both standards and samples. For quantification of d9-TMA, an external standard 
curve was prepared in BHI media supplemented with 1 mM choline-d9 and analyzed at concentrations 
ranging from 104 pg/µL to 627 pg/µL d9-TMA. To assess the statistical significance of individual data 
points, a Student t test (two-tailed, heteroscedastic) was used to calculate a P value testing the null 
hypothesis that the amount of d9-TMA is the same in the samples indicated on each graph. 
Perpendicular mode X-band electron paramagnetic resonance (EPR) spectra were recorded on a 
Bruker ElexSysE500 EPR instrument with a 100 K–600 K Digital Temperature Control system, ER 
4131VT (Bruker BioSpin), and data acquisition and baseline corrections were performed with Xepr 
software (Bruker). The magnetic field was calibrated with a standard sample of !,"-bisdiphenylene-#-
phenylallyl (BDPA), g = 2.0026 (Bruker). The experimental spectra were modeled with EasySpin for 
Matlab to obtain g values, hyperfine coupling constants, and line widths (37). EPR spectra represent the 
average of nine scans and were recorded under non-saturating conditions: temperature, 120 K; center 
field, 3,360 Gauss; range, 150 Gauss; microwave power, 63.25 µW; microwave frequency, 9.433602 GHz 
(choline fermentation media), 9.436572 GHz (pyruvate fermentation media); modulation amplitude, 0.1 
mT; modulation frequency, 100 kHz; time constant, 40.96 ms; conversion time, 163.84 ms; and scan 
time, 167.77 s. 
2.3.2: Identification of the cut (choline utilization) gene cluster in sequenced bacterial genomes 
A putative choline utilization gene cluster was identified within the sequenced genome of D. 
desulfuricans ATCC 27774 using the BLAST search tool at NCBI (http://blast.ncbi.nlm.nih. 
gov/Blast.cgi). Specifically, the following protein sequences from the ethanolamine utilization operon of 
Salmonella enterica subsp. enterica serovar Typhimurium were used as input for individual PSI-BLAST 
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searches of the D. desulfuricans ATCC 2774 genome: alcohol dehydrogenase EutG (AAA80211), 
aldehyde oxidoreductase EutE (AAA80209), and microcompartment protein cchA/EutM (AAA80207). 
The genes encoding the closest homologs of each of these three protein sequences were colocalized 
within the D. desulfuricans genome.  
The choline TMA-lyase (CutC) protein sequence from D. desulfuricans ATCC 27774 (EMBL 
accession number ACL49259.1) was used as a query for BLASTP searches against the nonredundant 
protein sequences (nr) database from NCBI (performed on 27 November 2014) and all genomes in the 
IMG database (performed on 29 November 2014) in order to locate additional choline utilization gene 
clusters. BLAST hits having an identity between 88 and 61% to CutC from D. desulfuricans were aligned 
using ClustalW2 (38) to confirm the presence of conserved active site residues. Strains containing a cutC 
homolog were classified according to the source of the isolate based on the information available at the 
Genome Online Database, the IMG database, or bibliographic searches. The content and arrangement of 
each of the cut clusters identified in the initial BLAST search were determined by the examination of the 
genetic context of the cutC gene. Putative functions were assigned to neighboring genes based on the 
genome annotations and similarities to the cut genes from D. desulfuricans. 
2.3.3: Bioinformatic analyses of choline TMA-lyase CutC 
Nucleotide and protein sequences were aligned with ClustalW2 using the default parameters. A 
CutC (Ddes_1357) homology model was generated with the HHPred interactive server 
(http://toolkit.tuebingen.mpg.de/hhpred) (39) using the crystal structure of B12-independent glycerol 
dehydratase (40) as a template [Protein DataBase (PDB) ID 1R9D]. An overlay of the CutC homology 
model with the glycerol dehydratase crystal structure revealed conservation of active site architecture and 
the essential catalytic glycine and cysteine residues. Multiple sequence alignment of Ddes_1357 with 
CutC homologs from other organisms containing cut gene clusters showed conservation of active site 
residues predicted from the CutC homology model. The maximum likelihood phylogenetic tree of 
representative glycyl radical enzymes was reconstructed using PHYML (12) with the general time 
reversible (GTR) nucleotide substitution model, the proportion of invariable sites and the ! parameter of 
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across-site rate variation (using four rate categories) was estimated from the dataset. Bootstrap support 
values were calculated with the same parameters (100 replicates). The sequence dataset used for this 
analysis was obtained starting from choline TMA-lyase Ddes_1357, other functionally characterized 
representatives of the glycyl radical enzyme family, and close BLAST hits from the GenBank nucleotide 
database (Table 2.2). These sequences were aligned using ClustalW and trimmed manually using 
MacClade. Translated CutC nucleotide sequences from isolates obtained via enrichment culturing and 
metagenomic clone libraries were aligned with CutC sequences from bacterial genomes. These 
alignments were manually edited to a final length of 104 aa. Maximum-likelihood trees were constructed 
in MEGA 5 (41) using the Jones-Taylor-Thorton (JTT) method of substitution for CutC and the Tamura-
Nei method for 16S rRNA. Statistical support for both trees was obtained by bootstrapping 100 iterations. 
Trees were visualized with iTOL (42). 
Table 2.2: Glycyl radical enzyme amino acid sequences used in CutC phylogenetic analysis. 
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2.3.4: Growth of Desulfovibrio bacterial strains on choline and quantification of TMA 
production from choline 
 
Desulfovibrio alaskensis G20 wild-type and C10(pB6) mutant strains were obtained from Lee 
Krumholz (University of Oklahoma, Norman, OK). The G20 strain (43) is a spontaneously nalidixic acid-
resistant derivative of strain G100A, a known choline degrader (14). The C10(pB6) mutant strain was 
generated previously using signature-tagged mutagenesis; this mutant contains a transposon insertion that 
disrupts the gene encoding predicted choline TMA-lyase CutC (Dde_3282) and was initially identified in 
a screen for D. alaskensis genes conferring sediment fitness (15). D. desulfuricans ATCC 27774 was 
obtained from João Nuno Carita (Universidade Nova de Lisboa, Lisbon). All strains were grown 
anaerobically at 37 °C on lactate-sulfate (LS), choline-sulfate (CS), and choline fermentation (C) media 
as described below. Kanamycin (1,050 µg/mL) was added to all cultures of the C10(pB6) mutant. 
Lactate-sulfate (LS) medium was used for routine cultivation and was prepared as previously described 
(44). All concentration values indicated correspond to final values. LS medium contains sodium lactate 
(60 mM, 1.2% wt/vol), sodium sulfate (50 mM), magnesium sulfate (8 mM), ammonium chloride (5 
mM), HEPES pH 7.2 (25 mM), calcium chloride (0.6 mM), yeast extract (Becton, Dickinson and 
Company) (0.1%), trace mineral solution [nitrilotriacetic acid trisodium salt (0.62 mM), iron (II) sulfate 
heptahydrate (19 µM), manganese (II) chloride tetrahydrate (6.3 µM), cobalt (II) chloride hexahydrate 
(8.9 µM), copper (II) chloride dihydrate (1.5 µM), zinc (II) sulfate heptahydrate (9.1 µM), sodium 
molybdate dihydrate (0.5 µM), and sodium selenate (1.0 µM)], vitamin solution (3) [pyridoxine 
hydrochloride (96 nM), thiamine hydrochloride (30 nM), riboflavin (27 nM), calcium pantothenate (42 
nM), lipoic acid (48 nM), p-aminobenzoic acid (73 nM), nicotinic acid (81 nM), vitamin B (7 nM), biotin 
(16 nM), folic acid (9 nM), and mercaptoethanesulfonic acid (141 nM)], and resazurin (2.5 µM). The pH 
of the medium was adjusted to 7.2. The medium was autoclaved for 5 min, sparged for 30 min with 
argon, dispensed into 18 ! 150 mm modified Hungate tubes (Chemglass Life Sciences; CLS-4209-10) 
and capped with butyl rubber stoppers and aluminum seals (10 mL media per tube). The tubes were 
autoclaved for an additional 20 min. After cooling, anaerobic and sterile aqueous solutions of potassium 
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phosphate dibasic (2.2 mM), sodium bicarbonate (8 mM), and cysteine-HCl (0.04%) were added. Tubes 
of anaerobic media were stored under a headspace of argon. Lactate fermentation media (L) was prepared 
in a similar manner to the LS media except that sodium sulfate was replaced with sodium chloride (100 
mM) and magnesium sulfate was replaced with magnesium chloride (8 mM). Choline-sulfate (CS) and 
choline fermentation (C) media were prepared in a similar manner to the LS and L media, except that it 
was supplemented with 0.01 mg/mL iron (III) ammonium citrate, and sodium lactate was replaced by 
choline chloride (60 mM), which was added as an anaerobic, filter-sterilized aqueous solution shortly 
before inoculation. Ethanolamine- and pyruvate-containing media [ethanolamine-sulfate (ES), 
ethanolamine fermentation (E), pyruvate-sulfate (PS), and pyruvate fermentation (P)] were prepared like 
CS and C media, except that choline was replaced with ethanolamine hydrochloride (60 mM) or sodium 
pyruvate (60 mM). For D. desulfuricans ATCC 27774 growth on LS, CS, C, PS, and P media, two 18 ! 
150 mm modified Hungate tubes containing 10 mL of medium and N2 in the headspace were inoculated 
with 0.1 mL of an overnight LS starter culture (OD600 = 0.85) and incubated at 37 °C. OD600 was 
measured periodically until the cultures reached stationary phase. For D. alaskensis G20 wild-type and 
C10(pB6) mutant strains growth on LS, CS and C media, four 18 ! 150 mm Hungate tubes containing 10 
mL of medium were inoculated with 0.05 mL (LS media) or 0.1 mL (CS and C media) of an overnight LS 
starter culture (OD600 = 1.0–1.1) and incubated at 37 °C until reaching stationary phase (!48 h). 
For quantitation of d9-TMA formation, the strains were grown on CS and C media containing 
(trimethyl-d9)-choline (60 mM). This substrate was added as an anaerobic, filter-sterilized aqueous 
solution shortly before inoculation. Kanamycin (1,050 µg/mL) was added to all cultures of the C10(pB6) 
mutant. Four 10-mL cultures of each media type (LS, CS, and C) were grown side by side at 37 °C until 
reaching stationary phase (!48 h). The concentration of d9-TMA in culture media was determined using 
LC-MS after derivatization with ethyl bromoacetate using a published procedure (45). Briefly, to a 10-mL 
glass vial sealed with a 13 ! 20 mm sleeve stopper (VWR) was added 100 µL of bacterial culture filtered 
through a 13 mm, 0.22 µm pore-size Acrodisc syringe filter with HT Tuffryn Membrane (Pall Life 
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Sciences), 100 µL of TMA (43.3 mM in water), 10 µL of concentrated ammonia (7 M in methanol), and 
120 µL of ethyl bromoacetate (20 mg/mL in acetonitrile). This mixture was incubated at room 
temperature for 30 min and then quenched by adding 4 mL of infusion solution [acetonitrile/water/formic 
acid, 50/50/0.025 (vol/vol/vol)]. A 0.5 µL aliquot of the resulting mixture was further diluted 2,000-fold 
with infusion solution and analyzed by LC-MS (3 µL injection volume) using the parameters described in 
materials and general methods. For analysis of D. alaskensis cultures, the derivatization reaction 
contained 100 µL of 22 µM aqueous TMA solution for the C10(pB6) mutant samples and 100 µL of 2.2 
mM aqueous TMA solution for the wild-type samples. The quenched derivatization reactions for the 
C10(pB6) mutant were analyzed without dilution, whereas for the wild-type samples, a 10 !L aliquot was 
diluted 100-fold before analysis. Media blanks consisted of 10 mL of uninoculated CS and C media 
containing (trimethyl-d9)-choline (60 mM).  
2.3.5: Cloning of CutC (Dde_3282) and CutD (Dde_3281) from D. alaskensis G20 and 
construction of CutC C489A and G821A mutants 
 
Genomic DNA from D. alaskensis G20 was isolated from a 10-mL LS culture using the 
UltraClean Microbial DNA Isolation kit from MoBio Laboratories. The sequences of primers used for 
amplification of cutC (Dde_3282) and cutD (Dde_3281) genes are provided in Table 2.3. Primers were 
designed to amplify both of the individual genes as well as the 3529-bp region (3270700–3274229) 
encoding both CutC and CutD. CutC was PCR amplified from genomic DNA using forward primer Dde-
3282-NdeI-start and reverse primer Dde-3282-XhoI-nostop. All PCR reactions (set up in triplicate) 
contained 25 µL of PfuTurbo Hotstart master mix (Stratagene), 2 µL of genomic DNA template, and 100 
pmol of each primer in a total volume of 50 µL. Thermocycling was carried out in a C1000 Gradient 
Cycler (Bio-Rad) using the following parameters: denaturation for 1 min at 95°C, followed by 40 cycles 
of 30 s at 95 °C, 1 min at 68.4°C, 5 min at 70 °C, and a final extension time of 10 min at 70 °C. PCR 
reactions were analyzed by agarose gel electrophoresis with ethidium bromide staining, pooled, and 
purified. Identical conditions were used to amplify cutD (forward primer Dde-3281-NdeI-start + reverse 
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primer Dde-3281-XhoI-stop) as well as cutC + cutD (forward primer Dde-3282-NdeI-start + reverse 
primer Dde-3281-XhoI-stop). 
Table 2.3: Primers used for cloning and site directed mutagenesis 
 
Amplified fragments were digested with NdeI and XhoI (New England Biolabs, NEB) for 2.5 h at 
37 °C. Digests contained 1 µL of water, 3 µL of NEB buffer 4 (10!), 3 µL of BSA (10!), 20 µL of PCR 
product, 1.5 µL of NdeI (20 units/µL), and 1.5 µL of XhoI (20 units/µL). Restriction digests were purified 
directly using agarose gel electrophoresis and the gel fragments were further purified using the Illustra 
GFX kit. The digests were ligated into linearized expression vectors using T4 DNA ligase (NEB). The 
CutC + CutD and CutD digests were ligated into linearized pET-29b(+) to encode untagged and C-
terminal His6-tagged constructs, respectively, whereas the CutC digest was ligated into linearized pET-
28a(+) to encode an N-terminal His6-tagged construct. Ligations were incubated at 16 °C for 24 h and 
contained 3.5 µL water, 1 µL T4 ligase buffer (10!), 0.5 µL digested vector, 3 µL digested insert DNA, 
and 2 µL T4 DNA ligase (400 units/µL). A total of 5 µL of each ligation was used to transform a single 
tube of chemically competent E. coli TOP10 cells (Invitrogen). The identities of the resulting pET-29b-
CutC/CutD, pET-29b-CutD, and pET-28a-CutC constructs were confirmed by sequencing purified 
plasmid DNA. These constructs were transformed into chemically competent E. coli BL21 (DE3) cells 
(Invitrogen) and stored at –80 °C as frozen LB/glycerol stocks. 
The C489A and G821A mutants of CutC (Dde_3282) were constructed separately in pET-29b-
CutC/CutD using site directed mutagenesis. The CutC (Ddes_1357) homology model identified these 
amino acid positions (which correspond to C491 and G823 in Ddes_1357 and are conserved in all glycyl 
radical enzymes) as sites of the thiyl and glycyl radicals involved in catalysis (11). The sequences of 
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primers used for mutagenesis are found in Table S5. The C489A mutant was constructed via PCR 
amplification of pET-29b-CutC/CutD using forward primer Dde3282-QC-C489A- for and reverse primer 
Dde3282-QC-C489A-rev. The G821A mutant was constructed via PCR amplification of pET-29b-CutC/ 
CutD using forward primer Dde3282-QC-G821A-for and reverse primer Dde3282-QC-G821A-rev. PCR 
reactions contained 36 µL of PfuTurbo DNA polymerase (2.5 units/µL; Stratagene), 5 µL of Pfu DNA 
polymerase reaction buffer (10!), 1 µL of 10 mM dNTP Mix (Bio-Rad), 50 ng DNA template, and 125 
ng of each forward and reverse primer in a total volume of 50 µL. Thermocycling was carried out using 
the following parameters: denaturation for 30 s at 95 °C, followed by 18 cycles of 30 s at 95 °C, 5 min at 
55 °C, and 9 min at 68 °C. Upon cooling to room temperature, 1 "L of DpnI (NEB) was added to each 
tube, and the resulting mixtures were incubated at 37 °C. After 1 h, an additional 1 µL of DpnI was added 
to each tube and incubation continued for an additional hour at 37 °C. A total of 5 µL of each digestion 
was used to transform a single tube of chemically competent E. coli TOP10 cells. The identity of the 
resulting pET-29b-CutC/CutD-C489A or -G821A constructs was confirmed by sequencing purified 
plasmid DNA. Chemically competent E. coli BL21(DE3) cells were transformed with pure pET-29b-
CutC/CutD-C489A or -G821A plasmid DNA and stored at –80 °C as frozen LB/glycerol stocks. 
2.3.6: Heterologous expression of CutC and CutD and quantification of TMA production from 
choline 
 
Individual cultures of LB medium (5 mL) containing 50 "g/mL kanamycin were inoculated with 
the pET-29b-CutC/CutD, pET-29b-CutD, pET-28a-CutC, pET-29b-CutC/CutD-C489A, and pET-29b-
CutC/CutD-G821A expression strains, as well as a control strain of E. coli BL21(DE3) containing an 
empty pET-29b(+) vector, and incubated at 37 °C overnight. Aliquots (500 µL) of each overnight culture 
(OD600 = 1.6–1.8), were used to inoculate four 18 ! 150 mm Hungate tubes containing 10 mL of LB 
medium (sparged with argon for 25 min) supplemented with NaCl (0.4 M), kanamycin (50 µg/mL), 
(trimethyl-d9)-choline chloride (105 "M), and iron (III) ammonium citrate (0.069 mg/mL). High salt 
conditions were used to ensure expression of high-affinity choline transporter, betT, which is required for 
transport of choline into E. coli (46). The cultures were incubated at 37 °C with shaking (190 rpm), and 
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protein expression was induced with 500 µM Isopropyl !-D-1-thiogalactopyranoside (IPTG) at an OD600 
of !0.3. Incubation continued for an additional 16 h at 37 °C. Four media blanks consisting of 18 " 150 
mm modified Hungate tubes containing the growth media described above were incubated at 37 °C 
alongside the E. coli cultures. The concentrations of d9-TMA in the media blanks and growth media of E. 
coli cultures were determined using LC-MS as described in materials and general methods. The transition 
used for quantitation was m/z 155.1 66.2. The derivatization reaction mixture contained the same 
components, except that the standard solution of TMA was not included. Quantitation was performed 
using a standard curve. Calibration standards were prepared by adding different concentrations of d9-
TMA hydrochloride solution to uninoculated LB media supplemented with 0.4 M NaCl (0.4 M), 
kanamycin (50 µg/mL), choline chloride (100 #M), and iron (III) ammonium citrate (0.066 mg/mL), such 
that the concentration of the derivatized d9-TMA in the solution obtained after quenching would be in the 
5 to 50 nM range. To ensure that the C498A and G821A CutC mutants were produced to the same extent 
as wild type, cell lysates from the heterologous expression experiments detailed above were analyzed 
using SDS-PAGE (Figure 2.16). 
 
Figure 2.16: SDS-PAGE of cell lysates from heterologous expressions of CutC and CutD in E. coli using 
a 4–15% (wt/vol) polyacrylamide Tris-HCl gel. Lane 1, 10–250 kDa protein ladder (New England 
Biolabs); lane 2, wild-type CutC + CutD; lane 3, CutC C498A mutant + CutD; lane 4, CutC G821A 
mutant + CutD; and lane 5, empty pET-29b vector control. The calculated molecular weight of CutC 
(Dde_3282) is 96 kDa. 
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2.3.7: Whole cell electron paramagnetic resonance spectroscopy 
D. desulfuricans ATCC 27774 was grown in serum bottles (outer diameter, 51.7 mm; height, 94.5 
mm, Supelco; 33110-U) containing 100 mL of choline fermentation (C) and pyruvate fermentation (P) 
media using a 1 mL inoculum from an overnight LS culture (OD600 = 0.84–0.85). A total culture volume 
of 500 mL was used to prepare each cell suspension. The cultures were incubated at 37 °C in an anaerobic 
chamber (Coy Laboratory Products) under an atmosphere of 98% nitrogen and 2% hydrogen until 
reaching mid-to-late exponential phase. The cultures were combined in 2 ! 250 mL polypropylene 
centrifuge tubes with plug seal caps (Corning; 430776) and centrifuged at 6,766 ! g for 20 min at 4 °C. 
Cell pellets were resuspended in 0.1 M 3-(N-morpholino) propanesulfonic acid (MOPS) buffer (pH 7.2) 
containing 5 mM DTT to a final volume of 220–300 µL in the anaerobic chamber. The final volume of 
cell suspension was scaled according to the final average OD of the bacterial cultures. The cell 
suspensions were transferred to 4-mm thin-wall Suprasil screw-cap EPR sample tubes (7” length, 
Wilmad-LabGlass; 734-TR-7). The contents of the tubes were frozen in an acetone/dry-ice bath and 
placed in the cavity of the EPR instrument at 120 K. EPR spectra were recorded and modeled as 
described in materials and general methods. 
2.3.8: Quantification of TMA production from choline for the other bacterial strains 
To confirm and quantify the TMA formed during microbial choline utilization, reference strains 
were grown anaerobically on rich media containing 1 mM (trimethyl-d9)-choline. LB media containing 20 
mM fumarate was used for E. coli BL21 and MS 69-1 (BEI Resources, NIAID, Human Microbiome 
Project reference strain) and Klebsiella sp. MS 92-3 (BEI Resources, NIAID, Human Microbiome Project 
reference strain); BHI media was used for P. mirabilis ATCC 29906, P. mirabilis HI4320, P. mirabilis 
BB2000, C. citroniae WAL-17108 (BEI Resources, NIAID, Human Microbiome Project reference 
strain), and S. dysgalactiae subsp. equisimilis ATCC 12394; and PYG media was used for Olsenella sp. 
oral taxon 809 F0356 (BEI Resources, NIAID, Human Microbiome Project reference strain) and 
Olsenella uli DSM 7084 (DSMZ). Media was autoclaved for 5 min, sparged with nitrogen for 30 min, 
and dispensed under anaerobic conditions into 25 x 44 mm 5 mL serum vials (Supelco, Bellefonte, PA) or 
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18 x 160 mm modified Hungate tubes. Vials and tubes were subsequently capped with butyl rubber 
stoppers and aluminum seals (4 mL media per vial) and autoclaved for an additional 15 min. Three 4 mL 
replicates were inoculated with 40 µL of an overnight starter culture and grown for 20 h (10 days for 
Olsenella strains) at 37 °C. The concentration of d9-TMA in culture media was determined using LC-MS 
after derivatization with ethyl bromoacetate. Media blanks consisted of 4 mL uninoculated media 
containing 1 mM (trimethyl-d9)-choline. 
2.3.9: Ex vivo incubation of a fecal sample with (trimethyl-d9)-choline  
A frozen fecal sample from a healthy individual was diluted 1:10 (wt/vol) in sterile prereduced 
phosphate-buffered saline (PBS). The dilution was vortexed for 1 min and allowed to settle for 15 min at 
room temperature. A 40-!l aliquot of the resulting supernatant was transferred to a capped 5-ml serum 
vial (Supelco, Bellefonte, PA) containing 4 ml of anaerobic BHI medium supplemented with 1 mM 
(trimethyl-d9)-choline. Samples were incubated in triplicate for 18 h at 37 °C. The concentration of d9-
TMA in culture medium was determined using LC-MS after derivatization with ethyl bromoacetate. 
Medium blanks consisted of 4 ml uninoculated medium containing 1 mM (trimethyl-d9)-choline. 
2.3.10: Detection of cutC via degenerate PCR 
To amplify an internal fragment of cutC, degenerate primers were designed based on an 
alignment from 85 CutC sequences from different species. These primers amplify a 314 bp conserved 
portion of the cutC gene. Primer sequences are 5’-TTYGCIGGITAYCARCCNTT-3’ (Fw cutC-dPCR-
389 aa-A) and 5’-TGNGGRTCIACYCAICCCAT-3 (Rv cutC-dPCR-492 aa-B). This primer set was used 
to amplify cutC from genomic DNA isolated from both reference strains and isolates obtained from 
enrichment culturing. PCR reactions contained 1X PCR buffer, 1.5 mM MgCl2, 0.2 mM dNTPs, 4 ng of 
DNA template, 0.2 µM of each primer, and 0.4 U of Takara Taq Hot Start Version (Takara Bio Inc., Otsu, 
Japan) in a total volume of 20 µL. Thermocycling was carried out in a MyCycler gradient cycler (Bio-
Rad) with an initial denaturation period of 5 min at 95 °C, followed by 65 cycles of 30 s at 95 °C, 30 s at 
58 °C, and 30 s at 72 °C, with a final extension time of 10 min at 72 °C. PCR reactions were analyzed by 
agarose gel electrophoresis with ethidium bromide staining. Bands of the expected length (314 bp) were 
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gel purified and cloned into the pCR4-TOPO vector using the TOPO TA Cloning Kit for Sequencing 
(Invitrogen). The identity of each clone was confirmed by sequencing. 
To assess the amplification bias of the degenerate primers a ‘mock’ community DNA template 
containing equal amounts of genomic DNA from E. coli MS 69-1, Klebsiella sp. MS 92-3, C. citroniae 
WAL-17108, and S. dysgalactiae subsp. equisimilis ATCC 12394 was prepared. PCR reactions and 
cycling conditions were the same as described above. Amplified fragments were gel purified and cloned 
into the pCR4-TOPO vector using the TOPO TA Cloning Kit for Sequencing (Invitrogen). 60 clones 
were randomly chosen for analysis. Plasmid purification and sequencing were performed by Beckman 
Coulter Genomics (Danvers, MA). Low-quality, unsuccessful, and no-insert reactions were discarded 
reducing the number of clones to 57. Clones were identified by aligning cutC sequences from the 
corresponding organisms with the obtained nucleotide sequences. 
2.3.11: Clone library construction and sequence analysis  
A clone library specific for cutC was constructed by amplification of human fecal DNA with the 
degenerate primers described above. The PCR mixture and cycling parameters tested were the same as 
those used for the amplification of cutC from genomic DNA, except for the template DNA concentration, 
which was changed to 300 or 50 ng. PCR products were analyzed by agarose gel electrophoresis with 
ethidium bromide staining. Amplified PCR products from different template DNA concentrations were 
pooled, gel purified, and cloned into the pCR4-TOPO vector using the TOPO TA cloning kit for 
sequencing (Invitrogen) according to instructions from the manufacturer. A total of 96 clones were 
randomly selected for sequencing. Plasmid purification and sequencing were performed by Beckman 
Coulter Genomics (Danvers, MA). Low-quality, unsuccessful, and no-insert reaction mixtures were 
discarded, which reduced the size of the library to 66 clones. Nucleotide sequences were subjected to 
BLASTN searches against the NCBI and IMG databases and translated to protein sequences to perform a 
BLASTP search against the NCBI database. All translated sequences had 90 to 98% amino acid identity 
to CutC sequences in the database. 
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2.3.12: Enrichment culturing 
Six types of media were prepared for enrichment culturing. All indicated concentration values 
correspond to final values. “A” media contained choline chloride (1 mM), ammonium chloride (20 mM), 
yeast extract (Becton, Dickinson and Company, Franklin Lakes, NJ) (0.1% w/v), potassium phosphate 
monobasic (3.3 mM), potassium phosphate dibasic (2.6 mM), sodium chloride (154 mM), magnesium 
chloride (0.4 mM), calcium chloride (0.8 mM), hemin (15 !M), sodium bicarbonate (4.8 mM), iron (III) 
ammonium citrate (0.1 mg/mL), HEPES pH 7.2 (25 mM), mineral solution (2), vitamin solution (2), and 
resazurin (2.5 !M). “C” media had the same composition as “A” media, except that ammonium chloride 
was replaced with casitone (Becton, Dickinson and Company) (1% w/v). “P” media contained choline 
chloride (60 mM), trypticase peptone (Becton, Dickinson and Company, Franklin Lakes, NJ) (1% w/v), 
yeast extract (Becton, Dickinson and Company, Franklin Lakes, NJ) (0.1% w/v), potassium phosphate 
monobasic (3.3 mM), potassium phosphate dibasic (2.6 mM), sodium chloride (154 mM), magnesium 
chloride (0.4 mM), calcium chloride (0.8 mM), hemin (15 !M), sodium bicarbonate (4.8 mM), iron (III) 
ammonium citrate (0.1 mg/mL), HEPES pH 7.2 (25 mM), mineral solution (2), vitamin solution (2), 
resazurin (2.5 !M), vitamin B12 (200 nM), vitamin K1 (0.0001% w/v) and L-cysteine (0.05% w/v). The 
pH of the media was adjusted to 7.2. The media was autoclaved for 5 min, sparged for 30 min with argon 
or nitrogen, dispensed into 18 " 150 mm modified Hungate tubes (Chemglass Life Sciences, Vineland, 
NJ; CLS-4209-10), and capped with butyl rubber stoppers and aluminum seals (10 mL media per tube). 
Tubes were autoclaved for an additional 20 min. Additionally; different electron acceptors were 
supplemented to “P” media by adding to each tube an anoxic sterile solution of fumarate, nitrate, or 
tetrathionate at a final concentration of 0.4 mM. 
All experiments were performed under the guidance of the Harvard Committee on the Use of 
Human Subjects in Research. Two healthy volunteers (samples 1 and 2) provided an intact fecal sample 
that was stored at –80 °C before use. We do not have information regarding the diet and past antibiotic 
usage of the volunteers. 
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For the first type of enrichment ~200 mg of fecal sample 1 was thawed inside a Coy anaerobic 
chamber, dissolved in 1 mL of anoxic “A” media, and briefly centrifuged to allow particulates to settle. 
The mixture was diluted 10-fold with “A” media, and a 50 !L aliquot of each was used to inoculate tubes 
of “A” media and “C” media. The cultures were incubated for approximately 4 days at 37 °C before 
transferring to 10 mL of fresh media. The incubation and transfer steps were then repeated. At the end of 
each passage, a small volume (10 !L) of culture was plated on the corresponding agar media and 
incubated for 4 days at 37 °C. TMA levels in each of the liquid cultures were analyzed by LC-MS after 
derivatization with ethylbromoacetate. Qualitatively, the levels of TMA observed in the enrichment 
cultures were at least 1000-fold higher than in media blanks. At the end of the incubation period for the 
plates, 24 isolated colonies were chosen (3 from each plate in order to maximize the diversity of colony 
morphology) and used to inoculate tubes of corresponding media. The cultures were incubated for 
approximately 3 days at 37 °C, and their TMA levels were analyzed by LC-MS at the end of the 
incubation, as described above. Eight out of 24 cultures produced significant (greater than 1000-fold) 
amounts of TMA as compared to the media blanks.  
In the second type of enrichment ~360 mg of frozen fecal sample 2 was diluted 1:10 (w/v) in pre-
reduced PBS inside a Coy anaerobic chamber. Diluted samples were vortexed and large particulate matter 
was allowed to settle. A 100 µL aliquot was used to inoculate 10 mL of “P” media with no electron 
acceptor, fumarate, nitrate, or tetrathionate. The enrichments were incubated at 37 °C for two days and 
then transferred to fresh medium. After a two day incubation at 37 °C, cultures were serially diluted on 
the corresponding agar plates for isolation. Sixteen colonies from each condition were chosen and used to 
inoculate tubes of corresponding media containing (trimethyl-d9)-choline. The cultures were incubated for 
approximately 20 hours at 37 °C, and their TMA-d9 levels were analyzed by LC-MS at the end of the 
incubation. 45 of 64 cultures produced significant amounts of TMA-d9. 
To further verify that the TMA produced by these cultures originated from choline, each of the 
isolates was grown on anoxic BHI media supplemented (or “P” media for isolate Pep7) with choline-d9, 
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and TMA-d9 was quantified as described using an alternate method that does not involve derivatization. 
Three 200 !L replicates were inoculated with 2 !L of a starter culture and incubated for 20 h at 37 °C 
under anaerobic conditions in a 96-well plate sealed with aluminum film. An aliquot of 50 !L of each 
culture was diluted 333 fold with 80% acetonitrile/ 20% 5 mM ammonium formate with 0.1% formic 
acid, and the concentration of TMA-d9 in the culture media was calculated based on an external standard 
curve analyzed at concentrations ranging from 104 pg/µL to 627 pg/µL TMA-d9. Isolates able to convert 
choline into TMA were chosen for 16S rRNA and cutC gene sequencing. 
2.3.13: 16S rRNA sequencing  
PCR amplification of 16S rRNA genes was performed on genomic DNA isolated from all of the 
new choline utilizing strains using previously reported specific primers, fD1 (5’-
TCCTACGGGAGGCAGCAGT-3’) and rP2 (5’- GGACTACCAGGGTATCTAATCCTGTT-3’) (5). 
PCR reactions contained 1X PCR buffer, 0.2 mM dNTPs, 100 ng of DNA template, 100 pmoles of each 
primer, and 1.25 U of Takara Taq Hot Start Version (Takara Bio Inc.) in a total volume of 50 µL. 
Thermocycling was carried out in a MyCycler gradient cycler (Bio-Rad) using the following parameters: 
denaturation for 5 min at 95 °C, followed by 30 cycles of 10 s at 98 °C, 30 s at 50 °C, 2 min at 72 °C, and 
a final extension time of 5 min at 70 °C. PCR reactions were analyzed by agarose gel electrophoresis with 
ethidium bromide staining. PCR products were gel purified and sequenced to determine the identity and 
purity of the isolates. DNA sequences were analyzed with a BLASTN search against the Nucleotide 
collection (nr/nt). 16S rRNA gene sequences with >98% identity were classified as the same species. 
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 Chapter 3: Characterization of Choline Trimethylamine-Lyase Expands the Chemistry of 
Glycyl Radical Enzymesa 
 
3.1: Introduction 
Nature harnesses radical chemistry to accomplish many challenging biochemical transformations 
(1). As described in Chapter 1, glycyl radical enzymes (GREs) utilize protein-based radical intermediates 
to catalyze a variety of reactions, including nucleotide reduction (class III ribonucleotide reductase 
(RNR)), C–C bond formation (benzylsuccinate synthase (BSS)), C–C bond cleavage (pyruvate formate-
lyase (PFL) and 4-hydroxyphenylacetate decarboxylase (4-HPAD)), and dehydration (B12-independent 
glycerol dehydratase (GDH)) (1). In this Chapter, we report the in vitro characterization of a new GRE 
from anaerobic microbes, the C–N bond cleaving enzyme choline trimethylamine (TMA)-lyase (CutC) 
(2). This work reveals the exquisite selectivity of CutC for choline cleavage and provides insights into the 
molecular basis for its function that will inform efforts to develop small molecule inhibitors of this 
microbial metabolic activity. 
As detailed in Chapter 1, microorganisms in the human gastrointestinal tract and other anaerobic 
environments utilize choline as a source of carbon and energy. This process involves generation of TMA, 
an exclusively microbial metabolite (Figure 3.1.A) (3, 4). While choline is an essential nutrient for 
humans (5), excess conversion of choline to TMA by the gut microbiota and its further oxidation to 
trimethylamine N-oxide by liver enzymes is implicated in a number of diseases, including non-alcoholic 
fatty liver disease (6), atherosclerosis (7), and the metabolic disorder trimethylaminuria (fish malodor 
syndrome) (8). TMA is also a carbon source for bacteria and is converted by archaea to the greenhouse 
gas methane in various marine habitats (9). 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
a This chapter is an unofficial adaptation of the article: Craciun S, Marks JA, & Balskus EP (2014) 
Characterization of choline trimethylamine-lyase expands the chemistry of glycyl radical enzymes. ACS 
Chem Biol 9(7):1408-1413.  
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Figure 3.1: Choline trimethylamine-lyase (CutC): a predicted glycyl radical enzyme (GRE) involved in 
anaerobic choline metabolism. (A) Microbial generation of TMA from choline and its subsequent 
processing in biological systems. (B) The choline utilization (cut) gene cluster and the biochemical role of 
predicted GRE CutC and GRE activase CutD. (C) Shared mechanistic hypothesis for GRE function and 
proposed activities for CutC and CutD. SAM = S-adenosylmethionine; dA = 5’-deoxyadenosine; Met = 
L-methionine. 
 
In Chapter 2, we presented the discovery of the first genes responsible for anaerobic microbial 
choline metabolism (2). The choline utilization (cut) gene cluster, which is widely distributed among 
sequenced bacteria and found in many human gut isolates, encodes a predicted bacterial 
microcompartment-associated GRE (CutC) and an S-adenosylmethionine (SAM) dependent GRE 
activating protein (CutD). We confirmed that CutC and CutD were responsible for the initial C–N bond 
fragmentation that generates TMA and acetaldehyde (Figure 3.1.B) using genetics and heterologous 
expression (2). As this transformation impacts human disease and represents a new reaction for the GRE 
family, we decided to further examine the activity of CutC and CutD in vitro.  
The GREs characterized to date are hypothesized to share certain mechanistic features (Figure 
3.1.C), as described in detail in Chapter 1 (1). The glycine-centered radical required for enzyme function 
is generated by the action of a separate activating protein, a member of the radical SAM enzyme family 
(10). These [4Fe-4S] cluster-containing enzymes homolytically cleave SAM, generating a 5’-
deoxyadenosyl radical that abstracts an !-hydrogen atom from an active site glycine of a partner GRE. 
Substrate binding may trigger reaction of the glycyl radical with a nearby cysteine residue, possibly 
generating a thiyl radical that may initiate the reaction through formation of a substrate-based radical. 
! 
" 
# 
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Following further reaction or rearrangement, a product-centered radical may react with the active site 
cysteine, regenerating the thiyl radical. The catalytic glycine and cysteine residues are conserved in all 
known GREs, including choline TMA-lyase, underscoring their importance for function, but there is not 
yet direct evidence for the thiyl radical intermediate. With this knowledge, we hypothesized that the 
putative glycyl radical activating enzyme CutD would generate a glycyl radical on CutC, and that upon 
activation, CutC would convert choline to TMA and acetaldehyde. In addition to reconstituting the 
choline-cleaving activity of these enzymes in vitro, we also sought to investigate their substrate 
specificity and identify additional active site residues that may contribute to catalysis.  
3.2: Results and discussion 
3.2.1: Overexpression and purification of CutC from D. alaskensis G20 and Escherichia coli MS 
69-1 
 
We initiated our studies by cloning CutC and CutD from Desulfovibrio alaskensis G20 genomic 
DNA and individually overexpressing the proteins in Escherichia coli as N- and C-His6-tagged fusions, 
respectively. CutC was expressed and purified aerobically, and the full-length enzyme was employed for 
initial activity assays and all site-directed mutagenesis experiments. While scaling up the original 
purification procedure for analysis by electron paramagnetic resonance spectroscopy (EPR), we observed 
aggregation and precipitation during dialysis. Most CutC homologs are clustered together with genes 
encoding putative microcompartment structural proteins, suggesting that these enzymes might be 
microcompartment-associated in vivo. We thus hypothesized that the instability of full length CutC from 
D. alaskensis G20 could be due to aggregation in the absence of the microcompartment. Previous work 
with proteins from the 1,2-propanediol (11) and ethanolamine (12) utilization pathways revealed that 
short N-terminal sequences are responsible for packaging proteins into bacterial microcompartments. 
Removal of this 27 amino acid sequence led to an improved in vitro solubility of ethanolamine ammonia-
lyase (EAL) subunit EutC from E. coli, without negatively impacting activity (12). 
We performed a multiple sequence alignment of CutC from D. alaskensis G20 with several CutC 
homologs, three of which were not microcompartment-associated based on genomic context (Figure 3.2). 
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We observed that the N-terminal regions of these proteins have a lower degree of similarity (32%) than 
the rest of the sequences (74%). Thus, we proposed that the aggregation of full length CutC in vitro could 
be due to a short (up to ~50 amino acid) N-terminal sequence. Upon generation of truncated variants of 
CutC lacking the first 18, 30 or 52 amino acids (aa) (CutC–18 aa, CutC–30 aa, CutC–52 aa), we observed 
that these proteins possessed significantly improved solubility and stability in comparison to the full-
length enzyme. As a result, the –52 aa truncated variant was used for EPR and kinetics experiments. 
Analytical gel filtration revealed a dimeric oligomerization state for full length CutC and all of the 
variants (Figure 3.3), a state similar to that of GDH (13), PFL (14), and class III RNR (15). 
 
Figure 3.2: Multiple sequence alignment of the N-terminal regions of representative choline TMA-lyase 
homologs reveals that this region might target CutC to a protein microcompartment. The last three 
homologs (marked with blue) are part of cut operons that do not contain putative microcompartment 
proteins. N-terminal methionine residues were omitted to prevent spurious alignment of the divergent 
termini. The percent similarity of these regions is 32%, as opposed to 74% for the rest of the sequences.  
 
 
! 88 
 
Figure 3.3: Determination of the oligomeric state of CutC from Desulfovibrio alaskensis G20 via size 
exclusion chromatography. (A) FPLC chromatogram of molecular weight standards, (B) full-length CutC, 
(C) CutC (–18 aa), (D) CutC (–30 aa), (E) CutC (–52 aa). 
 
 When searching for homologs of CutC from D. alaskensis G20 (2), we discovered that all of the 
putative choline TMA-lyases from facultative anaerobic bacteria contain an extra ~ 300 amino acid N-
terminal domain that does not appear to share similarity with the rest of the protein. As described in 
Chapter 1, the GRE pyruvate formate-lyase from E. coli is encoded next to a small protein (YfiD) similar 
in sequence to the glycyl radical domain of PFL and which was found to rescue the activity of oxygen-
damaged PFL.  We cannot infer the function of the extra 300 amino acid N-terminal domain of CutC 
solely from function, so we aimed to biochemically characterize the full length and a N-terminal domain 
–334 aa truncation variant of CutC from Escherichia coli MS 69-1. Both proteins were purified to 
homogeneity as C-His6-tagged fusions in very good yields. However, analytical size exclusion 
chromatography (Figure 3.4) revealed that the oligomeric state of these proteins was highly 
heterogeneous, with the predominant state as the tetrameric one.   
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Figure 3.4: Determination of the oligomeric state of full length CutC and CutC–334 aa truncated variant 
from Escherichia coli MS 69-1 using analytical size exclusion chromatography. The major peak, marked 
with an asterisk, was found to correspond to the tetramer. 
 
3.2.2: CutD is a SAM-dependent glycyl radical enzyme activating protein 
Expression, purification, and reconstitution of putative GRE activase CutD from D. alaskensis 
G20 with a C-terminal His6-tag were performed under strictly anaerobic conditions with co-expression of 
the E. coli isc operon (16). Interestingly, the co-expression of the isc operon improved CutD yields by ~2-
fold, while the co-expression of the suf operon (typically used to repair oxidatively-damaged [4Fe-4S] 
cluster proteins) (17) interfered with the expression of CutD, providing greatly reduced yields of protein. 
Maltose binding protein-tagged and Strep-tagged CutD also purified in ~10-fold lower yields, so the C-
His6-tag construct was chosen for characterization. Analytical gel filtration revealed CutD to be a 
monomer, similarly to PFL-AE (10) (Figure 3.5). Multiple sequence alignment of CutD with 
characterized GRE activases revealed the conserved [4Fe-4S]-binding CX3CX2C motif, as well as 
putative SAM and GRE binding sites (Figure 3.6) (10). CutD also appeared to possess two “Clostridial”-
type CX2–5CX2–4CX3C motifs, indicating the possibility of auxiliary [4Fe-4S] clusters (18). These motifs 
are typically present in ferredoxins, ubiquitous proteins in bacteria and archaea that typically mediate 
electron transfer within proteins (19). In the case of CutD, it is likely that the additional [4Fe-4S] clusters 
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could shuttle electrons from an electron donor (such as a reduced flavodoxin protein) to the SAM-bound 
[4Fe-4S] cluster, but generally, the roles of auxiliary [4Fe-4S] clusters in radical SAM enzymes are still 
poorly understood and difficult to study (20).  
 
Figure 3.5: Determination of CutD molecular mass via size exclusion chromatography. (A) FPLC 
chromatogram of molecular weight standards. (B) FPLC chromatogram of CutD. 
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Figure 3.6: Multiple sequence alignment of putative choline TMA-lyase activating enzymes and known 
glycyl radical activating enzymes. Asterisks indicate conserved binding motifs. GenBank accession 
number identifies amino acid sequences used. 
 
The UV-Vis spectrum of reconstituted CutD displayed features typical of [4Fe-4S]2+ clusters: a 
broad peak at 380-420 nm which decreased in intensity upon reduction to the [4Fe-4S]+ state using excess 
sodium dithionite (NaDT) (Figure 3.7) (21). Analyses of CutD-bound iron and sulfide indicated the 
possibility of as many as two [4Fe-4S] clusters (8.4 moles of Fe and 7.6 moles of S per mole of CutD), 
although we could not rule out adventitious binding of iron. The CutD extinction coefficient at 410 nm 
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prior to reduction was ~ 12.6 mM–1 cm–1, suggesting that not all iron-sulfur centers had been properly 
reconstituted ([4Fe–4S]2+ !410 ~15 mM–1 cm–1) (21). The EPR spectrum of NaDT-reduced CutD supported 
this hypothesis. At 9 K, the spectrum contained an axial signal with g|| of 2.045 and g! of 1.94 which 
broadened at 40 K and did not change upon addition of excess SAM (Figure 3.8). The g-values and 
temperature dependence of this signal further confirmed the presence of [4Fe-4S]+ centers in reduced 
CutD, while its intensity (0.8 spins per CutD monomer) is consistent with incomplete reconstitution. We 
also examined the activity of NaDT-reduced CutD toward SAM in the absence of CutC using high 
performance liquid chromatography (HPLC) assays (22) and observed generation of cleavage products 
5’-deoxyadenosine and L-methionine, as previously found for other GRE activating proteins (23) (Figure 
3.9). Together, these analyses confirm the assignment of CutD as a radical SAM enzyme. 
 
 
Figure 3.7: UV-Vis spectrum of purified CutD before (red) and after (blue) reduction with sodium 
dithionite (NaDT). 
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Figure 3.8: EPR characterization of the iron-sulfur cluster in CutD. (A) Spectrum at 9K of NaDT-
reduced CutD. (B) Spectrum at 9 K of NaDT-reduced CutD incubated for < 5 min with excess SAM. (C) 
Spectrum at 40 K of NaDT-reduced CutD. Acquisition parameters are described in ‘materials and general 
methods’. 
 
 
 
Figure 3.9: HPLC assays for characterization of SAM cleavage products generated in the presence of 
CutD. (A) Detection of 5’-deoxyadenosine (5’-dA), after the 5’-dA• is quenched by the solvent. (B) 
Detection of L-methionine as an OPA derivative. 
 
3.2.3: The !-proton of the CutC glycyl radical is exchangeable with solvent 
We performed additional experiments to investigate the reactivity of CutD toward CutC. Spectra 
of anaerobic reaction mixtures containing CutD, CutC, SAM, and NaDT taken at 77 K revealed a signal 
centered at g = 2.0037 and characterized by a 2-fold splitting of ~1.46 mT (Figure 3.10.A). The line 
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shape of this signal and its g value closely resemble those of the glycine-centered radicals from activated 
PFL (24) and class III RNR (15). Under the conditions described in ‘materials and general methods’, we 
observed activation to the glycyl radical species of only 9.3% of the CutC–52 aa truncated polypeptides 
from D. alaskensis G20, and 3.6% and 3.4% of CutC–full length and –334 aa truncated polypeptides from 
E. coli MS 69-1, respectively. Activation of CutC–52 aa from D. alaskensis G20 was not improved by 
employing catalytic amounts of CutD or by including choline in the reaction mixture. Use of the 
NADPH:flavodoxin reductase – flavodoxin system from E. coli (25) reduced glycyl radical formation (<1 
% of the CutC dimer), and 5-deazariboflavin did not prove to be a suitable reductant for CutD, contrary to 
the results obtained for the activation of PFL (24).  
When the CutC activation assay was run in Tris-buffered D2O, the resulting EPR spectrum 
revealed no hyperfine splitting, indicating that the remaining !-proton of the glycyl radical is 
exchangeable with solvent (Figure 3.10.B). Analogous behavior, which is likely unrelated to the reaction 
mechanism, has been observed for other GREs (PFL (24), BSS (26), and 4-HPAD (27)) and has been 
attributed to participation of the conserved cysteine via thiyl radical formation. A CutC mutant lacking 
this cysteine (C489A) was still activated by CutD (Figure 3.10.C) but did not undergo exchange in D2O 
(Figure 3.10.D), consistent with this residue’s involvement in the exchange. These EPR experiments 
therefore not only confirm the biochemical function of CutD as a GRE activase, but also support the 
hypothesized functional similarities between CutC and other members of the GRE family. 
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Figure 3.10: EPR spectra of activated CutC from D. alaskensis G20 reveals a glycyl radical with 
an !-proton that is exchangeable in the presence of Cys489. Experimental EPR signals of wild type CutC 
(–52 aa) activated in (A) buffered H2O (g = 2.0037, A = 1.46 mT) and (B) buffered D2O (g = 2.0035, A = 
0.18 mT). Experimental EPR signals of C489A mutant CutC (–52 aa) activated in (C) buffered H2O (g = 
2.0033, A = 1.48 mT), and (D) buffered D2O (g = 2.0033, A = 1.46 mT). The indicated g-values and 
isotropic hyperfine coupling (A-value) were deduced from simulations of the experimental spectra. 
Acquisition parameters and simulations are detailed in ‘materials and general methods’. 
 
 3.2.4: CutC is a C–N cleaving glycyl radical enzyme 
We initially examined the reactivity of the two-enzyme system using an end point assay 
containing choline, CutC and CutD from D. alaskensis G20, SAM, and NaDT. We observed complete 
conversion of choline to TMA (via LC-MS/MS) and acetaldehyde (via GC-MS/MS) only in strictly 
anaerobic assays that contained all of the reaction components, irrespective of the truncated CutC variant 
used (Figures 3.11, 3.12, Table 3.1). Together with EPR data, these experiments confirm that CutC is a 
C"N bond cleaving GRE. In order to assess the catalytic parameters of CutC-catalyzed choline cleavage 
and determine differences in activity of CutC from obligate anaerobic vs. facultative anaerobic bacteria, 
we performed a continuous spectrophotometric coupled assay, in which the formation of acetaldehyde 
from choline by activated CutC was coupled to the reduction of acetaldehyde by NADH-dependent yeast 
alcohol dehydrogenase (YADH) (13). We observed consistent activity for the CutC –52 aa truncated 
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variant from D. alaskensis G20, and CutC–full length and –334 aa truncated variant from E. coli MS 69-
1. All proteins displayed kinetic parameters similar to each other and in accordance to those reported for 
other GREs (Table 3.1, Figure 3.13).  It appears that under the experimental conditions we used, CutC 
from E. coli has a 5-fold greater affinity towards choline than CutC from D. alaskensis. The in vivo 
relevance of these values is unclear, as these experiments cannot replicate the environment of the bacterial 
microcompartment, which is likely to control substrate concentrations (2).     
 
Figure 3.11: Reconstituted CutC from D. alaskensis G20 cleaves choline to TMA and acetaldehyde. LC-
MS end point assays quantifying TMA production from choline by CutC. Each bar represents the mean ± 
standard error of the mean (SEM) of three replicates.  
 
Figure 3.12: LC-MS assays detecting TMA produced from cleavage of choline by full length CutC 
(purified with either Tris-HCl or potassium phosphate buffers) and truncated CutC variants from D. 
alaskensis G20. Each bar represents the mean ± standard error of the mean (SEM) of three replicates. 
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Table 3.1: Kinetic parameters of CutC and comparison to those of other glycyl radical enzymes.  
Enzyme Substrate Km (!M) Vmax (!mol min-1 mg-1) kcat (s-1)a 
kcat/Km (!M-1 s-
1) 
CutC–52 aa  
D. alaskensis G20 
choline 302.5 ± 7.9 22.7 ± 0.2 374 ± 14 1.24 
CutC–full length 
E. coli MS 69-1 
choline 60 ± 0.01 16.1 ± 0.4 239 ± 6 3.98 
CutC–334 aa 
E. coli MS 69-1 
choline 63 ± 0.01 25.9 ± 0.6 282 ± 6 4.48 
4-HPAD HPA 649 ± 90 15.0 ± 0.2 110b 0.17c 
PFL pyruvate 2050 16.6 1100b 0.536c 
BSS toluene < 100 0.0074 N/A N/A 
GDH 1,2-propanediol N/A 1560 N/A N/A 
class III RNR 
CTP (with 0.1 
mM ATP as 
modulator) 
450 1.4 6.8c 0.015c 
a Turnover number shown is based on the amount of active protein. b Value previously reported.  
c Value calculated from published data.  
 
 
Figure 3.13: Michaelis-Menten kinetics of CutC–52 aa truncated variant from D. alaskensis G20, and 
CutC–full length and –334 aa truncated variant from E. coli MS 69-1. 
 
3.2.5: Investigation of CutC specificity toward alternate substrates 
Several CutC homologs had been identified prior to our work via bioinformatics and were 
postulated to mediate diol dehydration, potentially calling into question our annotation of CutC as a 
choline-cleaving GRE (28). We thus investigated the specificity of CutC by examining its activity toward 
alternate substrates using LC-MS/MS for TMA formation and GC-MS/MS for aldehyde formation. As 
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described below, we were unable to detect cleavage products in any assays involving physiological 
relevant small molecules such as L-carnitine, propanediol, dimethylaminoethanol, or glycine betaine 
(Figures 3.14.A, 3.15, 3.17.A, B). The results of preliminary end point assays indicated that CutC can 
catalyze the C-N cleavage of both 2-methylcholine enantiomers (Figure 3.16) and N-(2-hydroxyethyl)-
N,N-dimethylpropan-1-aminium (Figure 3.17.D), but we have not yet examined the kinetic parameters of 
these substrates. The high selectivity of CutC therefore disproves the hypothesis that these enzymes are 
diol-cleaving GREs. In addition, it appears that the presence of a trimethylammonium group is necessary, 
but not sufficient, for CutC-catayzed C–N cleavage of a small molecule. Overall, these results indicate 
that CutC is likely a specific molecular marker for anaerobic choline metabolism. 
 
Figure 3.14: Substrates examined for cleavage by CutC using LC-MS/MS for trimethylamine analysis or 
GC-MS/MS for acetaldehyde, propionaldehyde, or 3-hydroxypropionaldehyde analyses. No cleavage 
products were detected for the molecules in (A), whereas the molecules in (B) were cleaved by activated 
CutC. 
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Figure 3.15: LC-MS assays detecting TMA produced from cleavage of choline, glycine betaine, betaine 
aldehyde, or DL-carnitine by CutC. Each bar represents the mean ± standard error of the mean (SEM) of 
three replicates. 
 
 
Figure 3.16: LC-MS assays detecting TMA produced from cleavage of choline, (R)-2-methylcholine and 
(S)-2-methylcholine by CutC. Each bar represents the mean ± standard deviation of two replicates. 
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Figure 3.17: GC-MS assays for CutC activity with choline and other potential substrates. (A) 
Quantification of acetaldehyde production with alternate substrates. Bar graphs represent the mean ± 
standard error of the mean (SEM) of three independent experiments. (B) Selected ion recording (SIR) 
chromatogram for CutC incubated with 1,2-propanediol. (C) SIR chromatogram for CutC incubated with 
glycerol. (D) SIR chromatogram for CutC incubated with indicated alternate substrates.  
 
3.2.6: Homology modeling of CutC structure and choline binding 
To better understand the molecular basis for this specificity, we identified CutC active site 
residues involved in substrate binding and catalysis. An undergraduate student in the group, Jonathan 
Marks, built a series of CutC homology models using Modeller (29). The model chosen for further 
evaluation utilized two GDH structures as templates (PDB IDs: 1R8W and 2F3O) and passed multiple 
structural quality benchmarks (Table 3.2, Figure 3.18). He also utilized Schrödinger Suite 2012 (30) for 
active site refinement and induced-fit docking of choline (Figure 3.19). Overall, the predicted CutC 
active site closely resembled that of other GREs, with the conserved glycine and cysteine residues 
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(Gly821 and Cys489) located in identical positions. The orientation of choline in the active site revealed 
multiple contacts that could contribute to binding and catalysis. Some of these interactions, such as the 
hydrogen bonding between Glu491 and the choline C1 hydroxyl group, are also observed in the crystal 
structure of glycerol-bound GDH (13), suggesting that both enzymes may use Glu491 as a general base. 
However, the contacts between the protein scaffold and the trimethylammonium group appear unique to 
CutC and might help to distinguish it from other GREs: an electrostatic interaction with Asp216, 
hydrophobic packing with the methyl groups of Thr334 and Thr502, and a cation-! interaction with 
Phe395. Similar interactions were also observed in crystal structures of other choline and acetylcholine 
binding proteins (31, 32), suggesting that proteins might have evolved a common strategy to bind 
substrates containing a trimethylammonium group.  
Table 3.2: Comparison of structure quality benchmarks for CutC homology model with those for the 
crystal structures of GDH (1R8W) and the predicted GDH GRE from A. fulgidus (2F3O). 
 
Overall Scoring Metrics CutC Model 1R8W 2F3O 
DOPE (from Modeller) -101582.21a -104901.53 -107507.26 
Verify3D average per residue 0.35417a 0.45087 0.45981 
DFIRE2 Energy -1557.36 -1584.73 -1613.4 
dDFIRE Energy -2019.05 -2046.52 -2079.01 
QMean6 0.776 0.808 0.774 
QMean6 z-score 0.142 0.494 0.125 
ERRAT Quality Factor 78.777a 97.301 94.51 
PROVE Score 0.988 1.055 1.414 
Backbone conformation z-score -4.518 -5.185 -3.377 
    
Ramachandran    
Z-score (WHATCHECK) 1.46 -2.312 -0.969 
% of residues in favorable regions 91.9 90.4 88.4 
% of residues in allowed regions 8 9.5 11.6 
% of residues in disallowed regions 0.1 0.1 0 
aDenotes metrics that are particularly affected by the presence of the long disordered N-terminal tail of CutC. 
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Figure 3.18: (A) Comparison of the DOPE profiles for the CutC homology model (blue), the published 
GDH structure (1R8W, red), and the predicted GDH (A. fulgidus) structure (2F3O, green). (B) 3D-1D 
profile of the CutC homology model (blue), the published GDH structure (red), and the predicted GDH 
(A. fulgidus) structure (green). (C) Ramachandran plot of homology modeled CutC structure, generated 
with Schrödinger Maestro. Most favored regions are shown in red. Additional allowed regions are shown 
in yellow. Disallowed regions are shown in white. 
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Figure 3.19: Docking of choline in the active site of a CutC homology model. 
 
3.2.7: Preliminary investigation of the role of CutC active site residues in catalysis 
We investigated the contributions to enzyme function of CutC active site residues identified in the 
homology model using site-directed mutagenesis of full length CutC. We aimed to change these residues 
to isosteric ones that lack the hypothesized functionality. Although all of the mutants expressed well, only 
T334S and T502S retained the ability to generate TMA from choline in an endpoint assay (Figure 3.20). 
At the time of this assay, we did not possess data regarding the extent of activation of each mutant to the 
glycyl radical form. Therefore, we assumed that incubating each mutant CutC with the activation assay 
components and choline for 3 hours would be sufficient to determine whether the mutation had an effect 
on its ability to cleave choline. We later realized that our procedure for activating these mutants to the 
glycyl radical form was suboptimal, and thus the lack of activity could have also stemmed from a defect 
in activation.  
 
Figure 3.20: LC-MS end point assays quantifying TMA production from choline by by CutC active site 
mutants. Each bar represents the mean ± SEM of three replicates. WT = wild type. 
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Multiple sequence alignments of CutC homologs (2) (60-80% aa similarity) revealed 
conservation of all the active site residues identified in the homology model for CutC. Notably, 
alignments of CutC with other characterized GREs indicated that the combination of amino acids 
hypothesized to interact with the trimethylammonium group (Asp216, Thr334, Phe395, and Thr502) is 
not found in the active sites of other GREs (Figure 3.21). The discovery of CutC amino acids that are 
both unique and required for function further supports the use of this sequence as specific marker for 
anaerobic choline metabolism. 
 
Figure 3.21: Multiple sequence alignment of choline TMA-lyase homologs and characterized glycyl 
radical enzymes. Asterisks indicate putative CutC active site residues. GenBank accession number 
identifies amino acid sequences used. 
 
3.2.8: Mechanistic proposals for CutC-catalyzed choline cleavage 
Combining the knowledge gained from modeling and mutagenesis experiments, and precedent 
from other radical-utilizing enzymes, we propose two preliminary mechanistic hypotheses for CutC-
catalyzed choline cleavage (Figure 3.22). As is postulated for other GREs (1), the glycyl radical of 
activated CutC may react with Cys489 to form a thiyl radical. Subsequent hydrogen atom abstraction 
from C1 of choline would produce an initial substrate-based radical. Elimination of TMA, potentially 
involving a radical cation or radical anion intermediate, would generate a vinoxy radical that could 
abstract a hydrogen atom from Cys489 to generate acetaldehyde. This scenario closely resembles the 
proposed C–O bond-cleaving step in the mechanism of RNR (33); calculations have also suggested a 
similar mechanism would be possible for B12-independent GDH (34). However, at this point, our data did 
not rule out an alternative scenario involving heteroatom migration that would be analogous to the 
generally accepted mechanisms of B12-dependent eliminating enzymes, including ethanolamine ammonia-
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lyase (35). We also do not yet have any direct evidence for participation of a thiyl radical in catalysis. As 
described in Chapter 4, we conducted a structural study of CutC, which will likely inform further 
mechanistic and computational efforts aimed at fully illuminating the molecular details of choline 
cleavage by CutC.  
 
Figure 3.22: Proposed mechanisms for CutC-catalyzed choline cleavage. 
 
3.2.9: Reactivity of CutC toward C1-13C-labeled choline and stereospecifically-labeled [1-2H]-
choline  
 
As an additional test of our docking model and an initial probe of mechanism, we examined the 
reactivity of CutC toward [1-13C]-labeled choline, (R)-[1-2H]-choline and (S)-[1-2H]-choline. We were 
able to purchase [1-13C]-choline and use GC-MS/MS to compare the 13C enrichment of the acetaldehyde 
resulting from overnight incubation of activated CutC with either labeled or unlabeled choline. Based on 
the MS/MS spectra presented in Figure 3.23, we concluded that 13C was fully incorporated into C1 of 
acetaldehyde. This result is consistent with an initial C-H abstraction occurring at this position to generate 
a C1-centered radical, in agreement with mechanisms proposed for B12-independent glycerol dehydratase 
(34), and ethanolamine ammonia-lyase (35). 
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Figure 3.23: Reactivity of CutC toward 13C-labeled choline. (A) General scheme for the assay. 
(B) MS/MS spectrum of acetaldehyde generated from reaction of CutC with unlabeled choline. (C) 
MS/MS spectrum of acetaldehyde generated from reaction of CutC with [1-13C]-choline.  
 
The orientation of choline within the active site of our homology model for CutC suggested that 
the putative thiyl radical on Cys489 might preferentially access the pro-S hydrogen atom at C1 for initial 
abstraction. By either proposed mechanism, the abstracted C1 hydrogen would be added to C2 after C–N 
cleavage, provided exchange does not occur with solvent or proton acceptors adjacent to Cys489 during 
the course of the reaction. In addition, the hydrogen atom not undergoing abstraction would remain on 
C1. Aiming to verify this hypothesis, we drew inspiration from a similar study of EAL-catalyzed cleavage 
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of deuterated ethanolamine analogs (36), and accessed deuterium labeled (R)-[1-2H]-choline and (S)-[1-
2H]-choline, according to the synthetic route detailed in Figure 3.24. Our initial attempts to work with 
starting materials that had an unprotected amine group did not afford the desired products, so we decided 
to utilize the tert-butyloxycarbonyl (Boc) protecting group. Stereoinduction was achieved by reducing a 
deuterium labeled Boc-protected 2-aminoacetaldehyde with either (R) or (S)-Alpine Borane (37). Due to 
issues with aldehyde stability, we performed this reduction without prior purification. In addition, we 
observed that acid-catalyzed removal of the Boc group could lead to the formation of black, polymerized 
side products, which were difficult to purify away from the desired product. Future efforts to optimize this 
synthesis should thus focus on exploring alternate protecting strategies, such as a carboxybenzyl (Cbz) 
group. Nonetheless, we were able to obtain the desired deuterium labeled choline analogs, and we 
determined their purity and deuterium content by LC-MS/MS using the internal standard (trimethyl-d9)-
choline. Due to the poor solubility of choline in organic solvents, we verified only the stereochemical 
purity of the deuterated ethanolamine precursors. We achieved this by 1H NMR, after derivatization with 
(1S)-(–)-camphanic chloride to afford the N,O-dicamphanoyl product, as previously done for the 
deuterated etanolamine analogs that were tested with EAL (Figure 3.25) (38). Using this assay, we could 
not detect the minor enantiomer, and thus concluded that we were able to access both (R)-[1-2H]-choline 
and (S)-[1-2H]-choline in >95% ee. 
 
Figure 3.24: Synthetic scheme for accessing (R)-[1-2H]-choline and (S)-[1-2H]-choline. 
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Figure 3.25: NMR assay to verify the stereochemical purity of deuterium labeled ethanolamine analogs.  
 
We tested the stereochemical outcome of the initial hydrogen atom abstraction from choline by 
performing preliminary deuterium nuclear magnetic resonance (2H NMR) experiments. We incubated 
stereospecifically deuterated choline analogs with activated CutC for 2 hours (Figure 3.26). Since this 
was an end point assay, we were unable to determine the kinetic parameters of these substrates. The 2H 
NMR spectra indicated that the deuterium atom from (R)-[1-2H]-choline is exclusively retained at C1, 
while the D atom from (S)-[1-2H]-choline is distributed between C1 and C2 over the course of the 
reaction (Figure 3.26). These experiments must be interpreted with caution as they are still preliminary, 
and the reaction does not appear to have gone to completion for any of the substrates. Nonetheless, one 
explanation for this apparent lack of stereospecificity of CutC could be that pro-S hydrogen atom 
abstraction from C1 of choline is much faster than pro-R hydrogen atom abstraction, but that a large 
deuterium isotope effect allows the pro-R hydrogen atom abstraction to become more dominant in the 
pro-S labeled substrate. Further work (e.g., running the 2H NMR experiments until complete substrate 
consumption, and determining the kinetic parameters of CutC-catalyzed cleavage of deuterated choline 
analogs) will be required in order to verify the stereochemical course of this hydrogen abstraction step by 
CutC.  
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Figure 3.26: Preliminary investigation of the stereochemistry of C1 hydrogen abstraction by CutC. 
Deuterium-labeled and unlabeled choline were reacted with activated CutC, and the resulting 
acetaldehyde was reduced by yeast alcohol dehydrogenase (YADH)/NADH. The resulting labeled ethanol 
was detected by 2H NMR (400 MHz).  
 
3.2.10: Conclusions 
In summary, we successfully reconstituted the activity of CutC, the first C!N bond cleaving 
GRE, and gained initial insights into the basis for its substrate specificity and catalytic activity. 
Understanding the relationship between the amino acid sequence of CutC and its function enables the use 
of this enzyme as a biomarker for anaerobic choline metabolism. As we have detailed in Chapter 1, the 
identification of unique active site residues allowed us to distinguish the sequences of CutC homologs 
identified in genomic sequencing data from those encoding other GREs, which facilitated the 
characterization of choline metabolism in microbial communities, including the human gut microbiota. 
Ultimately, this biochemical knowledge also helps to access CutC inhibitors, as we will present in 
Chapter 5. In addition to providing valuable mechanistic information, such molecules would also be 
Me3N OH
HR
HS
0.5 µM CutC, 2 µM CutD
20 µM YADH
NaDT, SAM, NADH
Tris HCl pH 8, 1 h
OHMe
D
or D OH
(S)-[1-D]-choline: HS = D
(R)-[1-D]-choline: HR = D
! 110 
important tool compounds for understanding the role of anaerobic choline metabolism in the human gut 
and its connection to disease. 
3.3. Materials and methods 
 3.3.1: Materials and general methods 
All chemicals and solvents were purchased from Sigma-Aldrich, except where otherwise noted. 
Luria-Bertani Lennox (LB) medium was purchased from EMD Millipore, d9-trimethylamine (TMA) from 
CDN Isotopes, choline chloride-1-13C from Sigma-Aldrich, and d4-acetaldehyde and NMR solvents from 
Cambridge Isotope Laboratories. Methanol, acetonitrile, and water used for liquid chromatography-mass 
spectrometry (LC-MS) were B&J Brand high-purity solvents (Honeywell Burdick & Jackson). 
Oligonucleotide primers were synthesized by Integrated DNA Technologies. Recombinant plasmid DNA 
was purified with a Qiaprep Kit from Qiagen. Gel extraction of DNA fragments and restriction 
endonuclease clean up were performed using an Illustra GFX PCR DNA and Gel Band Purification Kit 
from GE Healthcare. DNA sequencing was performed by Genewiz or Beckman Coulter Genomics. 
Multiple sequence alignments were performed with Clustal W (39), and the results analyzed with 
Geneious Pro 6.1.6 (40). 
Nickel-nitrilotriacetic acid agarose (Ni-NTA) resin was purchased from Qiagen. SDS-PAGE gels 
were purchased from BioRad. Protein concentrations were determined according to the method of 
Bradford using bovine serum albumin (BSA) as a standard (41), or using a NanoDrop 2000 UV-Vis 
Spectrophotometer (Thermo Scientific) for CutC (! = 128 870 M-1 cm-1 for all CutC variants from D. 
alaskensis, ! = 128 167 M-1 cm-1 for CutC–full length from E. coli MS 69-1, ! = 91 684 M-1 cm-1 for 
CutC–334 aa truncation from E. coli MS 69-1). The extinction coefficients for CutC were obtained using 
the ExPASy protparam tool (http://www.expasy.org/tools/protparam.html). 
All anaerobic experiments were conducted in an MBraun glovebox (MBraun) under an 
atmosphere consisting of 99.997% N2 with less than 5 ppm O2, or in an anaerobic chamber (Coy 
Laboratory Products) under an atmosphere of 98% nitrogen and 2% hydrogen. Gel filtration experiments 
were performed on a BioLogic DuoFlow Chromatography System (Bio-Rad) equipped with a Superdex 
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200 10/300 GL column (GE Healthcare). Bovine thyroglobulin (670 kDa), bovine !-globulin (158 kDa), 
chicken ovalbumin (44 kDa), horse myoglobin (17 kDa), and vitamin B12 (1350 Da) were used as 
molecular weight markers (Bio-Rad, #151-190). The molecular weights of the proteins analyzed by gel 
filtration were calculated from their elution volume, using a second-degree polynomial for the 
relationship between log(molecular weight) and retention time. 
Circular dichroism (CD) spectra were taken with a Jasco J-710 Spectropolarimeter in the 
wavelength range 185–300 nm. The scan speed was 50 nm min–1, the data pitch 0.1 nm, the bandwidth 
0.5 nm, and four scans were accumulated per sample. The spectropolarimeter was equipped with a Jasco 
PTC-348W temperature controller set to 22 °C. The cuvettes used for CD measurements were Type 21 
quartz 0.4 mL cells with a PTFE stopper (1 mm path length, Starna Cells; 21-Q-1).  
Perpendicular mode X-band electron paramagnetic resonance (EPR) spectra were recorded on a 
Bruker ElexSysE500 EPR instrument fitted with a quartz dewar (Wilmad Lab-Glass) for measurements at 
77 K, or a cryostat for measurements at 9–40 K. All samples were loaded into EPR tubes with 4 mm 
outer-diameter and 8” length (Wilmad Lab-Glass, 734-LPV-7). Data acquisition was performed with 
Xepr software (Bruker). The magnetic field was calibrated with a standard sample of ",!-bisdiphenylene-
#-phenylallyl (BDPA), g = 2.0026 (Bruker). The experimental spectra for the glycyl radical were modeled 
with EasySpin for Matlab to obtain g values, hyperfine coupling constants, and line widths (42). Spin 
concentration measurements were performed for CutC activation assays by numerically calculating the 
double integral of the simulated spectra and comparing the area with that of a K2(SO3)2NO standard, 
without considering the difference in receiver gain because it was already accounted for by the EPR 
spectrometer. This standard is not stable for a long time (43), so it was prepared before each set of EPR 
measurements. Solid K2(SO3)2NO was dissolved under anaerobic conditions in anoxic 0.5 M KHCO3 and 
diluted to a final concentration of 0.3–0.5 mM. To account for any decomposition during dissolution, the 
concentration was measured at 248 nm ($ = 1690 M-1 cm-1) (43), using a NanoDrop 2000 UV-Vis 
Spectrophotometer. The standard used for quantification of the signal arising from the iron-sulfur clusters 
of CutD was prepared by combining 800 %M CuSO4 with 8 mM EDTA. For glycyl radical-containing 
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samples and the K2(SO3)2NO standard, EPR spectra represent the average of 16 scans and were recorded 
under the following conditions: temperature, 77 K; center field, 3370 Gauss; range, 200 Gauss; 
microwave power, 20 µW; microwave frequency, 9.45 MHz; modulation amplitude, 0.4 mT; modulation 
frequency, 100 kHz; time constant, 20.48 ms; conversion time, 20.48 ms; scan time, 20.97 s; receiver 
gain, 60 dB (for enzymatic assays) or 30 dB (for standards).  For iron-sulfur cluster-containing samples 
and the Cu-EDTA standard, EPR spectra represent the average of 4 scans, and were recorded under 
similar conditions except for: temperature, 9 – 40 K, center field, 3500 Gauss; range, 2000 Gauss; 
microwave power, 2 mW.  
Analytical HPLC was performed on a Dionex Ultimate 3000 instrument (Thermo Scientific). The 
spectrophotometric coupled assay for CutC activity was conducted at 20 ºC in 96-well plates using a 
PowerWave HT Microplate Spectrophotometer (BioTek). The absorbance of each well was monitored at 
340 nm for 10 min, with reads 20 s apart. Path length correction was employed such that absorbance 
values were reported for a path length of 1 cm. Data was analyzed using Gen5 Data Analysis Software 
and kinetic parameters were calculated using GraphPad Prism6. The UV-Vis spectra for CutD were 
collected using the same instrument and a quartz 96-well plate. 
LC-MS/MS analysis was performed in our research lab in the Department of Chemistry and 
Chemical Biology, Harvard University, on an Agilent 6410 Triple Quadrupole LC/MS instrument 
(Agilent Technologies), or in the Small Molecule Mass Spectrometry Facility at Harvard University on an 
Agilent 6460 Triple Quadrupole Mass Spectrometer with Agilent 1290 uHPLC (Agilent Technologies). 
The same LC-MS/MS method was used as previously described for the quantification of TMA (2), with 
the exception that for the Agilent 6460 Triple Quadrupole Mass Spectrometer, the drying gas temperature 
was maintained at 350 °C with a flow rate of 12 L min–1 and a nebulizer pressure of 25 psi. For the 
analysis of stereospecifically deuterated choline, the precursor-product ion pairs used in MRM mode 
were: m/z 113.2!m/z 69.2 (trimethyl-d9-choline), m/z 106.1!m/z 60.2 ([1-2H2]-choline), m/z 105.1! 
m/z 60.2 ([1-2H]-choline), m/z 104.1!m/z 60.2 (unlabeled choline), and the collision energy was 17 V. 
Liquid chromatography was performed as described in Chapter 2.   
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All GC-MS experiments were conducted using a Waters Quattro micro GC Mass Spectrometer 
(Waters) equipped with a Combi PAL headspace autosampler (CTC Analytics) and a split/splitless 
injector. The column used was a DB-624UI, 30 m x 0.32 mm x 1.80 !m (Agilent) and the inlet liner was 
a 1 mm straight single taper Ultra Inert liner (Agilent). The carrier gas was helium, held at 2.3 mL min–1 
constant flow. Samples were incubated at 37 °C for 30 min, with an agitator speed of 500 rpm. The GC 
injection port was set at 220 °C, the syringe temperature to 120 °C, and the needle flush time was 120 s. 
A headspace sample volume of 1 mL was injected into the inlet with a split ratio of 20:1. The column 
temperature was initially maintained at 30 °C for 3 min, then increased to 250 °C at a rate of 50 °C min–1 
with a total run time of 7.4 min. The GC was coupled to a mass spectrometer, equipped with an electron 
ionization source and a triple quadrupole mass analyzer with acquisition in positive mode. The GC 
interface temperature was maintained at 220 °C, and the ion source temperature at 200 °C. In order to 
identify the products present in enzymatic reactions, the mass analyzer was set to scan over a 45–100 m/z 
range for 0–1.3 min and a 20–100 m/z range for 1.3–6.2 min of the run. The Selected Ion Recording 
(SIR) function was used for detection and quantification of acetaldehyde over the first 6.2 min of the run. 
The monitored SIR ions were m/z 29 for unlabeled acetaldehyde and m/z 30 for d4-acetaldehyde. GC-MS 
data analysis was performed with the MassLynx software package. Peak intensities for the ions indicated 
above, at a retention time of "1.44 min, were used for the final quantification of acetaldehyde.  
Proton (1H), deuterium (2H), and carbon (13C) nuclear magnetic resonance (NMR) spectra were 
recorded in the Magnetic Resonance Laboratory in the Harvard University Department of Chemistry and 
Chemical Biology on a Varian Inova-500 (500 MHz, 125 MHz) or Varian Mercury-400 (400 MHz, 100 
MHz) NMR spectrometer. Chemical shifts are reported in parts per million downfield from 
tetramethylsilane using the solvent resonance as an internal standard for 1H (D2O = 4.75 ppm), and 13C 
(DMSO-d6= 39.52 ppm), and a small amount of deuterated solvent for 2H NMR (DMSO-d6 in H2O = 2.71 
ppm). Data are reported as follows: chemical shift, integration multiplicity (s = singlet, d = doublet, t = 
triplet), coupling constant, integration, and assignment. NMR spectra were visualized using ACD/NMR 
Processor Academic Edition. 
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High-resolution mass spectral (HRMS) data for the synthetic compounds were obtained in the 
Magnetic Resonance Laboratory in the Harvard University Department of Chemistry and Chemical 
Biology on a Bruker Micro QTOF-QII fitted with a dual-spray electrospray ionization (ESI) source. The 
capillary voltage was set to 4.5 kV and the end plate offset to –500 V, the drying gas temperature was 
maintained at 190 oC with a flow rate of 8 L min–1 and a nebulizer pressure of 21.8 psi. The liquid 
chromatography (LC) was performed using an Agilent Technologies 1100 series LC with 50% H2O and 
50% acetonitrile as solvent.  
3.3.2: Cloning!of cutC (wild type, truncated variants, and mutants) and cutD  
 
Table 3.3: Oligonucleotides used for cloning. Restriction sites are underlined. 
Oligonucleotide Target Sequence (5’ to 3’) Restriction site 
For cloning cutC and cutD from Desulfovibrio alaskensis G20 
Dde-3282-NdeI-start CutC GCATCATATGGATCTCCAGGACTTTTCACATAAGC NdeI 
Dde-3282-XhoI-stop 
CutC 
CutC (–18 aa) 
CutC (–30 aa) 
GATCCTCGAGTTAGAAACCATGCAGCATGG XhoI 
CutC-truncated-18aa-Ndel-start CutC (–18 aa) GCATCATATGCCGGCAGAACGTGCTTCG NdeI 
CutC-truncated-30aa-Ndel-start CutC (–30 aa) GCATCATATGGGCGTATCCGCCGAGGTCTTC NdeI 
CutC-truncated-52aa-Ndel-start CutC (–52 aa) GCATCATATGGGCATTCCCGACGGGCCTAC NdeI 
Ddes3282-NotI-stop CutC (–52 aa) GATTAA GCG GCC GCTTAGAAACCATGCAGC NotI 
Dde-3281-NdeI-start CutD GCATCATATGAGAACCGCAACACACAGAGACG NdeI 
Dde-3281-XhoI-nostop CutD GATTCTCGAGGTGGCGGATCACCGAAACC XhoI 
Dde3282-QC-D216N-for CutC-D216N GTGAACGGCGGCGGCAACTCCAACCCCGGTTAC ! 
Dde3282-QC-D216N-rev CutC-D216N GTAACCGGGGTTGGAGTTGCCGCCGCCGTTCAC ! 
Dde3282-QC-T334S-for CutC-T334S GTTGAAGAAAACCAGAGCGGTATGTCCATCGGC ! 
Dde3282-QC-T334S-rev CutC-T334S GCCGATGGACATACCGCTCTGGTTTTCTTCAAC ! 
Dde3282-QC-F395L-for CutC-F395L GCCGGGTACCAGCCTTTAGTGAACATGTGCGTG ! 
Dde3282-QC-F395L-rev CutC-F395L CACGCACATGTTCACTAAAGGCTGGTACCCGGC ! 
Dde3282-QC-C489A-for CutC-C489A CutC (–52 aa) C489A GACTACTGCCTGATGGGTGCCGTGGAACCGCAG ! 
Dde3282-QC-C489A-rev CutC-C489A CTGCGGTTCCACGGCACCCATCAGGCAGTAGTC ! 
Dde3282-QC-E491Q-for CutC-E491Q CTGATGGGTTGCGTGCAACCGCAGAAATCAGGCCGT ! 
Dde3282-QC-E491Q-rev CutC-E491Q ACGGCCTGATTTCTGCGGTTGCACGCAACCCATCAG ! 
Dde3282-QC-T502S-for CutC-T502S CGTCTGTACCAGTGGAGCTCCACCGGCTATACC ! 
Dde3282-QC-T502S-rev CutC-T502S GGTATAGCCGGTGGAGCTCCACTGGTACAGACG ! 
! 115 
Dde3282-QC-G821A-for CutC-G821A GTGGTGCGCGTGGCCGCATACAGCGCCTTCTTC ! 
Dde3282-QC-G821A-rev CutC-G821A GAAGAAGGCGCTGTATGCGGCCACGCGCACCAC ! 
For cloning cutC from Escherichia coli MS 69-1 
MS69CutCtrunc334aa-NdeI-
start CutC –334 aa GAGCGTCATATGGTTACCACACTATGTGCCGCC NdeI 
MS69CutC-Chis-NotI-nostop 
 
CutC 
CutC –334 aa GAATTAGCGGCCGCGAACTTCTCAATCACCGTAC NotI 
MS69CutC-NdeI-start CutC  GCCCCGCATATGCCACTGATAACAAGAACTGG NdeI 
 
Amplification of cutC (Dde_3282) and cutD (Dde_3281) from Desulfovibrio alaskensis G20 
genomic DNA, and of cutC (EFJ81575.1) from Escherichia coli MS 69-1 genomic DNA were performed 
according to a previously published procedure (2) using the primers listed in Table 3.3. Amplified 
fragments were digested with the appropriate restriction enzymes (NdeI, NotI, XhoI) (New England 
Biolabs, NEB), purified and ligated into linearized expression vectors as previously described (2), to 
afford pET-29b-CutD (C-terminal His6-tagged construct), pET-28a-CutC from D. alaskensis G20 (N-
terminal His6-tagged constructs), and pET-29b-CutC-full length and pET-29b-CutC-334aa from E. coli 
MS 69-1 (C-terminal His6-tagged constructs). These constructs were transformed into chemically 
competent E. coli BL21 (DE3) cells (Invitrogen) and stored at !80 °C as frozen LB/glycerol stocks. 
Site-directed mutagenesis of CutC (full length enzyme from D. alaskensis G20) was performed 
using the corresponding oligonucleotides listed in Table 3.3. PCR reactions of 20 µL contained 10 µL of 
Phusion High-Fidelity PCR Master Mix (New England Biolabs), 50 ng of pET-28a-CutC template, and 
100 pmoles of each primer. Thermocycling was carried out in a C1000 Gradient Cycler (Bio-Rad) using 
the following parameters: denaturation for 1 min at 95 °C, followed by 18 cycles of 30 s at 95 °C, 1 min 
at 67 °C, and a final extension time of 8 min at 72 °C. Digestion of the methylated template plasmid was 
performed with DpnI (NEB), and 5 µL of each digestion was used to transform a single tube of 
chemically competent E. coli TOP10 cells. The identities of the resulting pET-28a-CutC-D216N, pET-
28a-CutC-T334S, pET-28a-CutC-F395L, pET-28a-CutC-C489A, pET-28a-CutC-E491Q, pET-28a-CutC-
T502S, pET-28a-CutC-G821A, and pET-28a-CutC-52-C489A constructs were confirmed by sequencing 
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purified plasmid DNA. Chemically competent E. coli BL21(DE3) cells were transformed with plasmid 
DNA and stored at –80 °C as frozen LB/glycerol stocks.  
3.3.3: Large scale overexpression and purification of wild type CutC, truncated variants, and 
active site mutants 
 
An LB agar plate with 50 µg mL–1 kanamycin (Kan) was streaked with a frozen stock of E. coli 
BL21(DE3) cells transformed with a CutC-harboring plasmid. A single colony from each plate was 
inoculated into 50 mL of LB medium with 50 µg/ml Kan, which was grown overnight at 37 °C. These 
starter cultures were diluted 1:100 into 2 L of LB medium containing 50 µg mL–1 Kan, then incubated at 
37 °C with shaking at 175 rpm, induced with 500 µM IPTG (Teknova) at OD600 = 0.5–0.6, and incubated 
at 37 °C for 4–5 h (wild type CutC and active site mutants from D. alaskensis G20) or at 15 °C overnight 
(truncated CutC variants from D. alaskensis G20, CutC–full length and –334 aa truncation from E. coli 
MS 69-1). Cells from 2 L of culture were harvested by centrifugation (6,000 rpm x 10 min), resuspended 
in 45-50 mL of lysis buffer. The cells were lysed by passage through a cell disruptor (Avestin 
EmulsiFlex-C3) twice at 8,000–10,000 psi, and the lysate was clarified by centrifugation (10,000 rpm x 
30 min). The supernatant was incubated with 2 mL of Ni-NTA resin and 5 mM imidazole for 2 h (30 min 
for CutC from E. coli) at 4 °C. The mixture was centrifuged (3,000 rpm x 5 min) and the unbound 
fraction discarded. The Ni-NTA resin was resuspended in 10 mL of elution buffer, loaded into a glass 
column, and washed with 10 mL of elution buffer. Protein was eluted from the column using a stepwise 
imidazole gradient in elution buffer (25 mM, 50 mM, 100 mM, 200 mM, 500 mM), collecting 2 mL 
fractions. SDS–PAGE analysis (4–15% Tris-HCl gel) was employed to ascertain the presence and purity 
of protein in each fraction. Fractions containing the desired protein were combined and dialyzed twice 
against 2 L of storage buffer. Upon removal of any precipitated protein through centrifugation at 3,000 
rpm x 2 min, the solutions were concentrated using a Spin-X® UF 20 mL centrifugal concentrator with a 
30,000 MWCO membrane (Corning®), then frozen in liquid N2 and stored at –80 °C.  
All CutC mutants and the preparations of CutC WT used for MS assays from D. alaskensis G20 
were purified using this protocol and the following buffers: lysis buffer contained 20 mM Tris-HCl pH 8, 
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500 mM NaCl, 10 mM MgCl2, and half of a SIGMAFAST™ protease inhibitor cocktail tablet (Sigma-
Aldrich), elution buffer consisted of 20 mM Tris-HCl pH 8, 500 mM NaCl, 10 mM MgCl2, and 5 mM 
imidazole, and storage buffer contained 20 mM Tris-HCl pH 8, 50 mM NaCl, 10% (v/v) glycerol. This 
procedure afforded yields of 1–3 mg L–1 of bacterial culture for CutC WT, 2 mg L–1 for CutC-D216N, 6 
mg L–1 for CutC-T334S, 16 mg L–1 for CutC-F395L, 1.8 mg L–1 for CutC-C489A, 0.9 mg L–1 for CutC-
E491Q, 9 mg L–1 for CutC-T502S, and 1.5 mg L–1 for CutC-G821A (Figure 3.27). Proper folding of 
CutC WT and mutant proteins was verified by analyzing a 10 µM solution of each protein by circular 
dichroism, as outlined in ‘materials and general methods’. 
Since the yields obtained by purifying CutC WT with Tris-HCl pH 8 buffer were too low to allow 
its characterization by EPR, we optimized a purification procedure employing potassium phosphate buffer 
pH 8. This protocol was also used to purify the truncated variants of CutC from D. alaskensis G20: CutC 
–18 aa, CutC–30 aa, CutC–52 aa, the mutant CutC–52aa C489A, and CutC–full length and –334 aa 
truncated variant from E. coli MS 69-1. The overall procedure was similar to the one described above 
with the following exceptions: the lysis buffer contained 50 mM potassium phosphate pH 8 and 300 mM 
KCl; no protease inhibitor was added; the elution buffer contained 50 mM potassium phosphate pH 8, 300 
mM KCl, and 5 mM imidazole; and the storage buffer consisted of 50 mM potassium phosphate pH 8, 50 
mM KCl, and 10% (v/v) glycerol. For CutC from D. alaskensis G20, this procedure afforded yields of 6-
10 mg L–1 of bacterial culture for CutC WT, 17 mg L–1 for CutC (–18 aa), 20 mg L–1 for CutC (–30 aa), 
24 mg L–1 for CutC (–52 aa), and 25 mg L–1 for CutC (–52 aa) C489A. For CutC from E. coli MS 69-1, 
this procedure afforded yields of 20 mg L–1 of bacterial culture for CutC–full length and 17 mg L–1 for 
CutC–334 aa truncation. 
3.3.4: Determination of the molecular mass of CutC using size exclusion chromatography 
A ~30 µM solution of CutC (full-length or truncated variant) was analyzed by size exclusion 
chromatography, as described in ‘materials and general methods’ (50 µL injection volume). The proteins 
were eluted over 122 min with 50 mM potassium phosphate buffer pH 8, 50 mM KCl, 10% v/v glycerol 
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at 0.25 mL min–1. A solution of molecular weight markers (Bio-Rad, #151-190) analyzed under the same 
conditions and was used to construct a standard curve.  
3.3.5: Large scale overexpression and purification of CutD 
The best CutD yields were achieved when plasmid pPH149 (21) containing the E. coli IscSUA-
HscBA-Fd genes (ISC system) was co-transformed into chemically competent E. coli BL21 (DE3) cells 
(Invitrogen) together with pET-29b-CutD. An LB agar plate with 50 µg mL–1 Kan and 50 µg mL–1 
chloramphenicol (Cam) was streaked with a frozen stock of E. coli BL21(DE3) cells transformed with 
pET-29b-CutD and the ISC system. A single colony was used to inoculate 50 mL of LB medium with 50 
µg mL–1 Kan and 50 µg mL–1 Cam, which was grown overnight at 37 °C. This starter culture were diluted 
1:100 into a screw-capped 2.8 L flask with 2 L of LB medium supplemented with 50 µg mL–1 Kan, 50 µg 
mL–1 Cam, 2 mM iron (III) ammonium citrate, and 0.5 % (w/v) glucose. The culture was incubated at 37 
°C with shaking at 175 rpm until reaching an OD600 = 0.35–0.4, at which point it was placed at room 
temperature and sparged with argon gas for ~30 min. Upon addition of L-cysteine (2 mM final 
concentration) and sodium fumarate (20 mM final concentration), the culture was further sparged until 
reaching an OD600 = 0.5–0.6, at which point protein expression was induced with 500 µM IPTG 
(Teknova), the flask was capped tightly and wrapped with electrical tape, and the culture was incubated at 
15 °C overnight (~16 to 18 h) without shaking in an Mbraun glove box. 
All purification steps were performed in an anaerobic chamber at 11 °C (MBraun glove box), 
with the exception of cell lysis and centrifugation. Cells from 2 L of culture were harvested by 
centrifugation in 250 mL polypropylene centrifuge tubes (6,000 rpm x 10 min) and resuspended in 45-50 
mL of anoxic lysis buffer (50 mM HEPES, 200 mM NaCl, 10 mM MgCl2, pH 8) supplemented with half 
of a SIGMAFAST™ protease inhibitor cocktail tablet (Sigma-Aldrich), 8 mg of chicken egg lysozyme, 
and 5 mM DL-dithiothreitol (DTT). The resuspension was brought out of the anaerobic chamber and the 
cells were lysed by passage through a cell disruptor (Avestin EmulsiFlex-C3) twice at 8,000–10,000 psi 
while maintaining a nitrogen line above the receiving tube and one above the cell disruptor reservoir. For 
assays with CutC from E. coli MS 69-1, CutD-expressing cells were lysed under strict anaerobic 
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conditions, in a Coy Labs glove box at 4 °C, employing a sonifier (Branson). The lysate was clarified by 
centrifugation (10,000 rpm x 30 min), and the supernatant was incubated with 2 mL of Ni-NTA resin 
(previously sparged with nitrogen) and 5 mM imidazole for 2 h at 4 °C. The mixture was brought out of 
the anaerobic chamber, centrifuged (3,000 rpm x 5 min), and the unbound fraction discarded. The Ni-
NTA resin was resuspended inside the anaerobic chamber in 10 mL of elution buffer (50 mM HEPES, 
200 mM NaCl, 10 mM MgCl2, 5 mM imidazole, pH 8) and loaded into a glass column. Protein was eluted 
from the column using a stepwise imidazole gradient in elution buffer (10 mM, 25 mM, 50 mM, 100 mM, 
200 mM), collecting 2 mL fractions. SDS–PAGE analysis (4–15% Tris-HCl gel) was employed to 
ascertain the presence and purity of protein in each fraction. Fractions containing CutD were combined 
and stirred slowly for 13–16 h with 2 mM DTT, 0.2 mM Na2S, and 0.25 mM Fe(NH4)2(SO4)2 (the iron 
was added from a 10 mM stock 5 min after the DTT and Na2S solutions were added).  
Reconstituted CutD was filtered through a 25 mm, 0.22 µm pore-size Acrodisc syringe filter with 
HT Tuffryn Membrane (Pall Life Sciences) to remove particulates and was dialyzed with three 1 L 
batches of 50 mM HEPES pH 8, 50 mM NaCl, and 10 % (v/v) glycerol. Upon concentration, the protein 
solution was aliquoted into 0.5 mL cryogenic vials, frozen in liquid N2, and placed in 18 x 150 mm 
Hungate tubes (Chemglass) sealed with butyl stoppers and aluminum seals. This procedure afforded up to 
9 mg of CutD per L of bacterial culture (Figure 3.27), while expression without the ISC system provided 
a 2-fold lower yield, without impacting activity.  
 
Figure 3.27: SDS-PAGE (4-15% Tris-HCl gel) of CutC and CutD from D. alaskensis G20. Precision 
Plus Protein™ All Blue Standards (Bio Rad) (lanes 1 and 11), CutD (lane 2), CutC WT (lane 3), CutC 
mutants: CutC-D216N (lane 4), CutC-T334S (lane 5), CutC-F395L (lane 6), CutC-C489A (lane 7), CutC-
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E491Q (lane 8), CutC-T502S (lane 9), CutC-G821A (lane 10), CutC truncated variants: CutC–18 aa (lane 
12), CutC–30 aa (lane 13), CutC–52 aa (lane 14), CutC–52 aa-C489A (lane 15). 
 
3.3.6: Overexpression and purification of flavodoxin and flavodoxin reductase from E. coli K-12 
The plasmids for flavodoxin (pET-23b-Fld) and flavodoxin reductase (pET-28b-Fpr) from E. coli 
K-12 were constructed as previously described (44, 45). Overexpression and purification of these two 
enzymes employed a published method (45) with the following modifications: 10 µM of riboflavin was 
added to the growth medium prior to induction with IPTG, and the storage buffer used was 20 mM 
sodium phosphate pH 7.4, 50 mM NaCl, 10 % (v/v) glycerol. We obtained yields of 28 mg L–1 of 
bacterial culture for Fld, and 60 mg L–1 for Fpr.   
3.3.7: UV-Vis assay for assembly of the [4Fe-4S] cluster in CutD 
After reconstitution of CutD, the protein solution was diluted inside the anaerobic chamber to 10 
µM with anoxic buffer (50 mM HEPES pH 8, 50 mM NaCl), and its absorbance was measured over a 
250–800 nm range using a quartz 96-well plate as described in ‘materials and general methods’. To obtain 
the spectrum for reduced CutD, 10 µM of the protein was incubated with a 10-fold excess of sodium 
dithionite (NaDT) for 15 min prior to the absorbance measurement. 
3.3.8: Determination of iron content of CutD 
The iron content of a 6 µM solution of CutD was determined using Ferene (3-(2-pyridyl)-5,6-
di(2-furyl)-1,2,4-triazine-5 and 5’’-disulfonic acid disodium salt), according to a previously published 
procedure (46), with the exceptions that the assay volume was tripled and the standard curve was 
prepared with ammonium iron (II) sulfate hexahydrate (0-70 µM). 
3.3.9: Determination of sulfide content of CutD 
The sulfide content of a 6 µM solution of CutD was measured using a previously published 
procedure (47), with the following modifications: the assays were performed in microcentrifuge tubes, 
vortexing was used instead of stirring, and the mixture was incubated for 20 min at room temperature 
after addition of NaOH.  
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3.3.10: EPR characterization of CutD 
The samples for EPR analysis of the reduced iron-sulfur cluster contained 50 mM HEPES pH 8, 
50 mM NaCl, 40 !M CutD, and 4 mM NaDT, and were incubated at room temperature (22 °C) under 
anaerobic conditions for 20 min prior to freezing in liquid N2. In order to determine the effect of S-
adenosylmethionine (SAM) on the EPR signal, 4 mM SAM was added after the reduction, and the sample 
was frozen within less than 5 min. Quantification of the signal at 9 K for each sample was performed with 
a Cu-EDTA standard as described in the ‘materials and general methods’, and indicated the presence of 
~0.8 spins per CutD monomer in each case. Despite the apparent splitting noticeable in the (A) and (B) 
spectra from Figure 3.8 (which could be due to a superimposition of signals), the signal with g|| of 2.045 
and g of 1.94 can be unambiguously attributed to a [4Fe-4S]+ cluster, because this signal broadens and 
decreases in intensity at higher (40 K) temperatures, as shown in spectrum (C). The shape and amplitude 
of the EPR signal do not seem to change upon addition of excess SAM, an observation that has been 
made for other glycyl radical activating proteins (27, 48, 49). 
3.3.11: Detection of 5’-deoxyadenosine by HPLC 
The 5’-dA detection assay contained 25 mM Tris HCl buffer pH 8, 50 mM NaCl, 16 mM NaDT, 
40 µM CutD, and 1 mM SAM in a total volume of 100 µL. All components except for SAM were 
combined inside an anaerobic chamber in order to allow CutD to reduce and SAM was added after 15 
min. The reactions were incubated at room temperature in the chamber for 4 h, quenched with 2.56 µL 
formic acid, and centrifuged (13,200 rpm x 10 min) to remove precipitated protein. The supernatant was 
analyzed by HPLC (20 µL injection volume) on a Phenomenex Luna analytical C18 reverse phase 
column (5 µm, 4.6 x 250 mm, 100 Å), preceded by a HAIPEEK guard cartridge holder (Higgins 
Analytical) equipped with a CLIPEUS C18 (5 !m, 2 cm x 3.2 mm) cartridge (Higgins Analytical). The 
solvent system consisted of 40 mM ammonium acetate pH 6 (A) and acetonitrile (B), and the elution 
conditions were: 0% B for 2 min, 0-25% B over 25 min, 25-0% B over 2 min, 0% B for 5 min. The flow 
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rate was set to 1 mL min–1, the products were detected by UV at 216 nm and 260 nm, and commercial 5’-
deoxyadenosine was used as a standard.  
3.3.12: Detection of methionine by HPLC 
The methionine detection assay was performed in a similar manner as the 5’-dA detection assay, 
except that it contained 12 mM NaDT and 30 µM CutD, and it was incubated for 18 h. The reactions were 
quenched with 200 µL methanol, kept on ice for 10 min, and centrifuged (13,200 rpm x 10 min). The 
organic solvent was removed in vacuo, concentrating the mixtures to ~100 µL. A 20 µL aliquot of each 
assay was mixed with o-phthaldialdehyde (OPA) reagent (Sigma-Aldrich; containing 2 µL of 2-
mercaptoethanol per mL of incomplete reagent). After an incubation of 5-6 min, the samples were 
analyzed by HPLC (40 µL injection volume) on a Dionex Acclaim C18 reverse phase column (3 µm, 2.1 
x 150 mm, 120 Å), preceded by the same guard cartridge as for the 5’-dA assay. The solvent system 
consisted of water (A) and acetonitrile (B). The products eluted at 0.25 mL min–1 with the following 
elution conditions: 0% B for 1 min, 0-70% B over 15 min, 70-0% B over 5 min, 0% B for 2 min. OPA-
derivatized L-methionine was used as a standard and the products were detected by UV at 338 nm. 
3.3.13: Quantification of the glycyl radical content of CutC truncated variants from D. alaskensis 
G20 
 
All activation assays contained 25 mM Tris HCl buffer pH 8, 50 mM NaCl, 3 mM NaDT, 30 µM 
CutD, 7.5 µM CutC dimeric truncated variant (–18 aa, –30 aa, or –52 aa), and 3 mM SAM in a total 
volume of 300 µL. For all assays involving CutC, the enzyme was made anoxic by sparging with argon 
for 15-30 min. All components except for CutC and SAM were combined inside an Mbraun anaerobic 
chamber in order to allow CutD to reduce, then SAM was added after 20 min. The reactions were 
incubated at room temperature for approximately 60 min before being transferred to an EPR tube and 
frozen in liquid nitrogen. For each CutC truncated variant, the activation assay was performed in 
triplicate. Quantification of the amount of glycyl radical present in the assay was done with a K2(SO3)2NO 
standard as described in the ‘general materials and methods’. The extent of activation was calculated for 
each variant and is reported as % of CutC polypeptides converted to the glycyl radical form: 8.2 ± 0.2 % 
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for CutC (–18 aa), 8.6 ± 0.3 % for CutC (–30 aa), 9.3 ± 0.4 % CutC (–52 aa). Interestingly, for PFL (50) 
and class III RNR (25), the maximum extent of activation achieved in vitro is 50% of polypeptides, and 
the explanation for these results still remains unknown. So far, our attempts to increase the extent of CutC 
activation have been unsuccessful. The amount of glycyl radical observed by EPR was lower when the 
CutC:CutD ratio employed was 1:0.4 (with either 1 h or 5.5 h incubation), when choline (0.3 mM) was 
included in the activation assay, and when NaDT was replaced with 1.7 mM DTT, 4 !M Fld, 2 !M Fpr 
and 0.8 mM NADPH (the NADPH:flavodoxin reductase – flavodoxin system from E. coli). Preliminary 
experiments also indicated that the maximum amount of glycyl radical is obtained after 1 h of incubation 
and that the radical has a half-life of ~6 h.   
3.3.14: Quantification of the glycyl radical content of CutC from E. coli MS 69-1 
 
When we analyzed the glycyl radical content of CutC from E. coli MS 69-1, we had already 
carried out extensive efforts to optimize the activation of CutC from D. alaskensis G20 (detailed in 
Chapter 4 of this thesis). As a result, activation assays for CutC from E. coli MS 69-1 were set up in an 
MBraun anaerobic chamber in 1.5 mL polypropylene Eppendorf tubes and contained 50 mM potassium 
phosphate pH 8, 50 mM potassium chloride, 400 !M sodium dithionite, 400 !M AdoMet, 20 !M CutC 
dimer and 80 !M CutD from D. alaskensis G20 in a total volume of 200 !L. A mixture of buffer, CutD 
and sodium dithionite was incubated for 20 min prior to addition of AdoMet and CutC, then glycyl 
radical formation was carried out for 1 h at room temperature. X-band EPR spectroscopy and spin 
concentration measurements were performed as described in ‘materials and general methods’.  
3.3.15: Activation assays for CutC from D. alaskensis G20 conducted in buffered H2O and D2O 
In order to exchange CutC–52 aa (wild type or C489A mutant) and CutD from buffered H2O to 
D2O, a 25 mM Tris DCl pH 8, 50 mM NaCl buffer was prepared anoxically in 99.9% D2O and used to 
swell 0.5 g of Sephadex G-25 fine resin. A mixture of CutC–52 aa and CutD was passed through the 
resin, and the proteins were eluted with the D2O-containing buffer described above. In order to determine 
which of the 0.2 mL-fractions collected contained protein, 10 µL of each fraction was mixed with 90 µL 
Bradford reagent. The ones that afforded a color change were pooled and concentrated to ~280 µL with 
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Spin-X® UF 6 mL centrifugal concentrators with a 5,000 MWCO membrane (Corning®) placed in 50 
mL conical-bottom centrifuge tubes with plug seal caps. The activation assays were conducted as 
presented above and contained 25 mM Tris HCl (or DCl) buffer pH 8, 50 mM NaCl, 5 mM NaDT, 50 µM 
CutD, 12.5 µM CutC–52 aa (wild type or C489A mutant), and 1 mM SAM in a total volume of 300 µL. 
EPR spectra were recorded and modeled as described in the ‘materials and general methods’.  
3.3.16: LC-MS/MS assay for trimethylamine detection from in vitro assays 
A typical assay for LC-MS/MS detection of trimethylamine (TMA) contained 25 mM Tris HCl 
buffer pH 8, 50 mM NaCl, 2 mM NaDT, 5 µM CutD, 0.5 µM CutC (WT, truncated variant, or mutant), 
substrate (0.2 mM of choline, betaine aldehyde, glycine betaine, DL-carnitine, (R)-2-methylcholine, or 
(S)-2-methylcholine), and 1 mM SAM in a total volume of 250 µL. No difference in activity was 
observed between CutC purified with Tris-HCl pH 8 buffer and with potassium phosphate pH 8 buffer. 
To a 2 mL screw top amber vial (Agilent Technologies, 5188-6535) located inside the anaerobic chamber 
were added buffer, NaDT, and CutD, and the resulting mixture was incubated at room temperature for 15 
min in order to allow CutD to reduce. CutC, substrate, and SAM were added in this order, the vials were 
capped immediately with a screw top cap with PTFE/red silicone septa (Agilent Technologies, 5182-071
7), and the reactions were incubated at room temperature for 3 h (exception: the assay with DL-carnitine 
as substrate was incubated for 13 h). Upon removal from the anaerobic chamber, the TMA concentration 
in each assay was determined using LC-MS/MS after derivatization with ethyl bromoacetate (2) and using 
100 µL of d9-TMA (200 µM in water) as the internal standard. A 10 µL aliquot of the quenched 
derivatization mixture was diluted 50-fold with infusion solution [acetonitrile/ water/ formic acid, 
50/50/0.025 (v/v/v)] and analyzed by LC-MS (3 µL injection volume) as described in ‘materials and 
general methods’. For the assays that did not afford TMA, the concentration of internal standard used was 
0.3 µM, and the samples were not diluted before analysis. 
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3.3.17: GC-MS/MS assay for acetaldehyde, acetaldehyde-1-13C, propionaldehyde, and 3-
hydroxy-propionaldehyde detection 
 
The enzymatic reactions were conducted as described for the LC-MS/MS assays, except that 
different amounts of substrate were used (1 mM of choline chloride, choline chloride-1-13C, 
dimethylaminoethanol, methylaminoethanol, ethanolamine, or 1,2-propandiol, and 5 mM of N-(2-
hydroxyethyl)-N,N-dimethylpropan-1-aminium, 3-hydroxy-N-(2-hydroxyethyl)-N,N-dimethylpropan-1-
aminium, N-(2-hydroxyethyl)-N,N-dimethylbutan-1-aminium), and the incubation time was ~12 h. CutC 
WT used for these assays was purified with potassium phosphate buffer pH 8. Since both CutC and CutD 
are stored with 10% (v/v) glycerol (179 mM final concentration), no additional glycerol was added to the 
assays testing it as a potential substrate. Upon removal from the anaerobic chamber, reaction mixtures 
were kept at 4 °C for 1 h, uncapped, and the contents were quickly transferred to 10 mL headspace vials 
with screw tops (Sigma-Aldrich, SU860099) containing 1 mM d4-acetaldehyde (only for acetaldehyde 
quantification assays), 1.8 g NaCl, and water up to a final volume of 2.5 mL. The headspace of each vial 
was analyzed by GC-MS/MS as outlined in ‘materials and general methods’. For assays with choline 
chloride-1-13C, the % 13C incorporation was calculated based on the relative intensities of the fragments 
with m/z 29 and 30 from the MS/MS spectrum of 13C-acetaldehyde, also taking into consideration the 
abundance ratio of the fragments with m/z 28 and 29 in the MS/MS spectrum of unlabeled acetaldehyde.   
3.3.18: Spectrophotometric coupled assay for kinetic analysis of choline cleavage 
Before each assay, CutC–52 aa from D. alaskensis G20 was activated without substrate using the 
same conditions described for the EPR quantification of the glycyl radical. After 1 h of incubation, this 
activation mixture was diluted 75-fold and added to the kinetic assay. Each coupled assay contained 25 
mM Tris HCl buffer pH 8, 50 mM NaCl, 200 !M NADH, 320 nM yeast alcohol dehydrogenase, 8 nM 
CutC dimer–52 aa, 32 nM CutD, 3.2 !M NaDT, 3.2 !M SAM, and 0-2 mM choline, in a total volume of 
200 !L. Activation of CutC from E. coli MS 69-1 was carried out as described above. All assays with 
CutC–full length and CutC–334 aa from E. coli MS 69-1 contained 200 !M NADH, 50 mM potassium 
phosphate pH 8, 50 mM potassium chloride, diluted activation mixture (to achieve a final concentration 
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of 10 nM CutC dimer), YADH (0.4 !M) and choline (0-2 mM) in a total volume of 200 !L. All reactions 
were initiated by adding choline. The assays were carried out in triplicate in a 96-well plate and the 
NADH absorbance at 340 nm was monitored for 5 min. The absorbance decreased linearly in all cases, 
indicating a constant concentration of activated enzyme during the course of our measurements. The 
turnover numbers were calculated as the !moles of product formed per second per !mol of activated 
CutC (converted to the glycyl radical form). 
3.3.19: 2H NMR assays for detection of CutC-mediated production of deuterated acetaldehyde 
from stereospecifically deuterated choline 
 
 CutC–52 aa from D. alaskensis G20 was first activated to the glycyl radical form as described 
above. After 1 hr of incubation, this mixture was diluted 15-fold. Each coupled assay contained 25 mM 
Tris HCl buffer pH 8, 50 mM NaCl, 80 mM NADH, 20 !M yeast alcohol dehydrogenase, 0.5 !M CutC 
dimer–52 aa, 2 !M CutD, 0.2 mM NaDT, 0.2 mM SAM, and substrate (50 mM unlabeled choline, 38.9 
mM (R)-[1-2H]-choline, or 50 mM (S)-[1-2H]-choline) in a total volume of 600 !L. The assays were 
incubated in an Mbraun anaerobic chamber for 1 h before quenching with 15.4 !L formic acid and 
centrifuging at 13,000 rpm for 10 min to remove precipitated protein. Each resulting supernatant was 
transferred to an NMR tube together with a small amount of DMSO-d6 (final concentration of 5 mM), and 
analyzed by 2H NMR as described in ‘materials and general methods’.  
 3.3.20: Construction of the CutC homology model 
The work described in this section and in 3.3.20 was conducted by Jonathan Marks. The Basic 
Local Alignment Search Tool (BLAST) (51) was used to search the protein databank (PDB) to find 
templates for homology model creation, and templates were selected to maximize sequence identity and 
query coverage. Potential template structures with the highest identity were all GREs: glycerol 
dehydratase (GDH) from Clostridium butyricum (PDB ID: 1R8W) (13), a putative GDH from 
Archaeoglobus fulgidus (PDB ID: 2F3O) (52), a Kolbe-type decarboxylase from Clostridium 
scatologenes  (PDB ID: 2Y8N) (53), and pyruvate formate lyase (PFL) from E. coli (PDB ID: 2PFL) 
(54). Modeller v9.12 was used to generate five randomly-seeded homology models of CutC with each 
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individual potential template structure and with multiple alignment of the top two, top three, and top four 
template structures. Heteroatoms and water molecules were excluded from the calculations and multiple 
template alignment was performed using Salign (55). Following model generation using the automodel 
algorithm, models were optimized using Modeller’s built-in conjugate gradient optimization algorithm set 
to the highest setting and optimization was repeated twice per model. Models with the lowest Discrete 
Optimization Potential Energy (DOPE) score from each set of homology models were compared based on 
their DOPE profiles and putative active site geometries to determine the best set of template structures for 
homology model creation. The homology model based on the multiple alignment of GDH (1R8W) and 
the putative GDH GRE from A. fulgidus (2F3O) was selected due to its low DOPE score and favorable 
geometry, and 100 randomly-seeded models were generated using the same algorithm as above. The 
homology model with the lowest DOPE score was analyzed with the verify3D (56), PROCHECK (57), 
QMEAN6 (58), ERRAT (59), WHATCHECK (60), and PROVE (61) packages. 
The CutC homology model is consistent with known GRE structures and passes multiple 
structure quality benchmarks (Table 3.2). The canonical GRE fold with Gly821 and Cys489 surrounded 
by the characteristic 10-stranded !/" barrel within the homology model aligns well with other members of 
the GRE family. With an overall DOPE score that is within 3.1-5.5% of the published GDH and putative 
GDH (A. fulgidus) structures, respectively, and with a QMean score that is at the 55th percentile of all 
known structures (Z-score of 0.142), the CutC homology model is compatible with experimentally-
determined structures. In the DOPE profile (Figure 3.18.A) and the 3D-1D profile of the model (Figure 
3.18.B), there are few notable deviations from the template structure profiles, with the exception of the 
increased DOPE scores for the 209-220 loop in the predicted CutC structure. The Ramachandran plot 
statistics for the homology model reveal that 99.2% of the model residues are within allowable regions 
and fewer than 0.1% occupy disallowed regions, indicating good stereochemical quality (Figure 3.18.C). 
3.3.21: Induced fit docking of choline into the active site of the CutC homology model 
The Glide (30, 62) and Prime (63) programs within the Schrödinger suite of molecular dynamics 
programs have been successfully used in the past to detect and model enzyme active sites and substrate 
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binding orientations (64). In this study, Schrödinger Suite 2012 was used for active site refinement of 
CutC and induced-fit docking of calculated conformations of the choline substrate. 
The standard protein preprocessing protocol of assigning bond orders, adding hydrogen atoms, 
and capping termini was followed to prepare the selected receptor input file. Hydrogen bond assignment 
was optimized using PROPKA with a pH of 7.4, and a restrained minimization using the OPLS 2005 
force field was used to resolve a single atom-atom clash produced by hydrogen addition. The choline 
ligand was prepared using the LigPrep algorithm with an approximate pH of 7.4, and ligand 
minimizations were carried out using the OPLS 2005 force field.  
Preliminary docking was performed with Glide using SP precision and van der Waals scaling of 
0.5. The receptor grid (18.65Å x 18.65Å x 18.65Å) was centered on the centroid of the active site 
residues Asp216, Thr334, Phe395, Cys489, Glu491, and Thr502. Following preliminary docking, Prime 
was used to optimize the active site. All amino acids within 5.0 Å of the docked choline were refined and 
all putative active site residues were marked for additional refinement. Glide docking with XP precision 
was then used to re-dock the choline ligand within the refined active site, and calculated poses were 
compared based on their Glide XP docking scores, Glide Emodel scores, and Prime Energy scores as well 
as active site geometry. The scores for the best model were Glide: –4.95, Emodel: –38.55, and Prime: 
54491.94.  
3.3.22: Chemical synthesis procedures and characterization data  
Synthesis of 2,2-dihydroxy-N,N,N-trimethylethan-1-aminium chloride (betaine aldehyde) 
 
Betaine aldehyde (2,2-dihydroxy-N,N,N-trimethylethan-1-aminium chloride) was synthesized 
following a previously published procedure (65), with the exception that the recrystallization step was 
replaced with an ethyl acetate extraction to remove any unreacted acetal. Concentration in vacuo of the 
HCl-catalyzed hydrolysis reaction afforded 2,2-dihydroxy-N,N,N-trimethylethan-1-aminium chloride as a 
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light yellow solid (0.389 g, 49%). 1H NMR:  (500 MHz, D2O) 5.55 (t, 1H, CH(OH)2, J = 5.5 Hz), 3.42 (d, 
2H, NCH2, J = 5.5 Hz), 3.22 (s, 9H, N(CH3)3). 13C NMR (100 MHz, DMSO-d6): 86.28, 69.86, 55.50. 
HRMS (ESI): calcd for C5H12NO+ [M]+, 102.0913; found, 102.1071. 
Synthesis of 3-hydroxypropanal 
 
3-Hydroxypropanal was synthesized following a published procedure (66), with the following 
modification: upon neutralization with calcium carbonate, the final mixture was filtered and stored at 4 
ºC. The identity of the resulting 3-hydroxypropanal product was confirmed through GC-MS/MS. The 13C 
NMR data (Figure 3.28) also matched that reported previously, revealing a mixture of 3-HPA and 2-(2-
hydroxyethyl)-4-hydroxy-1,3-dioxane (HPA dimer) (66).  
 
Figure 3.28: GC-MS/MS spectrum of synthesized 3-hydroxypropanal.  
 
Synthesis of (R)-1-hydroxy-N,N,N-trimethylpropan-2-aminium ((R)-2-methylcholine) 
To a solution of (R)-2-amino-1-propanol (43 mg, 0.57 mmol) in methanol (3.6 mL), potassium 
carbonate (306 mg, 2.22 mmol) and 1-iodomethane (409 mg, 0.18 mL, 2.88 mmol) were added, and the 
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mixture was stirred overnight at room temperature, under a nitrogen atmosphere. The mixture was 
filtered, and the solvent removed in vacuo. Synthesis of the (S) enantiomer was performed in the same 
manner, except that (S)-2-amino-1-propanol was used as starting material. The weight of the resulting 
white solids was higher than the theoretical yield, likely due to the presence of potassium iodide since no 
organic impurities seemed present by NMR. Thus, the yield of each reaction was approximated by 1H 
NMR, using a known amount of ethyl acetate as standard (38% yield for (R)-2-methylcholine; 65% yield 
for (S)-2-methylcholine). HRMS (ESI): calc’d for C6H16NO+ [M]+, 118.1232; found, 118.1231. 1H-NMR 
(500 MHz; CD3OD) !: 4.41 (d, J = 5.3 Hz, 1H, N-CH), 3.48 (dd, J = 21.2, 13.5 Hz, 1H, CH-OH), 3.37 
(dd, J = 12.7, 11.0 Hz, 1H, CH-OH), 3.29 (s, 9H, N-CH3), 1.27 (d, J = 6.2 Hz, 3H, CH-CH3). 13C NMR 
(126 MHz; CD3OD) !: 72.6, 63.4, 55.1, 39.1, 22.29, 22.25. 
Synthesis of N-(2-hydroxyethyl)-N,N-dimethylpropan-1-aminium iodide 
 
To a solution of 2-dimethylaminoethanol (200 mg, 2.03 mmol) in methanol (MeOH) (5 mL), 
potassium carbonate (364 mg, 2.64 mmol) and 1-iodopropane (690 mg, 396 "L, 4.06 mmol) were added, 
and the mixture was stirred overnight at room temperature, under a nitrogen atmosphere. The mixture was 
filtered, and the solvent was removed in vacuo. The resulting solid was dissolved in water and washed 
twice with diethyl ether and twice with ethyl acetate. The water was removed in vacuo to afford a white 
solid (333 mg, 1.29 mmol, 63% yield). HRMS (ESI): calc’d for C7H18NO+ [M]+, 132.1388; found, 
132.1393. 1H-NMR (500 MHz; CD3OD) !: 4.01 (m, 2H, CH2OH), 3.48 (t, J = 4.9 Hz, 2H, CH2CH2OH), 
3.37 (dt, J = 8.2, 4.3 Hz, 2H, CH2N), 3.16 (s, 6H, CH3N), 1.87-1.79 (m, 2H, CH2-CH3), 1.01 (t, J = 7.3 
Hz, 3H, CH3CH2). 13C NMR (126 MHz; CD3OD) !: 68.1, 66.6, 56.7, 52.41, 52.35, 17.1, 10.9. 
Synthesis of 3-hydroxy-N-(2-hydroxyethyl)-N,N-dimethylpropan-1-aminium iodide 
The same procedure was employed as for N-(2-hydroxyethyl)-N,N-dimethylpropan-1-aminium 
iodide, except that 3-iodo-1-propanol (755 mg, 0.39 mL, 4.06 mmol) was used instead of 1-iodopropane. 
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The product was obtained as a white solid (521.5 mg, 1.89 mmol, 93 % yield). HRMS (ESI): calc’d for 
C7H18NO2+ [M]+, 148.1338; found, 148.134. 1H-NMR (500 MHz; CD3OD) !: 4.08 (m, 2H, CH2-OH), 
3.72 (t, J = 5.8 Hz, 2H, N-CH2), 3.65 (m, 4H, N-CH2, CH2-OH), 3.31 (s, 6H, N-CH3), 2.12-2.06 (m, 2H, 
CH2-CH2-OH). 13C NMR (126 MHz; CD3OD) !: 66.5, 64.2, 59.2, 56.7, 52.77, 52.74, 26.8. 
Synthesis of N-(2-hydroxyethyl)-N,N-dimethylbutan-1-aminium iodide 
The same procedure was employed as for N-(2-hydroxyethyl)-N,N-dimethylpropan-1-aminium 
iodide, except that 1-iodobutane (747 mg, 0.46 mL, 4.06 mmol) was used instead of 1-iodopropane. The 
product was obtained as a white solid (564 mg, 2.02 mmol, 99 % yield). HRMS (ESI): calc’d for 
C8H20NO+ [M]+, 146.1545; found, 146.1551. 1H-NMR (500 MHz; CD3OD) !: 4.08 (d, J = 1.8 Hz, 2H, 
CH2-OH), 3.65 (t, J = 4.6 Hz, 2H, N-CH2), 3.59-3.56 (m, 2H, N-CH2), 1.86 (dt, J = 15.8, 7.9 Hz, 2H, 
CH2-CH2-CH2), 1.47 (q, J = 7.4 Hz, 2H, CH2-CH3), 1.05 (t, J = 7.4 Hz, 3H, CH2-CH3). 13C NMR (126 
MHz; CD3OD) !: 66.37, 66.29, 56.7, 52.6, 48.8, 25.5, 20.4, 14.0. 
Synthesis of tert-butyl (2-(methoxy(methyl)amino)-2-oxoethyl)carbamate 
 
To a solution of N-(tert-butoxycarbonyl)-glycine (1.05 g, 6 mmol) in dichloromethane (DCM) 
(30 mL), N-(3-dimethylaminopropyl)-N"-ethylcarbodiimide hydrochloride (EDC) (1.4 g, 9 mmol), 4-
(dimethylamino)pyridine (DMAP) (1.1 g, 9 mmol), and N,O-dimethylhydroxylamine hydrochloride (0.55 
g, 9 mmol) were added, and the mixture was stirred overnight at room temperature, under a nitrogen 
atmosphere. The reaction was quenched by the addition of brine (30 mL), the layers were separated, and 
the aqueous layer was extracted with ethyl acetate (3 x 20 mL). The combined organic layers were 
washed with 1 M hydrochloric acid (2 x 20 mL) and with brine (20 mL), then dried over magnesium 
sulfate, filtered and concentrated in vacuo. The resulting white solid was purified with flash 
chromatography, eluting with 80% ethyl acetate in hexanes to give the pure product as a white solid (0.72 
g, 3.3 mmol, 55% yield). TLC: Rf=0.4 (silica gel, 1:1 ethyl acetate:hexanes). HRMS (ESI): calc’d for 
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C9H19N2O4+ [M+Na]+, 241.1159; found, 241.1159. 1H-NMR (500 MHz; CDCl3): ! 5.26 (s, 1H, NH), 4.03 
(s, 2H, CH2-NH), 3.67 (s, 3H, O-CH3), 3.16 (s, 3H, N-CH3), 1.41 (s, 9H, C-CH3). 13C NMR (126 MHz; 
CDCl3) !: 169.5, 156.0, 79.7, 61.6, 41.8, 32.5, 28.60, 28.56, 28.3. 
Synthesis of tert-butyl (2-oxo-[2-2H]-ethyl)carbamate 
 
To a solution of tert-butyl (2-(methoxy(methyl)amino)-2-oxoethyl)carbamate (360 mg, 1.65 
mmol) in tetrahydrofuran (THF) (9.5 mL) cooled to –20 ºC (using a brine-ice bath), a solution of lithium 
aluminum deuteride in THF (1 M, 3.3 mL, 138.3 mg, 3.3 mmol) was added dropwise, under an argon 
atmosphere. The reaction mixture was stirred for 1 h then diluted with cold diethyl ether (10 mL), and 
quenched by the dropwise addition of citric acid (20 % w/v, 0.5 mL). The reaction mixture was further 
diluted with citric acid (20 % w/v, 10 mL), and the aqueous layer was extracted with diethyl ether (3 x 10 
mL). The organic layers were combined, dried over magnesium sulfate and concentrated in vacuo. Care 
was taken to remove most of the solvent as quickly as possible and the product was immediately used in 
the following reaction without any purification, due to its instability. TLC: Rf=0.3 (silica gel, 1:1 ethyl 
acetate:hexanes). 1H-NMR (500 MHz; CDCl3) !: 5.21 (s, 1H, NH), 4.07 (d, J = 5.0 Hz, 2H, CH2-NH), 
1.44 (s, 9H, C-CH3). 
Synthesis of (S)-tert-butyl ([2-2H]-2-hydroxy-ethyl)carbamate 
 
To a solution of tert-butyl (2-oxo-[2-2H]-ethyl)carbamate (230 mg, 1.44 mmol) in THF (8.6 mL) 
cooled to 0 ºC, a solution of (R)-Alpine Borane in THF (0.5 M, 5.74 mL, 2.87 mmol) was added dropwise 
under an argon atmosphere. The ice bath was removed and the reaction mixture was stirred at room 
temperature for overnight (o/n). Upon cooling to 0 ºC, the excess Alpine Borane was quenched with ~50 
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!L acetaldehyde, while stirring under an argon atmosphere for 1 h. The reaction mixture was 
concentrated in vacuo, then diluted with diethyl ether and cooled to 0 ºC. A solution of ethanolamine (262 
!L, 266 mg, 4.35 mmol) in THF (0.5 mL) was added slowly to the reaction, the ice bath was removed, 
and the mixture was stirred at room temperature for 2 h. The white precipitate that formed during this 
time was dissolved in water, and the mixture was transferred to a separatory funnel. The organic layer 
was washed with 0.1 M HCl (10 mL), then brine (2 x 10 mL), dried over magnesium sulfate, filtered and 
concentrated in vacuo. The residue was purified by flash chromatography eluting with 80-100% ethyl 
acetate in hexanes to give the pure product as yellow oil (95 mg, 0.59 mmol, 41% yield). TLC: Rf=0.25 
(silica gel, 1:1 ethyl acetate:hexanes). The synthesis of (R)-tert-butyl ([2-2H]-2-hydroxy-ethyl)carbamate 
was carried out in the same manner, with the exception that (S)-Alpine Borane was used as reducing 
agent. HRMS (ESI): calc’d for C7H15DNO3+ [M+Na]+, 185.1007; found, 185.1008. 1H-NMR (500 MHz; 
CD3OD) ": " 3.53 (t, J = 5.5 Hz, 1H, OH-CHD), 3.14 (d, J = 5.7 Hz, 2H, CH2-NH), 1.44 (s, 9H, C-CH3). 
13C NMR (126 MHz; CD3OD) ": 130.5, 80.0, 61.83, 61.66, 61.49, 43.7, 28.7. 
Synthesis of (S)-[1-2H]-ethanolamine hydrochloride 
 
A solution of (S)-tert-butyl ([2-2H]-2-hydroxy-ethyl)carbamate (70 mg, 0.43 mmol) in 
hydrochloric acid (4 M, 3 mL) was stirred overnight at room temperature. The reaction mixture was 
transferred to a separatory funnel and washed with diethyl ether (3 x 10 mL). The water and hydrochloric 
acid were removed in vacuo to afford an off-white solid (34 mg, 0.35 mmol, 80% yield). Note that any 
impurities present in the starting material will become a brown-black polymer after this reaction. The 
synthesis of (R)-[1-2H]-ethanolamine hydrochloride was carried out in the same manner from the (R) 
enantiomer of the starting material. HRMS (ESI): calc’d for C2H6DNO [M+Na]+, 85.0483; found, 
84.9595. 1H-NMR (500 MHz; CD3OD) ": 3.74 (m, 1H, CH-OH), 3.03 (d, J = 4.6 Hz, 2H, CH2-NH3). 13C 
NMR (126 MHz; CD3OD) ": 58.70, 58.52, 58.35, 42.7. 
H
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O
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4 M HCl
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80% yield
t-Bu H3N OH
D
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Synthesis of (S)-[1-2H]-choline iodide 
 
To a solution of (S)-[1-2H]-ethanolamine hydrochloride (24.5 mg, 0.25 mmol) in methanol (2.4 
mL), potassium carbonate (132 mg, 0.96 mmol) and 1-iodomethane (176 mg, 77 !L, 1.24 mmol) were 
added, and the mixture was stirred overnight at room temperature, under a nitrogen atmosphere. The 
mixture was filtered, and the solvent removed in vacuo. Synthesis of the (S) enantiomer was performed in 
the same manner, except that (S)-[1-2H]-ethanolamine hydrochloride was used as starting material. The 
weight of the resulting white solids was higher than the theoretical yield, likely due to the presence of 
potassium iodide since no organic impurities seemed present by NMR. Thus, the purity of each product 
was approximated by LC-MS/MS, using (trimethyl-d9)-choline as internal standard. (S)-[1-2H]-choline is 
13.9% pure, 93% monodeuterated, 4.4% dideuterated, 2.6% unlabeled. (R)-[1-2H]-choline is 10.8% pure, 
83% monodeuterated, 13% dideuterated, 4% unlabeled. HRMS (ESI): calc’d for C5H13DNO+ [M]+, 
105.1138; found, 105.1140. 1H-NMR (500 MHz; CD3OD) ": 3.99 (s, 1H, CH-OH), 3.52 (d, J = 4.8 Hz, 
2H, N-CH2), 3.24 (s, 9H, N-CH3). 13C NMR (126 MHz; CD3OD) ": 69.0, 54.85, 54.82, 54.79, 52.2. 
Synthesis of the N,O-dicamphanoyl derivative of (S)-[1-2H]-ethanolamine hydrochloride 
 
 To a suspension of (S)-[1-2H]-ethanolamine hydrochloride (12 mg, 0.12 mmol) in diethyl ether 
(1.3 mL), dry pyridine (511 mg, 523 !L, 6.5 mmol) and (1S)-(–)-camphanic chloride (130 mg, 0.6 mmol) 
were added, and the mixture was stirred for 44 h under a nitrogen atmosphere. The excess (–)-camphanic 
chloride was quenched by the addition of 2 mL of water, and the mixture was concentrated in vacuo. The 
resulting residue was dissolved in chloroform (5 mL), washed twice with HCl (1 M, 5 mL), saturated 
MeI, K2CO3
MeOH
44 hrs, 22oC
50% yield
H3N OH
D
Cl
Me3N OH
D
I
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D
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Me Me
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! 135 
sodium bicarbonate solution (5 mL), and brine (5 mL), dried over magnesium sulfate and concentrated in 
vacuo to afford a white solid (33.7 mg, 0.08 mmol, 66 % yield). The syntheses of the (R) enantiomer and 
the unlabeled derivative were carried out in the same manner, using (R)-[1-2H]-ethanolamine 
hydrochloride or ethanolamine hydrochloride as starting materials, respectively. HRMS (ESI): calc’d for 
C22H31DNO [M+Na]+, 445.2056; found, 445.2064. 13C NMR (126 MHz; CD3OD) !: 180.08, 180.00, 
169.6, 168.7, 111.4, 93.7, 92.7, 56.4, 56.0, 55.3, 54.9, 39.1, 31.6, 31.2, 30.4, 29.95, 29.89, 17.13, 17.05, 
17.02, 9.93, 9.87. 1H-NMR for the (S) enantiomer (500 MHz; CDCl3) !: 6.76 (t, J = 5.6 Hz, 1H), 4.31 (dd, 
J = 6.6, 4.2 Hz, 1H), 3.66 (ddd, J = 14.5, 6.0, 4.2 Hz, 1H), 3.57 (dt, J = 14.5, 6.4 Hz, 1H), 2.48 (ddd, J = 
13.2, 10.4, 4.2 Hz, 1H), 2.39 (ddd, J = 13.5, 10.8, 4.2 Hz, 1H), 2.01 (ddd, J = 13.6, 9.3, 4.5 Hz, 1H), 1.94-
1.83 (m, 3H), 1.66 (ddd, J = 13.4, 9.1, 4.5 Hz, 2H), 1.08 (s, 3H), 1.07 (s, 3H), 1.07 (s, 3H), 1.03 (s, 3H), 
0.93 (s, 3H), 0.88 (s, 3H). 1H-NMR for the (R) enantiomer (500 MHz; CDCl3) !: 6.73 (t, J = 5.5 Hz, 1H, 
NH), 4.30 (dd, J = 6.5, 4.2 Hz, 1H, O-CHD), 3.70-3.66 (m, 1H, CD-CH), 3.59 (ddd, J = 14.6, 6.0, 4.3 Hz, 
1H, CD-CH), 2.50 (ddd, J = 13.1, 10.3, 4.2 Hz, 1H), 2.41 (ddd, J = 13.5, 10.8, 4.2 Hz, 1H), 2.03 (ddd, J = 
13.6, 9.3, 4.5 Hz, 1H), 1.96-1.84 (m, 3H), 1.67 (dtd, J = 13.7, 9.3, 4.9 Hz, 2H), 1.10 (s, 3H), 1.09 (s, 3H), 
1.09 (s, 3H) 1.05 (s, 3H), 0.96 (s, 3H), 0.89 (s, 3H). 1H-NMR for the unlabeled product (500 MHz; 
CDCl3) !: 6.78 (t, J = 5.6 Hz, 1H), 4.34-4.26 (m, 2H), 3.65 (dtd, J = 14.5, 6.2, 4.5 Hz, 1H), 3.57 (dtd, J = 
14.5, 6.2, 4.5 Hz, 1H), 2.47 (ddd, J = 13.2, 10.5, 4.2 Hz, 1H), 2.38 (ddd, J = 13.5, 10.8, 4.2 Hz, 1H), 2.00 
(ddd, J = 13.6, 9.2, 4.5 Hz, 1H), 1.93-1.81 (m, 3H), 1.64 (ddt, J = 13.4, 9.0, 4.5 Hz, 2H), 1.07 (s, 3H), 
1.06 (s, 3H), 1.06 (d, J = 1.2 Hz, 3H), 1.01 (s, 3H), 0.91 (s, 3H), 0.86 (s, 3H). 
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Chapter 4: Molecular basis of C–N bond cleavage by the glycyl radical enzyme choline 
trimethylamine-lyasea 
 
 
4.1: Introduction  
As described in Chapter 1, the anaerobic cleavage of choline by microbes to form acetaldehyde 
and trimethylamine (TMA) impacts both the environment and human health (Figure 4.1.A). Within the 
guts of ruminants and marine sediments, choline-derived TMA is converted to the powerful greenhouse 
gas methane by archaea (1, 2). TMA has been estimated to account for a significant portion of the 
methane produced in marine sediments (35-61%) (2), thus playing a major role in the greenhouse effect, 
as well as global nitrogen and carbon cycles. Although choline is an important nutrient for humans, 
conversion of choline to TMA by the gut microbiota and its further oxidation to trimethylamine N-oxide 
by liver enzymes (3) is implicated in a number of diseases, including nonalcoholic fatty liver disease (4), 
atherosclerosis (5, 6) and the metabolic disorder trimethylaminuria (fish malodor syndrome) (7). Chapter 
2 of this thesis described the discovery of the choline utilization (cut) gene cluster in Desulfovibrio 
species and the validation of its function (8). The key enzyme in this pathway is a novel C–N bond 
cleaving glycyl radical enzyme (GRE) choline trimethylamine-lyase (CutC), which converts choline into 
TMA and acetaldehyde (9). Subsequent bioinformatic analyses performed by Balskus group members 
have revealed that choline utilization is highly prevalent in human stool metagenomes and is widely 
distributed among both environmental and human-associated bacteria (10), highlighting the importance of 
CutC for TMA production in diverse anoxic microbial habitats.  
 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
a This chapter is an unofficial adaptation of an article submitted to Cell Chemical Biology, which was 
written together with Prof. Emily P. Balskus, Prof. Catherine L. Drennan (MIT), and Dr. Michael A. Funk 
(MIT). 
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Figure 4.1: Anaerobic metabolism of choline into trimethylamine (TMA) is a disease-associated 
microbial activity that utilizes the glycyl radical enzyme (GRE) CutC. (A) Anaerobic microbes generate 
TMA from choline in the human gut and in the environment. TMA is further metabolized to the 
greenhouse gas methane by archaea, or to the disease-associated metabolite trimethylamine N-oxide by a 
human liver monooxygenase. (B) General mechanistic hypothesis for GRE function: the 5!-
deoxyadenosyl radical (Ado•) is used by an AdoMet radical enzyme to produce a stable glycyl radical 
within GREs. A thiyl radical is proposed to serve as the active oxidant in all GREs and would be 
generated transiently within the active site. S = substrate, P = product. Following initial hydrogen atom 
abstraction to form an "-hydroxy radical, (C) CutC may perform base-catalyzed direct elimination of 
TMA. (D) Alternately, choline cleavage could involve a 1,2-migration of the trimethylammonium moiety 
followed by decomposition of the resulting carbinolamine. 
 
The glycyl radical enzyme (GRE) family has emerged as a remarkable class of biocatalysts that 
play central roles in anaerobic microbial metabolic pathways, including nucleotide reduction (class III 
ribonucleotide reductase) and carbon-source utilization (pyruvate formate-lyase) (11). As presented in 
Chapter 1, all GREs characterized to date must be post-translationally modified by a radical S-
adenosylmethionine (AdoMet) activating protein (CutD within the cut cluster), which installs a stable, "-
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carbon glycyl radical. During GRE catalysis, this glycyl radical species is proposed to generate a transient 
thiyl radical that initiates the reaction and is regenerated upon product formation (Figure 4.1.B). The 
discovery of CutC expanded the chemistry of GREs to include choline deamination, a net 1,2-elimination 
reaction that requires a radical enzyme due to the high pKa of the C1 proton of choline. The existence of 
CutC underscores the diversity of Nature’s approaches to radical-mediated C–N bond cleavage, which 
include two other enzymes: the adenosylcobalamin (AdoCbl)-dependent enzyme ethanolamine ammonia 
lyase (EAL) (12), and the radical AdoMet-dependent enzyme DesII, involved in desosamine biosynthesis 
(13). The main differences between CutC and these enzymes are the requirement of the 
trimethylammonium group for reactivity (9) and the lack of reliance on a 5!-deoxyadenosyl radical (Ado•) 
for initiating the elimination reaction.  
As presented in Chapter 3, we have previously envisioned two general mechanisms for choline 
cleavage by CutC (9). In a similar manner to other GREs, a CutC thiyl radical could cleave the C1 C–H 
bond of choline, generating a substrate-based "-hydroxyalkyl radical. Subsequent deprotonation of the 
alcohol would allow direct elimination of TMA, leading to a resonance stabilized vinoxy radical that 
could reform the thiyl radical through hydrogen atom abstraction, generating acetaldehyde (Figure 
4.1.C). This mechanism is analogous to those proposed for the C–O bond cleaving GRE glycerol 
dehydratase (GDH) (14) and the radical AdoMet-dependent enzyme DesII, which has not yet been 
structurally characterized (13).  Alternatively, the initial substrate based radical could undergo a 1,2-
migration of the trimethylammonium group to yield a carbinolamine radical (Figure 4.1.D), similar to the 
generally accepted mechanism for the AdoCbl-dependent enzyme EAL (12). Understanding the structure 
and mechanism of CutC is important not only for enhancing our knowledge of radical enzymes but also 
for designing inhibitors of TMA generation. Given that an inhibitor of gut microbial TMA production 
was found to attenuate atherosclerosis in a mouse model (15), small molecules that target CutC hold 
promise as tools for studying choline metabolism in complex microbial communities and for further 
development into therapeutics. Despite the availability of a CutC homology model (described in Chapter 
3) and a low-resolution crystal structure (9, 16), many questions remained regarding this enzyme’s 
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interactions with choline and mechanism of catalysis. In this chapter, I present the results of our 
collaboration with the research group of Prof. Catherine L. Drennan at Massachusetts Institute of 
Technology. A former graduate student in this group, Dr. Michael A. Funk, elucidated the crystal 
structures of CutC wild-type and mechanistically informative mutants from Desulfovibrio alaskensis G20 
in the presence of choline, while I purified these proteins and performed biochemical experiments. 
Overall, these results provide new insight into the mechanism of this C–N cleaving radical enzyme, thus 
broadening our understanding of radical-based enzyme catalysis. 
4.2: Results and discussion 
 4.2.1: A conserved GRE architecture is maintained in CutC 
The Drennan group crystallized CutC from D. alaskensis G20 and solved the structure by 
molecular replacement with AdoCbl-independent glycerol dehydratase (GDH) (PDB ID 1R8W) (17) as 
the search model. The four molecules in the asymmetric unit form two dimers with a large shared surface 
area (Figure 4.2.A). This tetrameric packing is similar to that seen in structures of other GREs (Figure 
4.3); however, size exclusion chromatography experiments indicated previously that CutC is a dimer in 
solution (9). The assembly observed in the crystal structure may thus be a crystallization artifact or may 
be relevant within bacterial microcompartments where CutC is thought to be localized (18, 19). Each 
CutC molecule adopts the canonical GRE fold: a ten-stranded !/" barrel (!1-!10) with two loops 
containing catalytic residues inserted into the center of the barrel (Figure 4.2.B). The Gly loop is located 
at the tip of the C-terminal glycyl radical domain, a structural unit believed to undergo conformational 
changes that can close or expose the active site during installation of the glycyl radical by the activating 
enzyme (20, 21). An absolutely conserved glycine (Gly821 in CutC) is found at the tip of the Gly loop, 
fully in the interior of the barrel. Next to the Gly loop in the enzyme interior is the Cys loop, which 
contains an absolutely conserved cysteine residue (Cys489 in CutC) and other residues that contribute to 
catalysis and are unique to specific GREs (17, 20, 22). The active site cavity is found directly above the 
Cys loop, consistent with reaction initiation by a transient thiyl radical generated on Cys489 by Gly821. 
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In agreement with these proposed roles in CutC, C489A and G821A mutants were found to be completely 
inactive in the production of TMA in an end point assay (9). 
 
Figure 4.2: Overall structure of CutC from D. alaskensis G20. (A) CutC crystallizes as a dimer or dimers, 
similar to several other GREs (see also Figure 4.3). The dimeric unit is shown below rotated 90º. (B) The 
active site cavity is found at the center of the (!/")10 barrel (solid ribbon), above the Cys loop. Residues 
C489 (location of putative thiyl radical) and G821 (location of putative glycyl radical) are shown in 
spheres. The glycyl radical domain (yellow) harbors the active site glycyl radical on the Gly loop in post-
translationally modified proteins. (C) Cross-section of the CutC active site displaying a ring of aromatic 
residues (sticks) at the top of the active site, including two residues on a helix that caps the top of the 
barrel (gray). Choline is shown in the active site (cyan sticks). 
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Figure 4.3: Tetrameric assemblies observed in the crystal lattices of GREs. For each GRE, four 
protomers are shown in roughly the same orientation. Choline TMA-lyase bound to choline, PDB ID 
5FAU (this work), is depicted. The other GRE structures shown are PDB ID 1R8W for glycerol 
dehydratase (GDH) (17), PDB ID 2F3O for pyruvate formate-lyase 2 (PFL2) (23), PDB ID 2YAJ for 
hydroxyphenylacetate decarboxylase (HPD; small subunit in yellow) (24), and PDB ID 4PKF for 
benzylsuccinate synthase (BSS; both small subunits in yellow) (25). For the BSS!"# complex, the upper 
dimer is oriented 90 º from where it is observed in the other GREs. No tetrameric assembly could be 
found for the BSS!# complex (PDB ID 4PKC) or PFL (PDB 1CM5) (20). Only PFL2 and HPD have 
been observed to adopt a tetrameric (or heterooctameric for HPD) structure in solution (23, 24).  
 
A notable feature of the CutC active site also observed in other GREs (26) is a hydrophobic cap 
formed by a helix extending from "3 (Figure 4.2.C). This cap packs against two tyrosine residues that 
participate in choline binding (described below) and appears to block access to the active site from the 
exterior of the protein; simple rotation of the side chains of Phe389 and/or Trp379 into adjacent, solvent-
filled regions may allow access to the active site. We hypothesize that the deeply buried active site 
captured choline during expression because our crystals of wild-type CutC contained a well-ordered 
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molecule of choline bound, despite dialysis of the protein during purification and no ligand added to the 
crystallization buffer. Recently, Kalnins et al. solved low resolution choline-bound and choline-free 
structures of a proteolytic fragment of a homologous CutC from the opportunistic pathogen Klebsiella 
pneumoniae (16). This CutC fragment is of a similar size to the CutC from D. alaskensis G20 and utilizes 
the same active site residues to bind choline. The structures determined by Kalnins et al. complement our 
work because they reveal that choline can trigger a conformational change in CutC from an open to a 
closed state and can stabilize the protein towards proteolysis. 
 4.2.2: Selective binding of choline involves unexpected interactions 
The CutC active site is formed by residues from the Cys loop and the top face of the barrel 
(Figure 4.4). Within this Cys loop, the backbone amide nitrogen of Gly488/Cys489 and the carboxylate 
of Glu491 form hydrogen bonds with the choline hydroxyl group, positioning C1 of choline at a distance 
suitable (3.6 Å) for pro-S hydrogen abstraction by the putative thiyl radical on Cys489. C2 of choline is 
also in proximity to Cys489 (4.2 Å) potentially facilitating reformation of the thiyl radical following 
choline cleavage. In turn, the Glu491 carboxylate is positioned by hydrogen bonds from the side chain 
alcohol of the !6 residue Thr502 and the Cys loop backbone carbonyl. There is also likely a substantial 
electrostatic component to choline binding that arises from interactions between the diffuse positive 
charge localized on the trimethylammonium methyl groups (27) and the negatively charged first-shell 
residues Asp216 and Glu491. The partial positive charge localized on C2 of choline establishes a face-on 
cation-" interaction with the aromatic ring of !3 residue Phe395 (C2 to ring center: 3.84 Å) (Figure 
4.4.A). The conservation of the Cys loop sequence motif GCVEP and of an aromatic residue at the 
Phe395 position in GDH suggests mechanistic similarities between these two classes of GRE lyases 
(Figure 4.5). The similar orientation of choline and glycerol in the active sites of CutC and GDH, 
respectively, also implies a shared mechanistic logic (17). The choline trimethylammonium group extends 
away from the Cys loop and is oriented gauche to the hydroxyl, with an average dihedral angle of 61 º in 
the four molecules in the asymmetric unit.  
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Figure 4.4: CutC binds substrate in a pocket above the Cys loop. (A) Stereoimage of CutC bound to its 
substrate, choline (cyan). The proposed hydrogen atom transfer pathway from G821 to C489 to C1 of 
choline is marked (red dashes). Hydrogen bonds (2.5-3.2 Å) are shown for residues within the active site 
(black dashes). The average choline dihedral angle (HO–C1–C2–N(Me3)) is 61 º. (B) Stereoimage of the 
CH–O bonds (yellow dashes) present in the CutC-choline complex. (C) Diagram of protein and water 
interactions with the trimethylammonium moiety of choline with CH–O and hydrogen bond distances 
(Å). CH–O bonds are indicated for C to O distances of 3.8 Å or less (yellow). Hydrogen bonds (black) 
and presumed cation-! interactions (gray) are shown between protein and substrate atoms. Distances (Å) 
are given in the diagram. The maximum-likelihood-estimated coordinate error is 0.20 Å.  
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Figure 4.5: Multiple sequence alignment of choline TMA-lyase homologs and characterized glycyl 
radical enzymes. The full sequence alignment was constructed with Clustal W(28), and regions of interest 
identified in the CutC structure are shown. The residues are numbered based on the sequence of CutC 
from Desulfovibrio alaskensis G20. Conserved residues are colored according to the residue property 
(green: polar; blue: nonpolar; purple: acidic; red: basic; orange: Gly; yellow: Pro; pink: Cys). GenBank 
accession numbers identify the amino acid sequences used. 
 
Unexpectedly, the primary choline-selective interactions observed within the active site involve 
the trimethylammonium substituent and the side chain oxygen atoms of Tyr208, Tyr506, and Asp216 
(Figure 4.4.B). These oxygen atoms approach the trimethylammonium methyl groups closely, displaying 
C to O distances (3.3 and 3.5 Å) shorter than a typical van der Waals distance. Such contacts, previously 
described as CH–O interactions or bonds, are ubiquitous features in protein and nucleic acid structures 
and are proposed to play an important, but underappreciated, role in stabilizing macromolecule structure 
(29). In cases where a partially positive-charged C–H bond is present, CH–O interactions contribute an 
estimated ~1.2 kcal/mol to the binding energy, comparable to weak hydrogen bonds (30). In the context 
of SAM-dependent lysine methyltransferases (e.g., SET7/9), these interactions were proposed to perform 
several functions in lysine methyl transfer, including enhancing AdoMet binding, stabilizing the partially 
positively charged transition state and aligning the methyl group for optimal transfer geometry (31). 
Within CutC, there are at least four close CH–O interactions (3.2-3.5 Å) and another three longer 
interactions (3.5-3.7 Å) (Figure 4.4.C). A single water molecule held in the active site by Tyr506 also 
participates in a close CH–O interaction. Typically, trimethylammonium-binding proteins use aromatic 
residues to create a hydrophobic pocket and to provide cation-! interactions with the diffuse positive 
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charge of the trimethylammonium group (27). Comparison of the structures of nine proteins that bind 
trimethylammonium-containing metabolites (choline, glycine betaine, carnitine, or trimethyllysine) 
reveals the presence of two to four CH–O interactions in each active site (Figure 4.6). Relative to the 
subset of these proteins that exclusively bind choline (Figure 4.6.A), CutC contains a large number of 
CH–O interactions (seven with distances less than 3.7 Å), which is perhaps reflective of this enzyme’s 
unique reactivity.  
 
Figure 4.6: CH–O interactions are common in quaternary-ammonium-binding proteins. (A) Structures of 
proteins in complex with choline: PDB ID 4KWA, putative Saccharomonospora viridis transcriptional 
regulator; PDB ID 4IWT, choline binding domain of lytic amidase LytA; PDB ID 4DOJ, betaine 
transporter BetP; PDB ID 4I90 phosphatidylinositol-specific phospholipase C; PDB ID 3PPQ, ABC 
transporter solute binding domain OpuC. (B) Trimethyllysine-binding proteins: PDB ID 4LXL, JmjC 
domain-containing histone demethylation protein 3B bound to histone H3, K9-trimethyllysine and 
pyridine-2,4-dicarboxylic acid coordinated to a Ni2+ ion; PDB ID 3QLA, ADD domain of transcriptional 
regulator ATRX with bound histone H3, K9-trimethyllysine. (C) PDB ID 1S5O, carnitine bound to 
human carnitine acetyltransferase. (D) PDB ID 1XL8, octanoylcarnitine bound to murine carnitine 
octanoyltransferase. PDB IDs and reported resolution are listed within each panel. All contacts closer than 
3.7 Å were taken to indicate CH–O interactions. The average C—O distance observed was 3.4 ± 0.2 Å. 
The median number of CH–O interactions per structure was three, with a large variation. 
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4.2.3: Comparison of CutC structure with its homology model reveals the difficulty in predicting 
active site features in GREs 
 
As detailed in Chapter 3, a CutC homology model was previously created based on the structure 
of GDH (37% sequence identity) (9). However, we found by elucidating the crystal structure of CutC in 
complex with choline that the secondary structural elements that line the CutC and GDH active sites are 
more divergent than expected (Figure 4.7). This divergence is due in part to unusual features associated 
with two of the !-strands adjacent to the active site: a short helix interrupts !1 and a bulge interrupts !6. 
Because the small helix has one turn in CutC instead of two as predicted, the homology model for CutC is 
shifted out of register such that Tyr208 is pointing out of the active site in the model, whereas in the 
crystal structure, this residue points into the substrate-binding pocket and interacts with choline (Figure 
4.7.B, C). In contrast, the position of Asp216 on one of the sheet-like regions of !1 is correctly predicted. 
Within !6, Thr502 and Tyr506 are placed in essentially the correct position, but the backbone 
conformation of the loop between these residues is different, with the result that Ser503 is interacting with 
choline in the model, whereas X-ray data place it out of the active site. Choline was docked into the 
homology model and its positioning largely matched that observed in the crystal structure, with the 
exception of the hydroxyl group location (up in the model toward Ser503 and Tyr506 instead of pointing 
down toward the amide nitrogen of Cys489 in the crystal structure) (Figure 4.7.D). Notably, the absence 
of Tyr208 from the model’s active site and the inability to computationally predict CH–O interactions left 
the upper face of the trimethylammonium moiety of choline completely without protein contacts, whereas 
in the structure, this group is tightly held by multiple interactions with CutC. It thus appears that despite 
the high identity between CutC and GDH enzymes (37 %), homology modeling of CutC based on the 
crystal structure of GDH missed a number of key active site features, a problem that may turn out to be 
common for other GREs. A previous bioinformatic study (22) identified a large number of GDH- and 
PFL-like genes that are 30-45 % identical to known enzymes, but lack conservation of residues within the 
Cys loop, and thus would likely not possess a known function. For these reasons, more effective 
computational tools are needed for the structural modeling and active site prediction of GREs.  
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Figure 4.7: Comparison of CutC structure with GDH-based CutC homology model. The orientation of 
(a)-(c) is ~90º from that shown in Figure 4.4. (A) GDH structure with bound glycerol (gray). (B) 
Homology model of CutC created in Modeller using GDH as the starting model; choline (cyan) was 
docked using Schrödinger Suite 2012 (9). Residues that differ substantially from the observed positions in 
the crystal structure are highlighted (pink). (C) The crystal structure of CutC bound to choline (cyan) in 
the same orientation as in (b). CH–O interactions (yellow dashes) and hydrogen bonds (black dashes) are 
shown as in Figure 3. (D) An overlay of CutC (green) and GDH (magenta) with residues involved in 
binding C1 and C2 (sticks); the orientation is similar to that in Figure 4.4. The Cys loop GCVEP motif is 
conserved between the two enzymes. An aromatic residue contributed from !3 coordinates C2 (gray 
dashes). The proposed hydrogen transfer pathways (red dashes) between the active site Gly, Cys, and C1 
are virtually identical in the two structures. 
 
4.2.4: Disrupting enzyme-substrate CH–O interactions impairs binding and catalysis 
Based on the crystal structure of CutC, Tyr208 and Tyr506 mutants were constructed to 
determine if the proposed CH–O interactions are important for binding choline or C–N bond cleavage 
(Table 4.1). The activation of these mutants by CutD occurred to a lesser extent than for wild-type CutC, 
perhaps due to disruptions in the conformational change required for glycyl radical installation or in the 
ability of the enzymes to stabilize and shield the glycyl radical from solvent. The fraction of the enzyme 
in radical form, however, appears stable over time (Figure 4.8.A). Kinetic analyses revealed retention in 
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affinity for choline in both CutC-Y208F and CutC-Y506F mutants, but a significant decrease (~57-fold) 
in the catalytic activity of CutC-Y208F. Given that Tyr208 establishes closer CH–O interactions (~3.3 Å) 
with the trimethylammonium group than Tyr506 (~3.5 Å), the greater impairment in activity for CutC-
Y208F speaks to the importance of these contacts in properly positioning the backbone of choline for C–
N cleavage. Interestingly, the double mutant CutC-Y208F/Y506F has pronounced defects in both binding 
(~12-fold increase in KM) and activity (~83-fold decrease in kcat).  
Table 4.1: Activation and kinetic parameters of CutC mutants. The values reported with standard 
deviation are the average of three replicates. Activity for the mutants was initially detected by analysis of 
TMA production in an overnight end point assay. With the exception of CutC-D216N, mutants with 
detectable activity were kinetically characterized using a coupled assay as described in the methods. The 
un-normalized kcat is given based on the total concentration of CutC. A normalized kcat was estimated by 
dividing kcat by the measured radical concentration. 
protein 
radicals per 
polypeptide 
(%) 
detectable 
activity (TMA) KM (mM) kcat (s-1) 
glycyl-radical-
normalized kcat (s-1) 
wild type 20.8 yes 0.13 ± 0.01 157 ± 2 377 ± 5 
E491Q 3.9 no ND ND ND 
E491A 10.5 no ND ND ND 
T502A <1 yes ND 0.036 ± 0.003 ND 
D216N <1 yes ND ND ND 
Y208F 5.5 yes 0.22 ± 0.03 0.73 ± 0.01 6.6 ± 0.1 
Y506F 1.9 yes 0.12 ± 0.03 3.27 ± 0.11 86 ± 3 
Y208F/ 
Y506F 1.7 yes 1.53 ± 0.12 0.15 ± 0.01 4.5 ± 0.1 
 
 
Figure 4.8: Glycyl radical stability of CutC-WT and mutants CutC-Y208F and CutC-T502A. (A) 
Stability of the glycyl radical signal for CutC-WT and CutC-Y208F was assessed by varying the 
incubation time of the activation mixture and measuring glycyl radical content by EPR. (B) The activity 
of CutC-T502A was used as a proxy for glycyl radical formation since the glycyl radical content of this 
protein was below the instrument’s limit of detection. CutC-T502A was activated with CutD for the 
specified periods of time before recording the activity using a spectrophotometric coupled assay for 
acetaldehyde detection, as described in the methods. For each data set, the results of a representative 
experiment are shown. 
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To further investigate the contribution of CH–O contacts to choline binding, we crystallized 
CutC-Y208F after incubation with 10 mM choline. A mostly unperturbed active site is observed in the 
structure, with choline positioned similarly to wild-type CutC (Figure 4.9.A). The loss of the CH–O 
interactions between the phenolic hydroxyl and two of the methyl groups of choline does not substantially 
affect choline binding, in line with the relatively weak contribution of each CH–O contact to the overall 
binding enthalpy (30). A water molecule is found in one of the two molecules in the asymmetric unit in 
place of the phenolic hydroxyl, but close contacts with adjacent residues appear to preclude full 
occupancy, as the density for this water is weaker than those of other nearby waters. Presumably, this 
water substitutes for the phenolic hydroxyl in those active sites where it is present and could thus be 
important for catalysis in this mutant. 
 
Figure 4.9: Structures of mutant CutC enzymes. (A, B, C) Composite omit density is contoured at 1.5! 
around active site residues (light blue) with changes to each mutant structure highlighted (yellow). 
Hydrogen bonds (black dashes), steric clashes (pink dashes), and hydrogen-atom transfer pathways (red 
dashes) are indicated. Crystals were grown in the presence of 10 mM choline. (A) CutC-Y208F (1.90-Å 
resolution) closely resembles the wild-type enzyme, with the only difference being the generation of a 
new partially-occupied water binding site (HOH*). (B) The E491Q mutant (1.60-Å resolution) has no 
density for choline. Instead, two new water molecules are bound in the active site (HOH*). The 
orientation of the side chain amide is deduced based on the contacts to hydrogen bond donors within the 
Cys loop. (C) T502A at 1.85-Å resolution is virtually identical to the wild-type CutC structure. 
 
4.2.5: Structure and mutagenesis support Glu491 as the putative catalytic base 
The CutC mechanistic hypotheses in Figure 4.1.C and 4.1.D require an acceptor for the choline 
hydroxyl proton, and Glu491 of the conserved GCVEP motif appears positioned to perform this function. 
Mutation of Glu491 would therefore be expected to have a large effect on substrate binding and catalysis. 
Indeed, we find that both CutC-E491Q and CutC-E491A are completely inactive in an overnight end 
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point assay (Figure 4.10.A, Table 4.1). To further investigate the source of the inactivity, we determined 
the crystal structure of CutC-E491Q. Mutant and wild-type enzymes are virtually identical in structure 
(root mean square deviation (RMSD) of 0.18 Å) including the arrangement of residues in the active site 
(RMSD of 0.09 Å for Cys loop residues). Despite inclusion of 10 mM choline in the protein solution prior 
to crystallization, no clear density is observed for choline within the active site (Figure 4.9.B). Instead, 
two new water molecules are bound: one replaces the hydroxyl group of choline and the other makes 
contacts to Asp216 and Thr502. 
 
Figure 4.10: LC-MS end point assays quantifying TMA production by CutC wild-type and active site 
mutants upon overnight incubation. (A) Assays were conducted with 100 mM choline in phosphate buffer 
with CutC purified by Ni-affinity chromatography (as described in Online Methods). No TMA was 
detected in samples containing CutC-E491Q or CutC-E491A, nor in the sample lacking CutD (limit of 
detection ~1 !M). (B) Assays conducted with 20 mM choline in Tris buffer with CutC further purified by 
size exclusion chromatography (as described in methods). Each assay was performed in triplicate and the 
bar represents the mean ± standard deviation of three replicates. WT = wild type, N/D = not detected. 
 
Analysis of predicted hydrogen orientations in wild-type CutC suggests that the choline C1 
hydroxyl acts as a hydrogen bond donor to Glu491 and acceptor to the backbone nitrogen of the 
Gly488/Cys489 peptide bond (Figure 4.11.A). In the E419Q mutant structure, the side chain amide 
carbonyl maintains a hydrogen bond to a backbone amide nitrogen atom of the Cys loop. This orientation 
requires the side chain amide nitrogen, which is a hydrogen bond donor, to point toward the choline-
binding site (Figure 4.11.B). Thus, the E491Q mutant lacks a hydrogen bond acceptor for the choline 
hydroxyl. We infer from the absence of density for choline in the active site of this mutant that CutC-
E491Q has a greatly reduced affinity for choline. Thus, we cannot determine the severity of the defect in 
catalysis for E491Q, but given the conserved positioning of this residue and the complete absence of 
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activity even at high choline concentrations (100 mM), we propose that Glu491 is the catalytic base 
required for choline cleavage. 
 
Figure 4.11: Putative hydrogen bonding networks in wild-type and mutant CutC enzymes. The 
orientation is shifted ~90º around the y-axis from Figure 4.4. Tyr506 and the Gly loop are not shown for 
clarity. Polar hydrogen atoms are shown within the networks based on inferred position given the 
available donor and acceptor groups, and considering that the pH of the crystallization was 8.0. Riding 
hydrogen atoms were added to the model during the final rounds of refinement. (A) In wild-type CutC, 
two networks of hydrogen bonds are highlighted (black dashes). Interactions between Glu491 and Thr502 
and a backbone amide suggest that it is deprotonated and able to act as a general base to accept a proton 
from choline (cyan). Asp216 is also likely to be deprotonated, sharing a single proton in a hydrogen bond 
(O–O distance of 2.7 Å) with Tyr208. A proposed connection (white dashes) between Thr502-Asp216 
would be possible if either of these residues were to change conformation. CH–O interactions to Tyr208 
and Aps216 are shown as in Figure 4.4. (B) In CutC-E491Q, the side chain carbonyl of Q491 is likely to 
be pointing down toward the backbone amide, leaving the side chain nitrogen to point toward Thr502. (C) 
In CutC-T502A, no connection is available between Glu491 and Asp216. 
 
4.2.6: A putative proton transfer network in the active site of CutC. 
In order to complete the catalytic cycle, the protonated active site base Glu491 must be 
deprotonated. The CutC active site does not appear to be set up to allow transfer of protons to or from the 
exterior of the protein as there is no direct solvent pathway from the active site in any of our crystal 
structures. Instead we suggest that TMA deprotonates Glu491 for the next round of catalysis. Direct 
deprotonation of Glu491 by TMA would require a conformational change of CutC as the nitrogen is 4.6 
Å away from the side chain of Glu491 prior to C–N bond cleavage and is sterically blocked by C1 of 
choline and Thr502 (Figure 4.11.A). While Thr502 establishes a close hydrogen bond with Glu491 (2.5 
Å), the hydroxyl group of Thr502 is too far away (5.0 Å) from the trimethylammonium nitrogen and its 
pKa is likely too high to perform a concerted proton transfer during C–N cleavage. Instead, Asp216 is 
positioned close to the trimethylammonium moiety such that it could serve as the general acid in the 
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correct protonation state (Figure 4.11.A). However, Asp216 is also too far from Glu491 for direct proton 
transfer (5.8 Å), requiring a ~3 Å movement of the Asp216 side chain, which appears to be blocked by 
Thr502. Our structures suggest that Thr502 may bridge the gap between Glu491 and Asp216 by 
simultaneously accepting and donating a proton. Thr502 is already in position to hydrogen bond with 
Glu491 (2.5 Å), and a simple rotation of Thr502 around !1 by 10-15º should allow the formation of a new 
hydrogen bond between Thr502 and Asp216. In fact, in the structure of CutC-E491Q, which may serve as 
a mimic for the protonated state of Glu491, the hydroxyl group of Thr502 is positioned in hydrogen-
bonding distance (3.6 Å) of Asp216 (Figure 4.11.A, B).  
To further explore the roles of Asp216 and Thr502, which are both absolutely conserved in CutC 
enzymes (Figure 4.5), we generated CutC-D216N and CutC-T502A mutant proteins. The activation of 
both mutant proteins was below the limit of detection of our EPR instrument, but both enzymes were 
active in an overnight endpoint assay for TMA detection (Figure 4.10.B). Unfortunately, the low activity 
of CutC-D216N in the overnight assay precluded further kinetic analysis of this mutant. For CutC-
T502A, a kinetic assay was performed and low activity was observed; however, this activity started to 
diminish after 30 min (Table 4.1, Figure 4.8.B). We were able to determine the structure of CutC-
T502A, which shows choline binding at full occupancy with no discernable differences from wild-type 
(Figure 4.11.C), except for the fact that the hydrogen bonding network is interrupted (Figure 4.11.A). 
4.2.7: Structure-based mechanistic proposals for CutC-catalyzed choline cleavage 
The C–N lyase chemistry performed by CutC is unique among GREs, but resembles that of other 
radical enzymes that promote 1,2-elimination reactions: the C–O cleaving GRE GDH, the AdoCbl 
dependent enzymes EAL and diol dehydratase, and the AdoMet radical enzyme DesII. Based on previous 
studies of these enzymes, we have considered two mechanisms for CutC (Figure 4.1.C and 4.1.D): a 
direct elimination of TMA from the substrate-based radical, similar to the one favored for GDH (14) and 
DesII (13), or a 1,2-migration, similar to the proposed mechanism for EAL (12) (Figure 4.12). The 
biochemical and structural data presented here appear to complement the elegant mechanistic studies 
performed with DesII using deuterated and fluorinated substrate analogs (32), and the structural and 
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computational studies for GDH (14, 17). As explained below, on the basis of these experiments, we favor 
a direct elimination mechanism for choline cleavage. 
 
Figure 4.12: Proposed mechanisms for reactions catalyzed by enzymes described in the text. (A) 
Ethanolamine ammonia lyase (EAL) utilizes AdoCbl to generate a putative, transient Ado• intermediate 
which abstracts a hydrogen atom from the substrate, ethanolamine (12). A radical-assisted 1,2-migration 
of the amine group is facilitated by Glu287, which forms a bridging hydrogen bond between the alcohol 
and amine (33) (see Figure 4.13). The resulting carbinolamine radical regenerates a transient Ado• 
(recombines with Cbl to form AdoCbl) and subsequently decomposes to ammonium and acetaldehyde. 
(B) GDH, like CutC, utilizes a putative thiyl radical intermediate to abstract a hydrogen from its substrate, 
glycerol. Glu435 is proposed to serve as an active site general base that can deprotonate the resulting 
radical (17). His164 is the proposed active site general acid that facilitates dehydration by protonating the 
leaving hydroxide to form water (14). The resulting product radical can regenerate the transient thiyl 
radical. The active site acid and base are close enough to exchange a proton directly to reset the charge 
state of the active site (14). (C) DesII utilizes AdoMet and an [4Fe-4S]+ cluster to generate a putative, 
transient Ado•, which removes a hydrogen from the substrate, TDP-D-quinovose (13). An unidentified 
active site general base is proposed to facilitate proton migration to the leaving amine, forming 
ammonium (32). We have chosen to illustrate two, distinct proton transfer steps, but a concerted 
elimination-protonation has also been suggested (32). The resulting product-based radical is reduced by 
an electron and protonated to form the deaminated product, TDP-3-keto-6-deoxy-D-glucose. Crucially, 
DesII does not regenerate AdoMet, but instead relies on an external source of reducing equivalents that 
has yet to be identified (34). 
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We propose that CutC-mediated catalysis is initiated by the formation of a transient thiyl radical 
(Figure 4.13, I). Even though the structures presented here are of unactivated CutC, the position of 
choline within the active site clearly supports the abstraction of a hydrogen atom from C1 (likely the pro-
S) by the Cys489 thiyl radical as the probable first step in choline cleavage. This observation is supported 
by our experiments with C1-deuterium labeled choline analogs presented in Chapter 3. Hydrogen atom 
abstraction from choline by the putative thiyl radical could be facilitated by Glu491 hydrogen bonding to 
the C1 hydroxyl of choline. This hypothesis is based on a previous study of the C–D vibrational 
frequencies in primary and secondary alcohols, which determined that the strength of ! C–H bonds of 
alcohols decreases upon increasing the strength of hydrogen bonding between the solvent and the 
hydroxyl group (35). It is important to note that the intermediacy of a thiyl radical in GRE catalysis has 
not yet been experimentally demonstrated. Nonetheless, our structures are similar to those of other GREs 
in further highlighting this key role of the thiyl radical. 
 
Figure 4.13: Mechanistic proposal for choline cleavage by CutC. 
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 Our characterization of the E491Q and E491A mutants supports a role for Glu491 as a general 
base that could deprotonate a C1 choline radical to generate a !-hydroxyalkyl radical (Figure 4.13, I to 
II). Typically, the pKa of this radical species is 4-8 units lower than that of the corresponding alcohol (36) 
(pKa of the choline hydroxyl ~13.9 (37)), making this deprotonation step well within the capability of 
Glu491. This residue also occupies a position in the GRE fold (GCVEP) that is often associated with 
acid/base chemistry (25, 38) and is also conserved in GDH. A computational study of the GDH 
mechanism concluded that proton transfer between the C1 hydroxyl group of glycerol and an active site 
Glu residue triggers dehydratation via direct elimination (14). EPR and kinetic isotope effect studies of 
DesII also implicate a general base in the direct elimination of ammonia from TDP-4-amino-4,6-dideoxy-
D-glucose, but the lack of a crystal structure for DesII precludes a specific assignment of this residue 
(13). A Glu is also present in the EAL active site, but its proposed role is different than in the other 
systems. By establishing close hydrogen bonds (2.8 Å) to both the ammonium and the hydroxyl moieties 
of ethanolamine, this residue may play a key role in stabilizing the transition state for the ammonium 
group migration (Figure 4.14). Thus, we propose that in CutC, Glu491 acts as a general base to form a 
transient ketyl radical, a species similar to those postulated in the 1,2-elimination of water by analogous 
radical dehydratases (39-41) and in the elimination of ammonia by DesII (13).  
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Figure 4.14: The CutC and EAL active sites are arranged to facilitate different chemistry. Protons were 
added to polar residues to make this figure using the H++ server (http://biophysics.cs.vt.edu/H++) (42); 
residues within 4 Å of the substrate are shown as sticks. Hydrogen bonds (black dashes) are shown 
between donor/acceptor pairs. (A) Stereoimage of the EAL active site with ethanolamine (yellow) bound 
(PDB ID 3ABO) (33). A 1,2 migration of the ammonium group is facilitated by Glu287, which forms 
hydrogen bonds with both the ammonium and the hydroxyl moieties of ethanolamine. A 1,2-elimination 
is disfavored by the side chain of Met392 (spheres), which is directly opposite the C–N bond, and 
sterically blocks the ammonium group from departing. Additionally, no suitable proton donor, such as 
Asp216 of CutC, is found adjacent to the substrate ammonium moiety. (B) The CutC active site, shown in 
a similar orientation to EAL relative to the substrate. CutC does not have a residue that is the equivalent 
of Glu287, which could assist in a migration reaction by forming hydrogen bonds with both the 
trimethylammonium and the hydroxyl group of choline. Additionally, there is no equivalent of Met392 to 
block elimination of the trimethylammonium, whereas there is a suitable proton donor (Asp216) for 
protonation of the trimethylamine leaving group. 
 
Following deprotonation of the !-hydroxyalkyl radical, we propose that a rapid heterolytic C–N 
bond cleavage allows the direct elimination of TMA (Figure 4.13, II, III). This proposal draws support 
from radiolysis experiments in which choline-derived radicals undergo C–N fragmentation very rapidly 
under neutral conditions (pH 6.5–7.5) (43). EPR studies of the DesII-generated, substrate-based radical of 
TDP-D-quinovose have revealed the importance of establishing overlap between the partially filled p-
orbital at the radical center and the "* orbital of the adjacent functional group to be eliminated (44). 
Within the active site of CutC, choline is oriented such that the pro-S C1 hydrogen atom is antiperiplanar 
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to the trimethylammonium group, potentially allowing hyperconjugation between the p-orbital of a C1 
choline radical and the C–N !* orbital. The observed CH–O interactions between the 
trimethylammonium group and the polar residues lining the back of the active site (Asp216, Tyr208, 
Tyr506) would also be expected to weaken the C–N bond of choline, by aligning the trimethylammonium 
group for cleavage. Our structure suggests these CH–O interactions likely play a role in both choline 
binding selectivity and in catalysis, consistent with the ~83-fold reduced catalytic efficiency of the CutC 
double mutant Y208F/Y506F. Although perturbation of these CH–O contacts diminishes activity, this 
mutant is nonetheless active. In contrast, mutation of residues in EAL that interact with the ammonium 
group of ethanolamine, such as Glu287 (Figure 4.14), effectively abolish catalysis by EAL or lead to 
inactivation through formation of off-pathway radical intermediates (45). We ascribe this difference in the 
behavior of CutC and EAL mutants to the difference in proposed mechanism: facilitating a 1,2-migration 
reaction such as the one catalyzed by EAL requires that exquisite control be exerted over the migrating 
group by active site residues. No such requirement is necessary for a 1,2-elimination; indeed, this reaction 
proceeds very rapidly in solution (43). Taken together, this evidence highlights that even in its 
unactivated form, CutC binds choline in a configuration that could facilitate direct cleavage of the C–N 
bond from a ketyl radical.    
Additional mechanistic steps to consider include deprotonation of the general base Glu491 to 
reset the CutC active site for the next round of catalysis (Figure 4.13, IV) and leaving group protonation 
(Figure 4.13, V). In GDH, the proposed general base for deprotonation of the C1 hydroxyl group is 
Glu435 (equivalent to Glu491), and the proposed general acid for protonation of the departing C2 
hydroxyl group is His164 (analogous to Asp216) (Figure 4.7.d). Proton transfer between these two 
residues is thought to occur directly (14), with no equivalent of Thr502 blocking the requisite 
conformational changes. In CutC, Glu491 and Asp216 are too distant to interact directly and Thr502 
appears to block the movement required for such interaction. Thus, we propose that the bridging/blocking 
residue Thr502 mediates proton transfer (Figure 4.13, IV), akin to what has been proposed previously for 
Ser and Thr residues in other systems (46, 47). We anticipate computational studies may provide 
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additional insights into this putative proton transfer network, which has been challenging to study 
experimentally.    
A subsequent mechanistic step (Figure 4.13, V) is re-abstraction of the hydrogen atom from 
Cys489 by the product-based radical species to reform the thiyl radical and generate acetaldehyde. For 
AdoCbl enzymes, this re-abstraction step to reform the 5!-deoxyadenosyl radical (5!-dA•) is energetically 
challenging. It has been proposed for EAL that 1,2-migration facilitates re-abstraction of a hydrogen from 
5!-dA, as this step was calculated to be exothermic by 1.2 kcal/mol (48). If base-catalyzed direct 
elimination were to occur in AdoCbl enzymes, the vinoxy radical formed would be stabilized by 
resonance (C–H bond enthalpy, ~95.5 kcal/mol (49)) and could not effectively regenerate 5!-dA• (5!-dA–
H bond enthalpy, 99.9 kcal/mol (50)). In contrast to 5!-dA•, the glycyl and thiyl radicals in GREs are 
much more easily regenerated by product radicals (Cys S–H bond enthalpy, ~87 kcal/mol (51)), removing 
the necessity for the migration mechanism. 
4.2.8: Conclusions 
With these structural and biochemical studies, we are beginning to develop a molecular view of 
how TMA is generated by CutC. Nonetheless, the mechanism of choline cleavage by CutC is still an open 
question, that could be perhaps answered using choline mimics (e.g., vinylcholine) that are converted into 
stabilized radicals upon C–N cleavage, as observed in the case of B12-dependent glycerol dehydratase 
inhibitor but-3-ene-1,2-diol (52). Given that a small molecule inhibitor of microbial TMA production was 
recently reported to diminish atherosclerotic plaque formation in mice (15), understanding TMA 
biogenesis is both timely and important. By dissecting the mechanistic details of CutC catalyzed C–N 
cleavage and elucidating the importance of active site residues for binding and catalysis, our work will 
facilitate the rational design of specific inhibitors for choline TMA-lyase. Such molecules could achieve 
target specificity either by mimicking the binding mode of choline or by intercepting the proposed radical 
intermediates. 
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4.3. Materials and methods 
 4.3.1. Materials and general methods 
All chemicals and solvents were purchased from Sigma-Aldrich, except that Luria-Bertani 
Lennox (LB) medium was purchased from (EMD Millipore). Acetonitrile and water used for liquid 
chromatography-mass spectrometry (LC-MS) were B&J Brand high-purity solvents (Honeywell Burdick 
& Jackson). Oligonucleotide primers for mutagenesis (Table 4.2) were synthesized by Integrated DNA 
Technologies. Recombinant plasmid DNA was purified with a Qiaprep Kit from Qiagen. DNA 
sequencing was performed by Beckman Coulter Genomics. Multiple sequence alignments were 
performed with Clustal W (53), and the results analyzed with Geneious Pro 6.1.6 (54). Nickel-
nitrilotriacetic acid agarose (Ni-NTA) resin was purchased from Qiagen. Protein gels were purchased 
from BioRad. Size exclusion chromatography experiments were performed on a BioLogic DuoFlow 
Chromatography System (Bio-Rad) equipped with a Superdex 200 Increase 10/300 GL column (GE 
Healthcare) for analytical size exclusion or with a HiLoad 16/600 Superdex 200 (GE Healthcare) for 
preparative-scale size exclusion chromatography. Protein concentrations were determined according to 
the method of Bradford using bovine serum albumin (BSA) as a standard (55), or using a NanoDrop 2000 
UV-Vis Spectrophotometer (Thermo Scientific) for CutC wild-type and mutants (! = 128,870 M-1 cm-1 for 
WT, T502A, E491Q, E491A, D216N, ! = 127,380 M-1 cm-1 for Y506F, Y208F and ! = 125,890 M-1 cm-1 
for Y208F/Y506F). The extinction coefficient for CutC was estimated using the ExPASy ProtParam tool 
(http://www.expasy.org/tools/protparam.html). Assays were conducted in a glove box (MBraun) under a 
N2 atmosphere with less than 5 ppm O2. Sonication for disrupting E. coli cells overexpressing CutD was 
performed with a Branson Sonifier S-450D equipped with a " inch horn in a glove box (Coy Laboratory 
Products) under an atmosphere of 96% nitrogen and 4% hydrogen, at 4 oC. The spectrophotometric 
coupled assay for CutC activity was conducted at 22 ºC in 96-well plates using a PowerWave HT 
Microplate Spectrophotometer (BioTek). The absorbance of each well was monitored at 340 nm for 10 
min, reads being 20 s apart. Path length correction was employed such that absorbance values were 
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reported for a path length of 1 cm. Data were analyzed using Gen5 software and kinetic parameters were 
calculated using GraphPad Prism6.  
Table 4.2: Forward primer sequences used for site-directed mutagenesis. The second primer used was the 
reverse complement of the given sequence. 
Name of target Sequence (5´ to 3´) 
CutC-Y208F GTGTCCGACTGCTCCTTCCATGCGGTGAACGGC 
CutC-D216N GTGAACGGCGGCGGCAACTCCAACCCCGGTTAC 
CutC-Y506F TGGACCTCCACCGGCTTTACCCAGTGGCCCATC 
CutC-T502A GGTATAGCCGGTGGAGGCCCACTGGTACAGACG 
CutC-E491A GGGTTGCGTGGCGCCGCAGAAATCA 
CutC-E491Q ACGGCCTGATTTCTGCGGTTGCACGCAACCCATCAG 
 
 4.3.2: Construct design, expression, and purification of CutC variants for crystallization  
Plasmids containing the wild-type D. desulfuricans G20 cutC gene or the same gene with an 18- 
or 52-residue, N-terminal truncation of the resulting protein sequence were constructed and assayed 
previously (9). The N-terminal truncations remove a putative microcompartment localizing sequence 
previously noted to induce aggregation in microcompartment-localized EAL (56). Both 18- and 52-
residue truncation constructs incorporate an N-terminal hexahistidine tag and thrombin cleavage site. 
Full-length and truncated constructs have similar activity, but the truncated proteins are more soluble and 
less prone to aggregation (9). The 52-residue truncated construct was favored for crystallization of active 
site mutants as it removes additional residues that are not conserved and that appear to be unstructured in 
the crystal structure of the 18-residue truncated construct. Site-directed mutagenesis to introduce the 
E491A, E491Q, Y208F, D216N, T502A, Y506F, and Y208F/Y506F mutations was performed as 
previously described (9). For assays, CutC wild-type and mutants were purified as previously described 
with phosphate buffer pH 8, but they were not concentrated after dialysis because the process of 
concentration after Ni-affinity chromatography was found to contribute to aggregation. In order to 
determine whether purification by size exclusion chromatography improved activity, CutC wild-type, 
CutC-T502A and CutC-D216N were fractionated on a HiLoad 16/600 Superdex 200 column using 50 
mM potassium phosphate buffer pH 8, 50 mM KCl, 10% v/v glycerol. The fractions corresponding to the 
dimer were combined and concentrated. CutD was also purified as previously described, with the 
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exception that the cells were disrupted using a sonifier inside a 4 oC oxygen-free chamber (9). All proteins 
were judged to be of high purity by denaturing polyacrylamide gel electrophoresis (Figure 4.15). 
 
Figure 4.15: Sodium dodecylsulfate denaturing electrophoresis (4-15% Tris-HCl polyacrylamide gel) of 
the proteins used in this work. Precision Plus Protein All Blue Standards (BioRad) (lane 1), CutD (lane 
2), CutC-WT (lane 3), CutC truncated mutants: CutC-E491A (lane 4), CutC-E491Q (lane 5), CutC-
Y208F (lane 6), CutC-Y506F (lane 7), CutC-Y208F/Y506F (lane 8), CutC-T502A (lane 9), CutC-D216N 
(lane 10). 
 
 4.3.3: Crystallization and structure determination of wild-type CutC 
Initial screening of non-post-translationally modified wild-type CutC protein with the intact N-
terminal hexahistidine tag and 18-residue truncation was performed exposed to air with the aid of an Art 
Robbins Phenix micro-pipetting robot and a Formulatrix Rock Imager. Numerous initial conditions were 
found, with optimization yielding a well solution containing 17% (w/v) polyethylene glycol (PEG) 8000, 
0.3 M lithium chloride, and 0.1 M Tris pH 8.0. Diffraction-quality crystals were obtained in hanging drop 
vapor diffusion trays at 21 ºC. Protein at 15 mg/mL in buffer containing 50 mM potassium phosphate pH 
8.0, 50 mM KCl, and 10% (v/v) glycerol was mixed with well solution in a 1:1 ratio. Plate-like crystals 
formed after 2-3 days of equilibration and grew to maximum size over one week. Crystals were 
cryoprotected by soaking for 15-30 min in solution containing 20% (v/v) glycerol, 25% (w/v) PEG 8000, 
0.5 M lithium chloride, and 0.1 M Tris pH 8.0. Choline was not added to the protein prior to 
crystallization but was included in the cryoprotection solution at 10 mM. 
Crystals were initially characterized using an in-house CuK! X-ray source (Rigaku) and indexed 
in space group P21 with cell edges a = 79.6 Å, b = 234.9 Å, c = 105.0 Å, " = 109.6º. High-resolution 
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diffraction images were collected at the Advanced Photon Source beamline 24ID-C at a wavelength of 
0.9795 Å on a Pilatus 6M detector (Dectris). Data were indexed, integrated, and scaled in HKL2000 (57) 
(statistics in Table 4.3). The structure of CutC was solved by molecular replacement in the Phenix 
implementation of Phaser (58). The structure of AdoCbl-independent glycerol dehydratase (PDB code 
1R8W, 37% identity) (17) was used to construct a search model after trimming of non-identical side 
chains in Phenix Ensembler (59). A solution with four molecules per asymmetric unit was found with an 
initial Rfree of 0.48 at 2.8-Å resolution. Several rounds of initial refinement in phenix.refine (59) with tight 
NCS restraints were sufficient to reduce Rfree values below 0.4, and manual building of side chains further 
reduced Rfree to ~0.3. NCS restraints were removed after initial refinement and addition of water 
molecules. Inclusion of explicit riding hydrogen atoms once the model was close to convergence 
improved both Rfree and the model geometry. Positional and B factor refinement continued at the full 
resolution until the model was complete (statistics in Table 4.3). Choline was fit into difference density 
and verified with simulated annealing composite omit maps. Parameter files for choline were generated in 
Phenix eLBOW. Water molecules were placed automatically after ligands were refined and were verified 
manually. The final model contains all native residues at the C terminus in all four molecules. No density 
is observed for the N-terminal hexahistidine tag or residues 19-52 in the 18-residue truncated construct, 
but all other residues (53-846) are present and well ordered in the model. Despite different crystal 
contacts for each molecule in the asymmetric unit, the structures of each monomer were essentially 
indistinguishable, with root-mean-square deviations of 0.11-0.14 Å. Structural figures were made in 
PyMOL v1.4.1 (Schrodinger).  
Table 4.3: Data collection and refinement statistics for wild-type CutC with choline. 
 
Data collection and processinga,b  
Resolution (Å) 50-1.90 
(1.93-1.90) 
Completeness (%) 99.3 (99.1) 
<I/!I> 12.5 (1.60) 
Rsym 0.09 (0.99) 
Rpimc 0.037 (0.430) 
Unique reflections 282491 
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Redundancy 6.7 (5.9) 
CC1/2 (0.68) 
  
Model refinement  
Resolution (Å) 50-1.90 
(1.92-1.90) 
Rwork, Rfree 0.14 (0.18) 
Rfree set size 8478 
Protein atomsd 25099 
Choline atomsd 28 
Other ligand atomsd,e 48 
Water molecules 2486 
Riding hydrogen atoms 24705 
RMSDf Bond length (Å) 0.006 
RMSD Bond angle (º) 0.999 
Coordinate error (Å) 0.20 
Rotamer outliers (%) 0.48 
Ramachandran plot (%)  
Most favored 97.3 
Additionally allowed 2.4 
Disfavored 0.3 
Average B factors (Å2)g  
Monomer A 48.3 
Monomer B 39.3 
Monomer C 36.9 
Monomer D 35.1 
Choline 32.3 
Other ligandse 55.7 
Water 42.9 
a Data were trimmed based on CC1/2 value rather than Rsym or <I/!I>. Inclusion of highest resolution data 
improved the quality of the electron density maps. 
b Values in parenthesis are for the highest resolution shell. 
c Rpim is reported due to the high redundancy of this datasets. 
d Non hydrogen atoms 
e Glycerol is bound at the protein surface. 
f RMSD, root-mean-square deviation 
g All atoms 
 
4.3.4: Crystallization and structure determination of CutC mutants 
  
 Initial attempts to crystallize CutC mutants in the same condition as wild-type CutC were 
unsuccessful. Therefore, new crystals of CutC mutants (E491Q, T502A, or Y208F) with an N-terminal 
52-residue truncation were identified in screening trays using the same setup as for wild type. Optimized 
crystals were grown using hanging drop vapor diffusion at 21 ºC (room temperature). CutC mutant 
protein at 8 mg/mL in buffer containing 50 mM potassium phosphate pH 8.0, 50 mM potassium chloride, 
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and 10 mM choline was mixed in a 1:1 ratio with well solution containing 1.0-1.2 M sodium malonate pH 
7.0-8.0. Crystals were rod-like and grew within 7 days. Crystals were cryoprotected by brief transfer into 
a solution containing 3.4 M sodium malonate pH 7.0 and 10 mM choline and cryocooled by plunging in 
liquid nitrogen. 
Diffraction images were indexed in space group P42212 with cell edges approximately a = b = 230 
Å, c = 79 Å. All data were collected and processed as for wild-type CutC (statistics in Table 4.4). Initial 
data processing in space group P42 suggested the presence of merohedral twinning in all datasets with 
twin fractions near 0.5. Despite this complication, the structure of each mutant could be solved 
unambiguously and with reasonable phasing statistics by molecular replacement in space group P42212 in 
the Phenix implementation of Phaser (58) using the wild-type monomer as a search model. Two 
molecules are present per asymmetric unit, but the dimer interface is crystallographic, resulting in an 
overall tetrameric structure similar to the wild type. Attempts at twin refinement in space group P42 
resulted in strong phase bias, little improvement in Rfree, and a refined twin fraction of 0.5. Thus, the 
structures were refined without consideration of twinning in space group P42212. Positional and B factor 
refinement was conducted with phenix.refine (59) (statistics in Table 4.4). Initially, refinement was 
performed only on the T502A structure, as the initial electron density maps were best for this dataset. 
Once the refinement converged, each mutant was refined separately (with Rfree flags propagated to the 
other datasets). NCS and reference model restraints were used initially to reduce overfitting of the model 
but were removed after convergence with no change in the Rfree values. Riding hydrogen atoms were 
included at the end of refinement, resulting in an improvement of Rfree and geometry. Each final model 
contains native protein residues 53-846 in each chain; residues 1-52 were omitted in the construct. The N-
terminal thrombin cleavage tag and linker are clearly visible in all chains; the hexahistidine tag is not 
ordered, but a single histidine residue is visible in one chain. Choline and active site waters were modeled 
into omit maps after refinement of the remainder of the protein. Three sodium ions and eight malonate 
ions are present in the final model, likely as a result of the high concentration of sodium malonate in the 
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crystallization solution. No sodium ions were found in the wild-type structure. All ligands and mutated 
residues were verified rigorously with composite omit maps. 
Protein coordinates and structure factors have been submitted to the Protein Data Bank under 
accession codes 5FAU (wild type), 5FAV (E491Q mutant), 5FAW (T502A mutant), and 5FAY (Y208F 
mutant). 
Table 4.4: Data collection and refinement statistics for mutant CutC proteins. 
 CutC T502A 
choline 
CutC E491Q CutC Y208F 
choline 
Data collection and processinga,b    
Resolution (Å) 50-1.85 
(1.88-1.85) 
50-1.60 
(1.63-1.60) 
50-1.90 
(1.93-1.90) 
Completeness (%) 99.9 (99.9) 100 (100) 99.7 (99.6) 
<I/!I> 15.3 (3.0) 13.4 (2.6) 12.0 (2.0) 
Rsym 0.154 (0.984) 0.128 (>1) 0.124 (>1) 
Rpimc 0.044 (0.301) 0.039 (0.382) 0.051 (0.443) 
Unique reflections 177353 273075 163497 
Redundancy 13.0 (11.4) 13.1 (12.2) 7.2 (6.6) 
CC1/2 0.73 0.69 0.63 
    
Model refinementb    
Resolution (Å) 50-1.85 
(1.87-1.85) 
50-1.60 
(1.62-1.60) 
50-1.90 
(1.92-1.90) 
Rwork, Rfree 0.171, 0.206 0.151, 0.178 0.159, 0.193 
Rfree set size 5327 8200 4901 
Protein atomsd 12709 12780 12753 
Choline atomsd 14 0 14 
Other ligand atomsd,e 66 66 66 
Water molecules 2374 2367 2372 
Riding hydrogen atoms 12521 12572 12565 
RMSDf Bond length (Å) 0.005 0.008 0.006 
RMSD Bond angle (º) 0.901 1.121 0.925 
Coordinate error (Å) 0.17 0.14 0.15 
Rotamer outliers (%) 0.52 0.51 0.44 
Ramachandran plot (%)    
Most favored 97.3 97.2 97.2 
Additionally allowed 2.5 2.5 2.5 
Disfavored 0.2 0.3 0.3 
Average B factors (Å2)g    
Monomer A 23.4 21.2 23.7 
Monomer B 25.2 24.1 26.9 
Choline 31.3 -- 43.6 
Water 37.1 37.4 39.9 
Other ligandsd 50.8 46.2 57.1 
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a Data were trimmed based on CC1/2 value rather than Rsym or <I/!I>. Inclusion of highest resolution data 
improved the quality of the electron density maps. 
b Values in parenthesis are for the highest resolution shell. 
c Rpim is reported due to the high redundancy of these datasets. 
d Non-hydrogen atoms 
e Malonate and sodium ions from the cryoprotectant are bound at the protein surface. 
f RMSD, root-mean-square deviation 
g All atoms 
 
4.3.5: Size exclusion chromatography to verify oligomeric state of CutC wild type and mutants 
A ~30 µM solution of CutC (wild type or mutant) purified with potassium phosphate buffer pH 8 
was analyzed by size exclusion with a 50 µL injection volume. The proteins were eluted over 122 min 
with 50 mM potassium phosphate buffer pH 8, 50 mM KCl, 10% v/v glycerol at 0.25 mL/min. A solution 
of molecular weight markers (Bio-Rad, #151-190) analyzed under the same conditions was used to 
construct a standard curve. CutC mutants are dimeric in solution (Figure 4.16), consistent with previous 
results (9). 
 
Figure 4.16: Determination of the oligomeric state of wild-type CutC and mutants by gel filtration 
chromatography. For this analysis, all proteins were purified by Ni-affinity chromatography. The major 
peak was found to correspond to the dimer. 
 
 4.3.6: Glycyl radical generation on CutC 
 Activation assays were set up in an MBraun glove box in 1.5 mL polypropylene Eppendorf tubes 
and contained 50 mM potassium phosphate pH 8, 50 mM potassium chloride, 150 "M sodium dithionite, 
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200 !M AdoMet, 10 !M CutC dimer, and 30 !M CutD in a total volume of 200 !L. A mixture of buffer, 
CutD and sodium dithionite was incubated for 20 min prior to addition of AdoMet and CutC, then glycyl 
radical formation was carried out for 1 h at room temperature. This incubation time was determined as 
optimal based on the stability of the glycyl radical signal for wild type CutC and CutC-Y208F (Figure 
4.8.A). The conditions used for CutC activation were optimized as described below. Despite additional 
attempts at optimization, no glycyl radical signal was observed for CutC-T502A when the activation 
assay was incubated for 30 min or 60 min. X-band EPR spectroscopy and spin concentration 
measurements were performed as previously described (Chapter 3) (9), without taking into consideration 
the difference in receiver gain for standard and enzymatic assays as this difference is already accounted 
for by the spectrometer. The limit of detection for this technique was estimated at ~0.5 !M. 
4.3.7: Optimization of glycyl radical formation on CutC  
The activation assay for glycyl radical formation was optimized with wild-type CutC using a 
coupled, spectrophotometric assay for acetaldehyde, as described for steady state kinetics (section 4.3.8). 
The parameters surveyed and their respective outcomes are described in Table 4.5.  
Table 4.5: Outcome of parameters surveyed for the optimization of glycyl radical formation on CutC.  
Parameter surveyed for activation assay Outcome 
incubation time (30 to 90 min) selected 60 min as incubation time 
buffer (25 mM Tris pH 8 vs. 50 mM potassium 
phosphate pH 8) 
selected 50 mM potassium phosphate pH 8 due to 
improved stability of the glycyl radical 
ratio of CutC to CutD (from 1:0.4 to 1:4) found that highest amounts of CutD afford best 
results, probably due to incomplete reconstitution 
of [4Fe-4S] clusters 
using size exclusion chromatography-purified CutC did not make a difference, but this step was found 
to decrease the stability of mutant CutC proteins 
using size exclusion chromatography-purified CutD did not make a difference, and avoiding this step 
might prevent potential oxygen damage of the 
[4Fe-4S] clusters  
reductant (sodium dithionite (NaDT), E. coli 
flavodoxin (60) reduced with NaDT, acriflavin, 
methyl viologen, titanium (III) citrate) 
moderate amounts of NaDT were found to afford 
best results 
concentration of NaDT (2-20 equivalents with 
respect to CutC) 
10-20 equivalents afforded best results 
concentration of AdoMet (10-80 equivalents with 
respect to CutC) 
20 equivalents afforded best results 
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For CutC-T502A, no glycyl radical signal was observed after 30 or 60 min incubation using the 
optimized activation conditions. In addition, no signal was observed after this mutant was purified by size 
exclusion chromatography, when Tris buffer was used instead of potassium phosphate, or when acriflavin 
(6 equivalents) was used instead of NaDT as reductant. For CutC-D216N, no EPR signal was observed 
when this mutant was assayed with Tris buffer after purification by size exclusion chromatography.  
4.3.8: Kinetic analysis of choline cleavage 
A spectrophotometric coupled assay monitoring oxidation of NADH by yeast alcohol 
dehydrogenase (YADH) was used to determine the kinetics of acetaldehyde production and thereby 
choline cleavage. Activation of CutC was carried out as described above. All assays contained 200 !M 
NADH, 50 mM potassium phosphate pH 8, 50 mM potassium chloride, diluted activation mixture (4000-
fold for wild type, 33-fold for Y208F, 150-fold for Y506F, 10-fold for Y208F/Y506F, 2.5-fold for 
T502A), YADH (0.4-4 !M) and choline (0-10 mM, except for T502A, for which 100 mM choline was 
used) in a total volume of 200 !L. The assay was carried out in triplicate in a 96-well plate and the 
NADH absorbance at 340 nm was monitored for 7 min. The absorbance decreased linearly, indicating a 
constant concentration of activated enzyme during the course of our measurements. 
4.3.9: LC-MS/MS assays for trimethylamine detection 
For E491A and E491Q mutant proteins, glycyl radical formation on CutC was carried out on a 40 
!L scale as described above, then 100 mM choline was added to the assays, followed by overnight (16 h) 
incubation in an Mbraun glove box at room temperature. For CutC-wild-type, CutC-T502A and CutC-
D216N purified by size exclusion chromatography, activation assays were carried out in a similar manner, 
but contained 25 mM Tris buffer pH 8, 50 mM sodium chloride, 200 !M sodium dithionite, 200 !M 
AdoMet, 10 !M CutC dimer, and 40 !M CutD in a total volume of 50 !L. Choline was added to a final 
concentration of 20 mM, and the assays were incubated overnight (16 hr) in an Mbraun glove box at room 
temperature. For LC-MS/MS analysis, 4 !L of each assay were diluted into buffer R (20% 5 mM 
ammonium formate pH 4 and 80 % acetonitrile). This mixture was centrifuged at 13,000 rpm for 10 min 
to remove particulates, diluted 20 fold with buffer R, then 3 !L were analyzed by LC-MS/MS using a 
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previously-described method for underivatized TMA detection (precursor-product ion pair: m/z 60.1 ! 
m/z 45, collision energy: 21 V, limit of detection after dilution: ~ 1 "M) (10). 
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Chapter 5: Towards preventing the production of trimethylamine by the  
human gut microbiota 
 
5.1: Introduction  
 
It has long been recognized that gut bacteria play important roles in human health and 
physiology. Collectively possessing over 150-fold more genes than the human genome, our gut microbes 
have metabolic and biosynthetic capabilities that greatly surpass those of human cells (1). As described in 
Chapter 1 of this thesis, such functions can be beneficial to the host, since gut bacteria synthesize 
essential vitamin and nutrients, influence the development of immune cells, and digest inaccessible food 
components (2). The gut microbiota has also been implicated in a number of diseases, including 
inflammatory bowel disease (IBD), obesity, nonalcoholic fatty liver disease (NAFLD), and colon cancer 
(3). Despite great advances in our understanding of correlations between changes in the composition of 
gut microbial communities and host physiological states, the molecular mechanisms underlying host-gut 
microbiota interactions are still largely unknown. One approach to elucidate the impact of microbial 
metabolic activities on community structure, dynamics, and functions is the use of small-molecule 
inhibitors that target gut microbial enzymes. Currently, this approach was employed only with the 
purpose of blocking the activity of sugar scavenging gut bacterial !-glucuonidase enzymes, which 
deconjugate xenobiotics by removing glucuronide groups for use as carbon source (4). In the case of the 
cancer drug SN-38, this mode of deconjugation within the gut lumen results in severe diarrhea (4). 
Relying on an understanding of the structure and activity of bacterial !-glucuonidases, Wallace et al. 
uncovered inhibitors that selectively target microbial enzymes !-glucuonidases and were not toxic to 
either bacteria or human cells (4). Thus, this study opened the possibility of ‘drugging the microbiota’, 
i.e., modulating the activity of specific microbial enzyme targets for scientific and clinical purpose (5).  
Recently, a link has emerged between a metabolite of gut microbial origin, trimethylamine N-
oxide (TMAO), and cardiometabolic disorders, such as NAFLD and atherosclerosis. As described in 
Chapter 1 of this thesis, the metabolite TMAO is primarily produced via a human-microbial co-metabolic 
pathway that begins with the conversion of the diet-derived nutrient choline to trimethylamine (TMA) by 
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gut microbes under anaerobic conditions (Figure 5.1). Phosphatidylcholine (PC) is believed to represent 
the main source of choline in the gut, as it is highly abundant in animal products and bile, and it can be 
converted into choline through the action of both human and microbial phospholipases (6). TMA is 
considered primarily to be a waste product of this metabolic pathway; bacteria utilize the resulting 
acetaldehyde as carbon source and only methanogenic Achaea present in low abundance in the human gut 
can further degrade TMA (7). As a result, most of the TMA produced in the gut is transported via the 
portal circulation to the liver, where flavin-dependent monooxygenase enzymes (FMOs), particularly 
FMO3, oxidize it to TMAO. Due to its high water solubility, TMAO is predominantly excreted by the 
kidneys into urine (8). Although TMA has been considered a normal constituent of human urine since the 
beginning of the past century, the exclusively microbial origin of this metabolite was not established until 
1992 (9).  As discussed below, due to recent reports linking high TMAO levels in urine and plasma to 
several diseases, the pathways leading to TMA and TMAO production have only lately been considered 
sources of new therapeutic targets (10).  
 
Figure 5.1: Overview of the human-microbial co-metabolic pathway for the conversion of choline into 
trimethylamine N-oxide (TMAO). 
 
Multiple clinical studies have found that elevated plasma TMAO levels represent a prognostic 
marker for cardiovascular disease, independent of traditional risk factors, renal function, and medication 
use (11-13). Feeding TMAO or its main precursors (choline, phosphatidycholine and L-carnitine) to 
female atherosclerosis-prone ApoE-/- mice enhanced plaque formation (12, 13), and TMAO was found to 
alter cholesterol transport, induce inflammation in endothelial cells, and directly contribute to thrombosis 
by enhancing platelet aggregation (12-15). Since a molecular target for TMAO has not yet been 
discovered and the contribution of TMAO to atherosclerosis was contested by a different study (16), 
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chemical tools that inhibit the formation of this metabolite would be tremendously useful to dissect its 
contribution to disease.  
Since TMAO is formed via a human-microbial co-metabolic pathway, recent studies investigated 
the effects of preventing its formation by flavin monoxygenase 3. Interestingly, FMO3 silencing using an 
antisense oligonucleotide in liver insulin receptor knockout (LIRKO) mice led to a decrease in circulating 
TMAO and a protective effect towards atherosclerosis development (17). However, it is difficult to 
decipher the cause of this outcome, since FMO3 knockdown also had a pronounced effect on lipid, 
glucose and insulin levels (17). These studies thus indicate that FMO3 has an important role in 
maintaining homeostasis, and that its inhibition via chemical tools is not a feasible approach to studying 
the role of TMAO on the progression of atherosclerosis. Instead, targeting TMA formation by gut 
microbes arises as a potentially more effective strategy. 
Gut bacterial TMA production is also linked to liver diseases. It is well known that choline 
deficiency leads to fat accumulation in the liver (18); recently, a metabolomics study described a gut 
microbiota-mediated mechanism underlying the development of fatty liver in a mouse model susceptible 
to fatty liver disease and insulin resistance (19). Dumas et al. concluded that a gut microbiota abundant in 
choline-utilizing bacteria could reduce choline bioavailability and cause non-alcoholic fatty liver disease 
(NAFLD) (19). This conclusion was also corroborated by another study revealing that NAFLD is 
transmissible to germ-free mice via microbiota transplant (20). Even though NAFLD is considered the 
most common cause of liver disease worldwide and affects 17% of the world’s population, therapeutic 
intervention strategies for this disease are limited to lifestyle changes, such as reducing caloric intake and 
increasing physical activity (21). Due to the contribution of gut microbial metabolism of choline to 
NAFLD, inhibitors of this microbial pathway would represent viable therapeutic options that could be 
part of a complex approach to treatment.  
The inherited metabolic disorder trimethylaminuria (fish malodor syndrome) arises from 
mutations in the gene encoding FMO3 that result in an inability of individuals to completely oxidize 
TMA to TMAO, and an associated socially and psychologically debilitating malodor (22). Since many 
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people suffering from trimethylaminuria remain undiagnosed for long periods of time, the frequency of 
this disorder is not precisely known, but genetic studies have estimated the incidence of heterozygous 
carriers to range from 0.5% to 11% depending on the ethnicity examined (22). Several holistic approaches 
are known to manage the intense odor associated with this disease (as detailed in Chapter 1), but no 
universally efficacious treatment options for trimethylaminuria have been developed (22). Therapeutic 
intervention using a small molecule inhibitor selective for TMA production would thus be a highly 
beneficial strategy. Such molecules would be less likely to perturb the beneficial activities of the gut 
microbiota, or interact with mammalian enzymes, as demonstrated in the case of gut bacterial  !-
glucuronidase inhibition (4).  
Prior to the discovery of the enzymes responsible for TMA formation by anaerobic microbes, 
several attempts were made to inhibit this activity in whole cell cultures (Streptococcus sanguis (23)) or 
cell lysates (Desulfovibrio desulfuricans (24, 25), Clostridium (26), Proteus mirabilis (27)) of anaerobic 
bacteria that converted choline into TMA and acetaldehyde. These studies determined that TMA 
production from choline was inhibited by 2,4-dintrophenol (mechanism still unknown (23-25, 27)), 
reagents that can react with cysteine residues (23-25, 27), iron-chelating reagents (24, 25, 27), a known 
choline uptake inhibitor (hemicholinium-3 (23)), and choline mimics (dimethylaminoethanol (23, 26) and 
betaine aldehyde (23)). Since the main purpose of these experiments was to gain information about the 
enzymes involved in TMA generation, the molecules listed above were not tested further to determine if 
they would be suitable for use with other strains of bacteria or in a host.  
As described in Chapter 1 of this thesis, the genetic and biochemical bases of TMA production by 
gut microbes were unknown until recently, and anaerobic choline metabolism had not been extensively 
studied. Since the human colon is a predominantly anaerobic environment (28), the contribution of a 
recently discovered oxygen-dependent pathway (yeaW/X) for TMA formation from choline by gut 
microbes is likely very limited (29). As described in Chapter 2 of this thesis, we used a genome mining 
approach to uncover the first bacterial gene cluster (cut cluster) involved in anaerobic bacterial choline 
metabolism (Figure 5.2) (30). We also established that the cut pathway could be a major mechanism for 
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the direct conversion of choline to TMA by gut bacteria (31). The key TMA-generating enzyme, choline 
TMA-lyase (CutC), is a new member of the glycyl radical enzyme family, and represents a specific 
molecular marker for choline metabolism, as detailed in Chapters 3 and 4. In collaboration with a 
postdoctoral fellow in the Balskus group, Dr. Ana Martínez del Campo, members of Prof. Federico Rey’s 
research group at the University of Wisconsin-Madison have also shown that organisms containing the 
cut genes, but not cutC mutants, produce TMA in gnotobiotic mouse models, including ApoE-/- mice 
(manuscript in preparation). This finding confirms that the cut pathway is functional in a host setting, and 
represents the first step towards investigating the impact of microbial choline utilization on host biology 
using tool compounds.  
 
Figure 5.2: The choline utilization (cut) gene cluster and model for choline metabolism in Desulfovbrio 
desulfuricans ATCC 27774.   
 
In this Chapter, I describe several strategies to discover small molecule inhibitors of gut microbial 
choline cleavage. An initial round of structure-guided inhibitor design afforded betaine aldehyde as a 
promising early lead. In vitro assays and X-ray crystallography indicated that this molecule specifically 
interacts with CutC, and could function as a reversible covalent inhibitor. Betaine aldehyde also inhibited 
the conversion of choline to TMA by a panel of various strains bacteria harboring the cut gene cluster and 
by a human fecal sample. I also describe the development of a high throughput screening approach to 
identify new inhibitors of choline metabolism by gut microbes, which could provide an orthogonal 
strategy to rational design approaches. Towards this end, a graduate student in the Balskus group, Marina 
Orman, and I optimized a media formulation containing choline as sole carbon source, ensuring that 
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bacterial survival would be dependent on the cut pathway. Under those conditions, betaine aldehyde 
inhibited choline-dependent but not glycerol-dependent growth of the cut gene cluster harboring strain E. 
coli MS 69-1. Overall, these preliminary results show that small molecules can interfere with anaerobic 
choline metabolism by gut microbes and set the stage for more extensive efforts to discover potent 
inhibitors this pathway. 
5.2: Results and discussion 
5.2.1: Rational design and testing of putative CutC inhibitors 
Our first approach towards discovering small molecule inhibitors of anaerobic microbial choline 
metabolism involved the rational design of compounds that are structural mimics of choline or can 
interfere with the mechanism of CutC. To this end, we have leveraged our knowledge of the activity, 
mechanism, and structure of CutC (Figure 5.3). Our in vitro biochemical studies described in Chapter 3 
revealed that the enzyme has high specificity for choline. We also confirmed the importance of two 
essential active site residues, the glycine that becomes a glycyl radical upon the action of the activating 
enzyme CutD, and a cysteine that would be converted into a thiyl radical upon substrate binding and 
could generate the choline-based radical at C1. The biochemical and structural studies described in 
Chapter 4 revealed that carbon-oxygen hydrogen (CH–O) interactions between the methyl groups of the 
trimethylammonium moiety of choline and O atoms of polar active site residues (Asp216, Tyr208, 
Tyr506) are important for both binding and catalysis. In addition, our insights enabled us to propose a 
mechanism for choline cleavage involving direct elimination of TMA from a substrate-based radical, 
upon deprotonation of the choline hydroxyl by Glu491 (Figure 5.3.C). Elucidating the molecular basis 
for choline binding and catalysis is extremely valuable for uncovering modulators of TMA production, 
providing us with the opportunity to perform rational design and structure-guided optimization of 
inhibitors.  
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Figure 5.3: Structure and proposed function of choline TMA-lyase (CutC). (A) Choline-bound structure 
of CutC. (B) CutC utilizes a protein-based glycyl radical to perform its function. (C) Proposed 
mechanism for choline cleavage by CutC; for details, see Chapter 4.  
 
For our inhibitor design we thus chose to focus on a variety of compounds similar in molecular 
weight to choline (Figure 5.4.A). We prioritized compounds that could potentially bind to other regions 
of the active site (compound 7), establish similar interactions as choline with active site residues 
(compounds 3, 4, 5, 6, 8, 12), engage the active site Cys residue (compounds 1, 2, 9, 10, 11, 13), or 
stabilize the radical formed upon initial hydrogen atom abstraction from C1 (compounds 2 and 10). We 
tested this small library of molecules (either purchased of synthesized as described in ‘materials and 
methods’) using in vivo assay for TMA-d9 formation by cut cluster-containing bacteria Escherichia coli 
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MS 200-1 grown for 3.5 h in rich media (Brain Heart Infusion broth, BHI) supplemented with 1 mM 
(trimethyl-d9)-choline (d9-choline) (Figure 5.3.B). The inhibitors were added when the cultures were 
inoculated, and during this time interval, all cultures grew to saturation, indicating that none of the 
compounds tested possessed antibiotic properties. For reasons still under investigation, the extent of d9-
TMA production by E. coli MS 200-1 from the d9-choline provided is ~30% under these conditions (3.5 h 
incubation), a value that matches the maximum possible conversion of choline into TMA (over 12 h) 
achieved by this strain of bacteria. Since the levels of d9-choline and d9-TMA at the end of our experiment 
add to approximately the concentration of d9-choline initially added (1 mM), it does not seem that this 
strain of bacteria utilizes choline for other purposes, except in the case of compound 13, in which choline 
might be diverted to other pathways.   
 
Figure 5.4: Small molecules inhibit anaerobic choline metabolism by Escherichia coli MS 200-1. (A) 
Rationally-designed molecules that were tested in our assays. (B) Results of an LC-MS/MS quantification 
of d9-choline and d9-TMA from cultures of E. coli MS 200-1, or (C) Proteus mirabilis ATCC 29906 
grown for 3.5 h at 37 oC in BHI supplemented with 1 mM d9-choline and 5 mM of each putative inhibitor. 
Stacked bar graphs represent the means ± standard deviations (SD) of three independent cultures; for 
compound 13, only the results for one culture are shown. Inhibition greater than 50% is marked with *. 
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Closely examining the results presented in Figure 5.4, it is clear that the presence of a 
trimethylammonium group in a putative inhibitor is more likely to ensure effective inhibition of TMA 
formation, in line with the significant contribution of CutC active site residues interacting with this 
substituent to binding and catalysis (as reported in Chapter 4). In addition, the ability of a molecule to 
interact with Cys489 appears to correlate with its inhibitory activity. Both betaine aldehyde (compound 1) 
and thiocholine (compound 3) emerged as effective inhibitors of TMA production, drastically diminishing 
the levels of TMA (to less than 10% of levels without inhibitor) under the conditions tested (5 mM 
inhibitor). In addition, cyanocholine (compound 11) appeared as a promising scaffold, lowering TMA to 
~40% of levels without inhibitor. While we have thus identified small molecules that can modulate 
anaerobic choline catabolism by E. coli, there is significant room for improvements in potency and 
structural novelty to create better candidates for use within a host. 
Our results with betaine aldehyde were in accordance with previous data from a study reporting 
that this molecule could inhibit TMA production (at 0.5 mM) from whole cells of Streptococcus sanguis, 
a cut gene cluster-harboring member of the oral cavity microbiota (23). Interestingly, betaine aldehyde is 
endogenous to our bodies, being produced as a short-lived intermediate in the oxidation of choline en 
route to glycine betaine in the mitochondria of liver and kidney cells (32). In order to determine the 
mechanism of inhibition by betaine aldehyde, future experiments should test whether this molecule can 
affect choline transport in bacteria (33), even it was not previously found to prevent low affinity choline 
transport in alveolar epithelial cells (34). Since choline metabolism in E. coli MS 200-1 (and most gut 
isolates (31)) is hypothesized to occur in a microcompartment, it is possible that betaine aldehyde could 
affect transport of choline into the microcompartment. This hypothesis could be tested in a similar manner 
as with whole cells, by using isolated microcompartments from a culture of E. coli MS 200-1 grown on 
choline as single carbon source (35). Another way in which betaine aldehyde could lower TMA 
production is by interfering with regulation of the cut pathway. This fact could be tested by comparing the 
transcription of proteins from the cluster when bacteria are grown on media containing choline with or 
without the addition of betaine aldehyde, using a procedure previously developed in the Balskus group 
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(31). Alternatively, the efficacy of betaine aldehyde against TMA production could be tested with bacteria 
grown to saturation and washed with buffer. Given that this molecule possesses an aldehyde moiety, we 
hypothesize that it could interfere with choline cleavage primarily by interacting with Cys489 of CutC to 
form a covalent bond. 
The Hazen group at the Cleveland Clinic also recently conducted a study to discover small 
molecule inhibitors of TMA production by gut microbes (33). They tested several choline mimics (in 
which the N atom of choline was replaced with a C, Si or P atom, and glycyine betaine) and identified 
3,3-dimethyl-1-butanol (DMB, compound 8) as a weak inhibitor of in vivo TMA production by cells of 
Proteus mirabilis ATCC 29906 harboring the cut cluster (1 mM DMB elicited a 60% reduction in TMA 
levels). Moreover, DMB was found to significantly thwart the development of aortic root lesions in 
ApoE-/- mice that were fed a high choline diet. Metabolomics experiments indicated that DMB is rapidly 
metabolized in mice to 3,3-dimethylbutyric aldehyde (DMBA, compound 9), a molecule that might also 
act as inhibitor of choline cleavage (33). In addition, it is likely that the observed phenotype in mice could 
be due to DMB or its metabolites interfering with other choline-binding proteins. In our experiments with 
E. coli MS 200-1, both DMB and DMBA appeared significantly less effective at preventing d9-TMA 
formation, despite testing these molecules at concentrations 2.5-fold higher than those used by the Hazen 
group. We also incubated DMB or DMBA with cultures of the same strain of Proteus mirabilis that was 
used in their study, and we could not detect inhibition of choline cleavage (Figure 5.4.C). Even though 
our quantification of d9-TMA for these experiments lacks some accuracy due to a conversion higher than 
the theoretical one, it is clear that neither DMB, nor DMBA, had any effect on TMA production from 
choline. In the experiments performed in the Hazen group, 8 mM DMB led to a ~80% reduction in TMA 
levels produced by cultures of Proteus mirabilis grown in rich media (nutrient broth) supplemented with 
inhibitor and 100 !M d9-TMA (33). We believe that one reason behind these different results is the fact 
that experiments in our group were performed with cells grown under strict anaerobic conditions, whereas 
the Hazen group appeared to run experiments under aerobic or microaerophilic conditions (performing 
assays for TMA production in gas tight vials). This fact might explain why the conversion of d9-choline 
! 191 
into d9-TMA observed by the Hazen group was only ~8% with whole cells of Proteus mirabilis. 
Interestingly, in our experiments, betaine aldehyde retained its inhibitory activity with Proteus mirabilis, 
prompting us to further examine its specificity for CutC and its ability to prevent TMA formation by other 
cut-cluster containing bacteria.  
5.2.2: Betaine aldehyde might function as a reversible covalent inhibitor of CutC 
In order to determine how betaine aldehyde interacts with CutC, Michael Funk from the Drennan 
group at Massachusetts Institute of Technology soaked this compound into crystals of CutC at 50 mM 
concentration. The resulting crystal structure at 2.2 " resolution (Figure 5.5.A) revealed the formation of 
a covalent, thiohemiacetal adduct with Cys489, which indicates that betaine aldehyde can directly interact 
with CutC and may function as a covalent, reversible inhibitor (Figure 5.5.B). It also appears that betaine 
aldehyde establishes similar interactions with other CutC active site residues as those observed in the 
choline-bound crystal structure and described in Chapter 4. Five CH–O interactions (3.3-3.7 Å) were 
observed between the methyl groups of the trimethylammonium moiety in betaine aldehyde and oxygen 
atoms of CutC active site residues (Asp216, Tyr208, Tyr506) or of the water molecule present in the 
CutC active site. Betaine aldehyde also interacts with Glu491 through a short hydrogen bonding 
interaction (2.4 Å) that might increase the stability of the thiohemiacetal formed with Cys489, by forcing 
the C–O bond of the intermediate out of the conformation needed for rehybridization. This fact is 
supported by the bond angles established between C1 and the surrounding atoms (~105-111 o) in the 
thiohemiacetal, indicating a ~sp3 hybridization.  
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Figure 5.5: Betaine aldehyde can directly interact with CutC and may function as a reversible covalent 
inhibitor. (A) Crystal structure of CutC in complex with betaine aldehyde revealing a covalent bond 
between C1 of the inhibitor and S of Cys489. Active site residues are in green; betaine aldehyde in pink. 
(B) Mechanism for the formation of the thiohemiacetal between betaine aldehyde and Cys489. (C) 
Preliminary in vitro results for the inhibition of CutC activity by betaine aldehyde. CutC activity was 
measured using a coupled spectrophotometric assay with yeast alcohol dehydrogenase, as described in 
‘materials and methods’. The results of a representative experiment are shown. (D) Putative inhibitor 
scaffolds that could interact with Cys489. R = alkyl group.  
 
In order to investigate the kinetic parameters of inhibition of CutC activity by betaine aldehyde, 
we performed a preliminary assay in which 10 !M of CutC dimer converted into the glycyl radical form 
was incubated with various concentrations of betaine aldehyde for different periods of time (Figure 
5.5.C) and the ability of CutC to convert choline into acetaldehyde was measured via a 
spectrophotometric coupled assay with yeast alcohol dehydrogenase. Since the activity of CutC in the 
presence of betaine aldehyde is lower than without the addition of this molecule but remains constant over 
30 min, these data support the proposed function of this molecule as a covalent reversible inhibitor 
(Figure 5.5.C). However, several experiments still need to be performed in order to fully classify the role 
of betaine aldehyde as inhibitor of CutC activity. Higher concentrations of betaine aldehyde would need 
to be tested in the assay described above to determine a dose-response curve and an IC50 value. In 
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addition, CutC should be incubated with betaine aldehyde for different amounts of time then dialyzed 
against storage buffer and tested in an activity assay, so as to establish whether the formation of the 
thiohemiacetal intermediate is reversible, and whether this molecule interacts preferentially with activated 
or unactivated CutC.       
Considering the small molecular weight of betaine aldehyde, these results are very promising for 
the development of more complex and effective inhibitors that would take advantage of the catalytic 
cysteine residue present in the CutC active site (Figure 5.5.D) (36). Recent research aimed at identifying 
small molecule inhibitors of kinases showed that selectivity for a specific kinase can be achieved when a 
weakly active electrophilic moiety is added to an efficient ligand for that enzyme (37). In our survey of 
other structurally characterized choline-binding proteins, we could not identify any protein that contains a 
Cys residue near the active site (as described in Chapter 4). We thus believe that our rational design 
strategy is likely to yield novel, potent and specific CutC inhibitors.   
5.2.3: Betaine aldehyde inhibits choline TMA-lyase activity in a panel of cut gene cluster-
containing bacteria  
 
In order to determine whether betaine aldehyde could inhibit TMA production by other bacteria 
harboring the cut gene cluster, we tested its efficacy at several different concentrations with cultures of 
Gram-positive (Clostridium sporogenes ATCC 15579) and Gram-negative (Proteus mirabilis BB2000, 
Escherichia coli MS 69-1, Klebsiella sp. MS 93-2) human gut isolates, using similar experimental 
conditions as with E. coli MS 200-1. As described in Chapter 2, we classified cut clusters into two groups 
based on their gene content: type I was present primarily in Firmicutes and contained ~20 genes, while 
type II was present in Proteobacteria and contained only ~10 genes (31). We do not know yet whether 
the protein microcompartments from the two types of organisms are different, since type I clusters contain 
more putative microcompartment genes than type II clusters. Nonetheless, Figure 5.6.A reveals that 
betaine aldehyde is effective against all the strains assayed, including the Firmicute Clostridium 
sporogenes, an encouraging result given that members of the Firmicutes phylum constitute ~50% of gut 
bacteria (38). The IC50 values we observed are within 7-fold of each other, perhaps due to differences in 
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cell wall or microcompartment architecture and permeability, or the activity of efflux pumps, known to 
contribute to drug resistance particularly in Gram-positive bacteria (39). In addition, one of the caveats of 
this experiment is the fact that the inhibitor is present in the medium as the cells are growing. Thus, the 
efficacy of betaine aldehyde should also be tested with bacteria grown to saturation in the presence of 
choline (to induce the transcription of the cut cluster) and washed with buffer to ensure that bacterial 
growth over the duration of the experiment is minimal. Taken together, our data indicate that small 
molecules can interfere with anaerobic choline metabolism in gut microbes, regardless of the type of cut 
cluster or cell wall and membrane architecture.   
 
Figure 5.6: Betaine aldehyde inhibits d9-TMA formation by (A) a panel of cut cluster-harboring bacteria 
(Escherichia coli MS 69-1, Klebsiella sp. MS 93-2, Proteus mirabilis BB2000, Clostridium sporogenes 
ATCC 15579) and (B) by a human fecal sample in a dose-dependent manner. Production of d9-TMA was 
measured by LC-MS/MS and each experiment was performed in triplicate for (A) and duplicate for (B).  
 
5.2.4: Betaine aldehyde inhibits TMA generation by a human fecal sample 
Our previous experiments detailed in Chapter 2 have shown that the cut pathway likely represents 
a major mechanism for TMA production from choline by gut microbes (31). One method to verify this 
hypothesis is to selectively inhibit CutC from a consortium of gut bacteria (such as the one found in a 
human fecal sample) using a small molecule inhibitor and assess the community’s ability to convert 
choline into TMA. In our earlier studies of the cut gene cluster (Chapter 4), we identified ex vivo 
conditions that allowed us to observe d9-TMA production when incubating fecal samples with d9-choline 
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(31). Employing these conditions and adding various amounts of betaine aldehyde at the beginning of 
incubation, we observed that this molecule is capable of abolishing TMA formation when used at mM 
concentrations (Figure 5.6.B). Even though we do not have yet a complete understanding of the proteins 
betaine aldehyde is interacting with, this result suggests that the efficacy of betaine aldehyde extends 
beyond the bacterial strains that we had tested to an intact community containing a diverse range of 
organisms. In addition, these data complement studies with gnotobiotic mice performed by the Rey group 
(40) (mentioned in Chapter 2), thus confirming that CutC-mediated TMA production is likely the major 
gut bacterial pathway for choline conversion into TMA.   
5.2.5: Development of a growth-based assay for high throughput screening for inhibitors of 
choline cleavage by Escherichia coli MS 69-1  
 
Our second, orthogonal approach towards discovering small molecule inhibitors of anaerobic 
microbial choline metabolism involves a high throughput screen that takes advantage of the ability of cut 
gene cluster harboring bacteria to utilize choline as a sole carbon source. Dr. Ana Martínez-del Campo 
has recently shown that organisms such as Escherichia coli MS 200-1 cannot grow in media containing 
choline as single carbon source when cutC or other genes from the cut gene cluster have been deleted 
(manuscript in preparation). However, these mutations do not impact growth in rich media or when 
alternate carbon sources, such as glucose or glycerol, are present. Our aim is thus to identify small 
molecules that inhibit growth on choline, but do not affect bacterial growth on an alternate carbon source, 
such as glycerol or glucose, so as to differentiate inhibitors of choline metabolism from molecules that 
possess antibiotic properties (Figure 5.7.A). To this end, we will utilize two strains of bacteria that harbor 
the cut gene cluster but differ in the cell membrane and possibly in the architecture of their cut 
microcompartment: Escherichia coli MS 69-1 (a Gram-negative strain with a type II cut gene cluster) and 
Lactobacillus paralimentarius (a Gram-positive strain with a type I cut gene cluster). We anticipate that 
using these two bacterial strains in the high throughput screen side-by-side will enable us to discover 
broad-spectrum inhibitors of microbial TMA production.  
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The success of the high throughput screen depends primarily on our ability to identify minimal 
media formulations for each strain of bacteria such that growth is dependent solely on the utilization of 
the carbon source provided. Our starting point for developing a minimal media for E. coli MS 69-1 was 
the “no carbon E” media utilized for achieving ethanolamine-dependent growth of Salmonella enterica 
(41). Marina Orman and I optimized the amounts of vitamins, minerals, electron acceptor (sodium 
fumarate) and nitrogen source (cas amino acids) such that a maximum OD600 value of 0.4 could be 
achieved with the addition of 30 mM choline, and an OD600 value of 1.2 with 30 mM glycerol (Figure 
5.7.B). In our initial experiments, we observed a significant (~8 h) delay in growth on choline. Previous 
experiments in our group determined that the cut cluster is induced many fold in the presence of choline 
(31), so we hypothesized that this delay could be due to a slow induction of the cut genes. As a result, we 
supplemented the overnight culture used for the inoculum with 1 mM choline, and were able to diminish 
the delay in growth. Unfortunately, using the same strategy for growing E. coli MS 69-1 with glycerol as 
carbon source did not reduce the growth delay observed initially and ongoing experiments are aimed at 
addressing this issue. In addition, future efforts in the Balskus group will focus on optimizing a minimal 
media formulation for the growth of L. paralimentarius on glucose or choline as sole carbon source.  
Since betaine aldehyde was effective at preventing anaerobic choline utilization when E. coli MS 
69-1 was grown in BHI supplemented with d9-choline (Figure 5.6.A), we tested whether it could interfere 
with choline utilization in the growth-based assay for this bacterial strain carried out in a 96-well plate. 
We observed that a high concentration of betaine aldehyde (20 mM) effectively abolished growth on 
choline but had no impact on the ability of E. coli MS 69-1 to utilize glycerol as carbon source (Figure 
5.7.B). It is thus clear that betaine aldehyde interferes with anaerobic choline utilization, although further 
experiments will need to be done to elucidate the protein target(s) of this molecule (proteins from the cut 
gene cluster or other choline-binding proteins). Nonetheless, we are able to use betaine aldehyde as 
positive control for the high throughput assay and to calculate a Z’ factor of this assay (a statistical 
parameter for assay quality assessment (42)), based on the OD600 of cultures grown on choline with or 
without the addition of betaine aldehyde. The value we obtained for the Z’ factor of this assay is ~0.84 at 
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14 h of incubation (out of a maximum Z’ of 1), which indicates that our assay is robust enough to be used 
as part of the high throughput screen. 
 
 
Figure 5.7: Growth-based assay for high throughput screening to identify inhibitors of anaerobic choline 
metabolism. (A) Differential growth-based screening approach with Escherichia coli MS 69-1 and 
Lactobacillus paralimentarius. (B) Representative growth curves for E. coli MS 69-1 in the presence and 
absence of CutC inhibitor betaine aldehyde. 
 
Our future work will focus on validation of this screening strategy and identification of initial 
lead molecules. To this end, we will utilize compound libraries from the Institute of Chemistry and Cell 
Biology at Harvard Medical School. We will follow up any hits with assays for human cell cytotoxicity 
(43) and choline transport inhibition (33). We will also evaluate each hit’s efficacy for inhibiting TMA 
production in both fecal samples and cut gene cluster-harboring gut bacteria. Since multiple cut genes are 
essential for growth on choline as sole carbon source, follow-up experiments will be performed to 
determine the mechanism by which our lead molecules interfere with anaerobic choline utilization. For 
instance, their ability to inhibit CutC, CutD, CutO or CutF in vitro could be determined using assays 
already developed in the Balskus group (31, 44). Electron microscopy might reveal whether inhibitors 
affect the assembly of the microcompartment (45), and interactions with other proteins could be 
elucidated by affinity chromatography using inhibitors immobilized on a solid phase (46). We expect that 
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further optimization of initial leads will afford potent molecules that could eventually be utilized with 
different mouse models of liver and heart disease in order to assess the impact of choline cleavage on host 
metabolism and disease progression.  
5.2.6: Conclusions 
In summary, we have demonstrated that small molecules can act as inhibitors of anaerobic 
choline metabolism in both Gram-positive and Gram-negative bacteria, as well as in human fecal 
samples. Using both structure-guided rational design and high throughput screening, we are now poised 
to discover improved inhibitors that could function as tools for the study of choline metabolism in 
complex microbial communities and in the host, or could be further optimized into novel therapeutics. 
Disorders involving gut microbial metabolism are currently treated with antibiotics, which damage this 
microbial community, abolishing its beneficial functions, and occasionally allowing multi-drug resistant 
pathogens to thrive (47). Because impairing choline metabolism does not appear to impact bacterial 
viability, the small molecules we develop may have significantly improved safety profiles. Overall, 
targeting specific gut microbial functions with small molecules is a new approach for studying gut 
microbial communities that may be applied broadly to other metabolic pathways. 
5.3: Materials and methods 
 5.3.1: Materials and general methods 
All chemicals were purchased from Sigma-Aldrich, except for d9-trimethylamine (TMA) 
hydrochloride (CDN Isotopes) and (trimethyl-d9)-choline chloride (Cambridge Isotope Laboratories). 
Acetonitrile and water used for liquid chromatography-mass spectrometry (LC-MS) were B&J Brand 
high-purity solvents (Honeywell Burdick & Jackson). All NMR solvents were purchased from Cambridge 
Isotope Laboratories. LC-MS/MS analysis for d9-TMA and d9-choline was performed without 
derivatization, as described in Chapter 2, in our research labs in the Department of Chemistry and 
Chemical Biology, Harvard University, on an Agilent 6410 Triple Quadrupole LC/MS instrument 
(Agilent Technologies, Wilmington, DE). The analysis for d9-choline was performed under very similar 
! 199 
conditions to that for d9-TMA, by modifying the precursor-product ion pair (m/z 113.2!m/z 45.1) and 
the collision energy (21 V).  
For LC-MS/MS analyses, bacteria were grown on a 200 "L scale in 96-well flat-bottom plates 
(Falcon) sealed with aluminum foil (VWR). Optimization of high throughput screening media 
formulation and growth assays were performed using either the same type of 96-well plates or in 384-well 
clear plates (Corning); lids were kept on the plate during the incubation but the sides were sealed with 
electric tape to prevent the media from evaporating. All growth and kinetic assays were conducted using a 
PowerWave HT Microplate Spectrophotometer (BioTek). Growth assays were performed at 37 °C, and 
the absorbance of each well was monitored at 600 nm for 16 h, with reads 20 min apart. Kinetic assays 
were performed at 22 °C, the absorbance of each well was monitored at 340 nm for 10 min, reads being 
20 s apart. Path length correction was employed such that absorbance values were reported for a path 
length of 1 cm. Data were analyzed using Gen5 software and EC50 values were calculated using GraphPad 
Prism.  
Protein purification was performed for CutC (–52) aa wild-type as described in Chapter 4. Protein 
concentrations were determined according to the method of Bradford (48) using bovine serum albumin 
(BSA) as a standard or using a NanoDrop 2000 UV-Vis Spectrophotometer (Thermo Scientific) for CutC 
(# = 128,870 M-1 cm-1). The extinction coefficient for CutC (–52) aa was obtained using the ExPASy 
protparam tool (http://www.expasy.org/tools/protparam.html). All anaerobic experiments were conducted 
in an MBraun glovebox (MBraun) under an atmosphere consisting of 99.997% N2 with less than 5 ppm 
O2, or in an anaerobic chamber (Coy Laboratory Products) under an atmosphere of 98% N2 and 2% H2. 
Proton nuclear magnetic resonance (1H NMR) spectra and carbon nuclear magnetic resonance 
(13C NMR) spectra were recorded in the Magnetic Resonance Laboratory in the Harvard University 
Department of Chemistry and Chemical Biology on a Varian Inova-500 (500 MHz, 126 MHz) NMR 
spectrometer. Chemical shifts are reported in parts per million downfield from tetramethylsilane using the 
solvent resonance as an internal standard for 1H (CD3OD, !H = 3.31 ppm) and 13C (CD3OD, !C = 49 ppm). 
Data are reported as follows: chemical shift, integration multiplicity (s = singlet, d = doublet, t = triplet), 
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coupling constant, integration, and assignment. NMR spectra were visualized using iNMR Version 5.4.5 
(Mestrelab Research). 
High-resolution mass spectral (HRMS) data for the synthetic compounds were obtained in the 
Small Molecule Mass Spectrometry Facility, FAS Division of Science at Harvard University on an 
Agilent 6210 TOF fitted with a dual-spray electrospray ionization (ESI) source. The capillary voltage was 
set to 4.5 kV and the end plate offset to –500 V, while the drying gas temperature was maintained at 190 
oC with a flow rate of 8 L/min and a nebulizer pressure of 21.8 psi. Liquid chromatography (LC) was 
performed using an Agilent Technologies 1100 series LC with 50% H2O and 50% acetonitrile as solvent.  
5.3.2: Crystallization and structure determination of wild-type CutC bound to betaine aldehyde 
Crystallization conditions for CutC with a 52-amino acid N-terminal truncation and His6-tag were 
identified as previously described in Chapter 4. Crystals were obtained in 16-19% PEG 8000, 0.2-0.4 M 
LiCl, and 0.1 M Tris 8.0 by hanging drop vapor diffusion at 21 ºC. A solution of CutC in 50 mM 
potassium phosphate pH 8.0, 50 mM KCl, and 10% (v/v) glycerol was preincubated at 80 !M with 10 
mM betaine aldehyde. Protein and precipitant were mixed in a 1:1 ratio and incubated for 3-5 days. 
Crystals were cryoprotected in a stabilization solution containing 20% (v/v) glycerol, 25% (w/v) PEG 
8000, 0.5 M lithium chloride, and 0.1 M Tris pH 8.0 and supplemented with 50 mM betaine aldehyde. 
Diffraction images were collected at the Advanced Photon Source beamline 24ID-C at a 
wavelength of 0.9795 Å on a Pilatus 6M detector (Dectris). The diffraction patterns were indexed, 
integrated, and scaled in HKL2000 (49). Crystals diffracted to 2.20-Å resolution in space group P21 with 
cell edges a = 105.2 Å, b = 234.7 Å, c = 159.0 Å, " = 109.0º. The structure was solved by molecular 
replacement in the Phenix implementation of Phaser (50) using the wild type monomer with all ligands 
removed as the search model. Betaine aldehyde covalently bound to Cys489 was modeled into difference 
density with Cys489 removed. The S configuration is probable based on the expected binding mode prior 
to nucleophilic attack; however, the stereochemistry cannot be unambiguously assigned by the electron 
density alone. Parameter files were made in Phenix eLBOW (51). Initial refinement was performed in 
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phenix.refine (51) with manual rebuilding in Coot (52). Water molecules were placed automatically. The 
final model contains all residues found in the wild type structure. 
5.3.3: In vitro assay for inhibition of CutC activity by betaine aldehyde 
 CutC (10 !M dimer) was first activated to the glycyl radical form in an MBraun glove box in a 
1.5 mL polypropylene Eppendorf tube. Activation assays contained 50 mM potassium phosphate pH 8, 50 
mM potassium chloride, 150 !M sodium dithionite, 200 !M SAM, 10 !M CutC dimer, and 40 !M CutD 
in a total volume of 450 !L. A mixture of buffer, CutD and sodium dithionite was incubated for 20 min 
prior to addition of SAM and CutC, then glycyl radical formation was carried out for 1 h at room 
temperature. The assay was divided into 5 tubes, to which betaine aldehyde was added in order to reach 
final concentrations of 5-200 !M. The mixtures were incubated for 2, 12 or 47 min prior to a 3,333-fold 
dilution for the kinetic activity assay. A spectrophotometric coupled assay monitoring oxidation of 
NADH by yeast alcohol dehydrogenase (YADH) was used to determine the kinetics of acetaldehyde 
production and thereby choline cleavage. All assays contained 200 !M NADH, 50 mM potassium 
phosphate pH 8, 50 mM potassium chloride, diluted activation mixture, YADH (0.4 !M) and choline (2 
mM), in a total volume of 200 !L. The assay was carried out in a 96-well plate and the NADH 
absorbance at 340 nm was monitored for 5 min. The absorbance decreased linearly, indicating a constant 
concentration of activated enzyme during the course of our measurements. 
5.3.4: LC-MS/MS assay for determining choline TMA-lyase activity of cut gene cluster-harboring 
bacteria 
 
A solution of inhibitor in 50 mM potassium phosphate buffer pH 7.4 was added to 200 !L BHI 
supplemented with 1 mM d9-choline to reach the final concentrations indicated in Figures 5.4 and 5.6.  
The mixture was inoculated with 2% v/v of an overnight culture (of Escherichia coli MS 200-1, 
Escherichia coli MS 69-1, Proteus mirabilis ATCC 29906, Klebsiella sp. MS 93-2, Proteus mirabilis 
BB2000, Clostridium sporogenes ATCC 15579) that had been grown to saturation in BHI with 1 mM d9-
choline. For C. sporogenes ATCC 15579, the media used instead of BHI was Reinforced Clostridial 
Media (Becton Dickinson). All cultures were incubated at 37 oC in 96-well plates with aluminum seals, 
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inside a vinyl anaerobic chamber (Coy Laboratories). Incubation times varied as follows: 3.5 h for E. coli 
MS 200-1 and P. mirabilis ATCC 29906, 8 h for C. sporogenes ATCC 15579, and 4 h for the other 
cultures. An aliquot of each culture (8 !L) was diluted (up to 2500-fold) with a mixture of 80% 
acetonitrile, 20% 5 mM ammonium formate buffer pH 4, and analyzed by LC-MS/MS for d9-TMA and 
d9-choline. 
5.3.5: Ex vivo incubation for inhibition of choline TMA-lyase activity in a fecal sample 
A frozen fecal sample from a healthy individual was diluted 1:10 (wt/v) in sterile anaerobic PBS. 
The dilution was vortexed for 1 min and allowed to settle for 15 min at room temperature inside a vinyl 
anaerobic chamber. A 95 !L aliquot of the resulting supernatant was transferred to a 96-well plate 
containing 5 !L of different concentrations of betaine aldehyde (10 !M–31 mM final concentration), and 
the mixtures were incubated for 16 h at 37°C. An aliquot of each culture (8 !L) was diluted 2500-fold 
with a mixture of 80% acetonitrile, 20% 5 mM ammonium formate buffer pH 4, and analyzed by LC-
MS/MS for d9-TMA and d9-choline. 
 5.3.6: Growth-based assay for high throughput screening with E. coli MS 69-1 
 The optimized minimal media for growth of E. coli MS 69-1 contained: 29 mM potassium 
phosphate monobasic, 28.5 mM potassium phosphate dibasic, 16.7 mM ammonium sodium phosphate 
dibasic, 1 mM magnesium sulfate, 1% v/v ATCC vitamin supplement, 1% v/v ATCC trace mineral 
supplement, 30 mM choline or 30 mM glycerol, 40 mM sodium fumarate dibasic, 0.4% wt/v casamino 
acids (Becton Dickinson). For the growth inhibition assay, betaine aldehyde was added to media in a 96-
well plate for a final concentration of 20 mM, and the mixture was inoculated with 1% v/v of an overnight 
culture grown in BHI supplemented with 1 mM d9-choline, in a total volume of 200 !L. The cultures 
were incubated at 37 oC for 16 h in an Mbraun glove box under nitrogen atmosphere and OD600 values 
were measured using a BioTek spectrophotometer, as mentioned in ‘materials and general methods’. The 
Z’ value for the assay was calculated using OD600 values at 14 hours for cultures without inhibitor 
(negative control) and with inhibitor (positive control) according to the following formula: Z’ = 1 – 
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[(3!neg + 3!pos)/(|µneg – µpos|)], where µ is the mean absorbance of three cultures, and ! is the standard 
deviation.  
 5.3.7: Chemical synthesis procedures and characterization data 
 Betaine aldehyde chloride (compound 1) was prepared according to the procedure described in 
Chapter 3 (44). 
Synthesis of 2-mercapto-N,N,N-trimethylethanaminium iodide (compound 3) 
 
A solution of acetylthiocholine iodide (390 mg, 1.35 mmol) in ethanol (19 mL) was sparged with 
Ar in an oven-dried 100 mL round bottom flask for 15 min. Upon addition of concentrated (12 M) HCl 
(0.7 mL), the flask was fitted with a reflux condenser and the mixture was heated at 37 oC for 16 h under 
an Ar atmosphere. Upon cooling, the mixture was transferred to an Ar-flushed flask via syringe, and most 
solvent was removed in vacuo. The resulting gel was dissolved in anaerobic water, frozen in liquid N2, 
and lyophilized overnight to afford a white solid (291 mg, 1.07 mmol, 80% yield). HRMS (ESI): calc’d 
for C5H14NS+ [M]+, 120.0847; found, 120.0851. 1H-NMR (500 MHz; CD3OD) !: 3.56 (t, J = 8.4 Hz, 2H, 
CH2SH), 3.17 (s, 9H, NCH3), 2.94 (t, J = 8.3 Hz, 2H, NCH2). 13C NMR (126 MHz; CD3OD) !: 69.5, 
53.69, 53.66, 53.63, 17.8.  
Synthesis of N-(2-hydroxyethyl)-N,N-dimethylhydroxylammonium (compound 6) 
 
To a solution of 2-dimethylaminoethanol (93 mg, 1.04 mmol) in water (5 mL), a solution of 
hydrogen peroxide in water (30% v/v, 0.24 mL, 2.09 mmol) was added. The reaction mixture was 
allowed to stir at room temperature overnight, then the solvent and excess reagent were removed in vacuo 
to afford a colorless gel (108 mg, 1.03 mmol, 99% yield). HRMS (ESI): calc’d for C4H12NO2+ [M]+, 
Me3N
SH
3
I
Me3N
S
I
Me
O
HCl, EtOH
reflux
80%
N
Me2
OHHO
6
Me2N
OH H2O2, H2O
99%
! 204 
106.0868; found, 106.0873. 1H-NMR (500 MHz; CD3OD) !: 4.04-4.02 (m, 2H, CH2OH), 3.49-3.47 (m, 
2H, NCH2), 3.27 (s, 6H, NCH3). 13C NMR (126 MHz; CD3OD) !: 72.7, 59.2, 57.4. 
Synthesis of N-(2-hydroxyethyl)-N,N-dimethylpropan-1-aminium iodide (compound 7) 
 
To a solution of 2-dimethylaminoethanol (200 mg, 2.03 mmol) in methanol (5 mL), potassium 
carbonate (364 mg, 2.64 mmol) and 1-iodopropane (690 mg, 396 "L, 4.06 mmol) were added, and the 
mixture was stirred overnight at room temperature, under a nitrogen atmosphere. The mixture was 
filtered, and the solvent was removed in vacuo. The resulting solid was dissolved in water and washed 
twice with diethyl ether and twice with ethyl acetate. The water was removed in vacuo to afford a white 
solid (333 mg, 1.29 mmol, 63% yield). HRMS (ESI): calc’d for C7H18NO+ [M]+, 132.1388; found, 
132.1393. 1H-NMR (500 MHz; CD3OD) !: 4.01 (m, 2H, CH2OH), 3.48 (t, J = 4.9 Hz, 2H, CH2CH2OH), 
3.37 (dt, J = 8.2, 4.3 Hz, 2H, CH2N), 3.16 (s, 6H, CH3N), 1.87-1.79 (m, 2H, CH2-CH3), 1.01 (t, J = 7.3 
Hz, 3H, CH3CH2). 13C NMR (126 MHz; CD3OD) !: 68.1, 66.6, 56.7, 52.41, 52.35, 17.1, 10.9. 
Synthesis of 2-fluoro-N,N,N-trimethylethanaminium iodide (compound 10) 
 
To a solution of 2-fluoroethylamine hydrochloride (100 mg, 0.9 mmol) in methanol (4.5 mL), 
potassium carbonate (481 mg, 3.48 mmol) and iodomethane (642 mg, 280 "L, 4.52 mmol) were added, 
and the mixture was stirred overnight at room temperature, under a nitrogen atmosphere. The mixture was 
filtered, and the solvent was removed in vacuo. The resulting white solid was washed four times with 
acetone (15 mL), and dried in vacuo, but potassium salts still remained as impurities (490.6 mg, 
quantitative yield by NMR, 43% purity calculated based on weight). HRMS (ESI): calc’d for C5H13FN+ 
[M]+, 106.1032; found, 106.1034. 1H-NMR (500 MHz; CD3OD) !: 5.04-4.92 (m, 2H, CH2F), 3.87-3.80 
(m, 2H, NCH2), 3.27 (s, 9H, NCH3). 13C NMR (126 MHz; CD3OD) !: 79.4, 54.9, 49.8. 
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